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3Abstract
The T cell receptor (TCR) repertoire has the potential to be a highly personalised
biomarker of historic or current immune challenges, and may hold clinically relevant
information. This thesis reviews aspects of the measurement and analysis of the TCR
repertoire, including approaches to obtaining high-throughput sequencing data and us-
ing these data to investigate features of the repertoire in health and disease. The thesis
then considers three topics related to computational and experimental analysis of the
TCR repertoire.
First, this thesis explores a technical challenge in obtaining accurate quantitative TCR
repertoire sequence data, observing substantial heterogeneity in the PCR amplification
step essential for most current high-throughput sequencing protocols. An important
conclusion of this chapter is that single molecule barcoding before amplification is
essential to obtain robust quantification of clone abundances from sequence data.
The second chapter considers the challenges of producing an effective TCR repertoire
which can provide broad coverage of potential pathogens while maintaining tolerance
to self-peptides. A computational model is explored which incorporates a linear pro-
gramming representation of peripheral tolerance, with dendritic cells acting as the cen-
tral agents reshaping the T cell population. The model is shown to maintain a pop-
ulation with restricted responsiveness to self-peptides while retaining a diverse and
cross-reactive repertoire.
In the final results chapter, TCR repertoire data from immunised mice is used to demon-
strate that within a simplified animal model of immune response, the antigen responsive
CDR3β s are almost completely private. However, exploration of the protein sequences
of the antigen associated CDR3β s suggests that there may be amino acid motifs defin-
ing the antigen response.
Overall, this thesis demonstrates the application of computational and modelling ap-
proaches to address questions regarding the TCR repertoire, facilitating interpretation
of high-throughput sequencing data and providing insight into maintenance of diversity
in the peripheral T cell population.
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Chapter 1
Introduction
1.1 The TCR repertoire
The immune system in an individual needs to protect against harmful pathogens in or-
der to avoid disease. The cells of the innate immune system (including monocytes,
macrophages, neutrophils and dendritic cells) each act to enable rapid detection of the
presence of pathogens and to launch broad immune responses. Additionally, certain
cells of the innate immune system are able to initiate an adaptive immune response
via activation of T and B lymphocytes in an antigen-specific manner. The antigen-
specificity of the T and B lymphocytes is determined by their T or B cell receptors, and
the repertoire of antigen-specific receptors in the lymphocyte population of an individ-
ual provides information about the status of their immune system.
1.1.1 TCR recognition of antigen
T cells recognise antigen through interactions between the T cell receptor (‘TCR’) and
peptide fragments in the context of major histocompatibility complex (‘MHC’) on the
surface of an antigen presenting cell (‘APC’) such as a dendritic cell. There are a num-
ber of factors that influence whether a particular TCR is able to recognise and respond
to a particular peptide-MHC (‘pMHC’) [82], and here the recognition is discussed more
generally.
The TCR is a membrane-bound heterodimer and in most T cells is formed of an α
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and a β chain, although a minority of T cells express a receptor formed of a γ and a
δ chain. Each chain contains constant (‘C’) and variable (‘V’) regions (Figure 1.1a).
The variable portion of the TCR is formed by imprecise rearrangement of gene seg-
ments, discussed in more detail in Section 1.1.2. There are a number of areas of the
TCR that are responsible for specific recognition of pMHC, each known as a comple-
mentarity determining region (‘CDR’). Each chain of the TCR has a highly variable
region called the CDR3, which is defined as the section between two conserved amino
acid motifs. The CDR3 is highly variable due to non-templated nucleotide additions
and nucleotide deletions occuring in this region of the TCR during the rearrangment
process. The CDR3 is the part of the TCR which is primarily responsible for contact
with, and therefore recognition of, the pMHC and as such is the major part of the TCR
defining the antigen specificity of the T cell [71]. Other regions of the receptor are
mostly responsible for contact with parts of the MHC, ensuring a stable and productive
interaction between the T cell and the APC.
MHC molecules are glycoproteins and come in two different classes, class I and class
II. The classes are expressed to different degrees in different cell types, and have dif-
ferent structures. However, both are formed of 4 subunits, with the pair of subunits
furthest from the membrane forming a ‘groove’ into which a peptide fragment can bind
(Figure 1.1b, c). Polymorphisms in both classes of MHC molecules are mostly located
in the peptide-binding cleft [20], meaning that individuals with different MHC types
will be able to present different peptide fragments to the T cell population.
APCs, such as dendritic cells, process proteins into short peptide fragments that may
be able to be presented in groove of MHC molecules and these pMHC complexes are
then transported to the surface of the cell [150]. The proteins that are processed and
presented can either be cellular or exogenous, in which case they must be endocytosed
or phagocytosed into the antigen presenting cells. Only peptide stretches that are com-
patible with the MHC molecule are able to be presented, and as such both the overall
structure of the MHC and the MHC type of the individual limits the antigens presented
to T cells. In general class I MHC can only present a more restricted set of peptides,
with the majority of presented peptides being 9 or 10 amino acids long, while class II
can accomodate longer peptides [62].
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Figure 1.1: TCR structure and recognition of peptide-MHC complexes
All panels taken from [107]
(a) The T cell receptor is formed of two chains (generally α and β , although some
T cells express a receptor formed of γ and δ chains), each consisting of a constant
region (C) and a variable region (V). The region of the TCR responsible for antigen
recognition spans the variable regions of both chains.
(b) MHC Class I molecules are formed of a membrane bound α chain, consisting
of three domains (α1, α2 and α3) and a β2 microglobulin.
(c) MHC Class II molecules are formed of two membrane-bound chains (α and β ),
each consisting of two domains.
(d) When a TCR expressed on a T cell interacts with sufficient binding strength
with a compatible peptide fragment (x) in the context of a compatible MHC
molecule presented by an antigen presenting cell there is antigen recognition.
(e) When a TCR binds to a peptide:MHC class I complex the TCR interacts with
parts of both the α1 and α2 domains of the MHC and with parts of the presented
peptide fragment.
1.1. The TCR repertoire 16
With some exceptions (for example, invariant T cells which recognise non-MHC anti-
gen, and activation by super-antigens which does not require costimulation), T cells
are activated through interaction between TCR and pMHC on the surface of an APC
(Figure 1.1d,e), in the presence of costimulatory signals and appropriate environmen-
tal conditions. In order for a TCR-pMHC interaction to yield T cell activation and
an immune response there needs to be sufficient affinity between the receptor and the
antigen. Understanding the factors that determine whether a TCR will interact with a
pMHC with sufficient affinity or for a sufficient duration to initiate activation is there-
fore a key question if we wish to understand whether a given T cell population will
mount a succesful immune response against a given pathogen, or if we want to know
which clones in a repertoire are important in a particular disease setting. However, how
to predict the interaction between the TCR and pMHC, and therefore produce a map-
ping between TCR clones and the antigens to which they are able to mount an immune
response, is not fully understood.
1.1.2 Generation of a diverse TCR repertoire
In order to be able to recognise and respond to the unknown potential pathogens an
individual might encounter, the T cell population needs to express a range of TCRs
with diverse specificities. This is achieved by stochastic recombination of gene seg-
ments in each developing T cell, rather than by expression of germ-line encoded recep-
tors, meaning that even two genetically identical individuals will possess different TCR
repertoires.
The TCR is a heterodimer, and in most T cells is made of an α chain and a β chain.
Each chain is created through a series of somatic recombination events while the T cell
is developing in the thymus, which rearrange one of a number of variable (‘V’) and
joining (‘J’) gene segments (and in the β chain only, one of a number of diversity (‘D’)
segments) together while the intermediary DNA encoding the other gene segments is
excised [8]. This rearranged DNA is transcribed and spliced to a constant (‘C’) gene to
give the receptor chain (Figure 1.2). The gene recombination is performed by enzymes,
particularly RAG, recognising recombination signal sequences (‘RSS’) that flank each
of the V, D and J genes.
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Figure 1.2: Recombination of TCR gene segments
Taken from [107]
Schematic of TCR α and β chain rearrangement.
In addition to the combinatorial potential to create a large number of different TCRs
from the number of different V, D and J genes available in the recombination process,
additional receptor diversity is introduced by the imprecise nature of the recombination
machinery. At each of the junctions between gene segments (V-J for α , V-D and D-J
for β ), the enzymes involved in the recombination process delete a varying number of
the germline nucleotides and include a varying number of non-templated nucleotides
[48], allowing for a massive number of potential TCR types.
One study has estimated that there are 1015 potential different αβ TCRs [37], using
a combinatorial approach considering the gene segment options plus the effect of nu-
cleotide deletions and non-templated nucleotide insertions, while Janeway’s Immuno-
biology [107] calculates a theoretical αβ diversity of 1018. Both of these estimates
of the number of potential TCRs vastly exceed the number of T cells in a human so
this level of diversity will never be realised in an individual. An early TCR reper-
toire study [11] estimated that there are approximately 106 distinct β chains in human
blood, each of which paired with on average 25 different α chains, giving a lower
bound on the diversity that is realised in a single individual as 2.5×107, demonstrating
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the vast difference between the theoretical and realised diversity of the TCR repertoire.
More recently, a mathematical model has been used to estimate the number of distinct
clonotypes present in a human [90], finding that the mean clone size, over the life of
a clonotype, is of the order 10. Therefore, since a human contains in the order 1010
T cells an estimate of 109 distinct clonotypes is reached.
Given the difference between the potential and realised TCR diversity, only a small
fraction of the possible TCRs will be rearranged in any individual. With these re-
arranged TCRs, the immune system needs to be able to provide broad coverage of
antigens that indicate the presence of dangerous pathogens that the individual might
encounter, while avoiding a harmful immune response to self-peptides that are con-
tinuously presented on MHC by APCs. To achieve this, the developing T cells pass
through two rounds of TCR-dependent selection in the thymus, as reviewed in e.g.
[106].
First, developing T cells encounter thymic epithelial cells that present a selection of
self-peptides loaded into MHC (‘spMHC’), and they must bind with strong enough
affinity to receive necessary survival signals to pass positive selection [80]. Secondly, if
a T cell binds too strongly to spMHC complexes presented by thymic APC it is deleted
under negative selection [72]. To create tolerance to the full range of self-peptides that
peripheral T cells might encounter, the AIRE transcription factor causes expression of
a full range of tissue-specific proteins within thymic epithelial cells [9]. Together, these
selection processes ensure that the cells that reach the periphery are enriched for those
that are able to recognise peptide loaded into MHC molecules without recognising too
strongly ‘harmless’ self-peptides.
However, it is now recognised that the thymic selection process is somewhat ‘leaky’
[163] and there are self-reactive T cells present in the periphery, some of which may
be at frequencies equivalent to those of nonself-reactive T cells. As such, there needs
to be mechanisms in the periphery to ensure the T cell population does not cause auto-
immunity through recognition of and response to self-antigens, discussed further in
Section 1.1.4. In Chapter 3 we develop a model of maintenance of peripheral immune
tolerance and investigate the effects of this model on the repertoire.
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1.1.3 Clonal differentiation and expansion
When a T cell encounters cognate antigen (pMHC which is ‘recognised’ by its TCR
with enough binding strength), in the presence of costimulation (e.g. from CD80 and
CD86 on the antigen presenting cells) and additional ‘danger’ signals [96] from the
innate immune system acting either on the APC or the lymphocytes directly, it be-
comes activated. Activation of T cells initiates signalling cascades which result in cell
differentiation and clonal expansion [27]. Some cells in the activated clone become
long-lived memory cells, allowing a more rapid immune response if the same pathogen
is encountered by the individual again. Others become effector T cells, providing a tar-
geted, antigen-specific immune response against the pathogen that activated the clone.
A key feature of this clonal expansion is that all progeny of a given T cell carry the
same TCR, allowing them to effectively act to clear, in a targeted manner, the pathogen
that initiated the immune response. This clonal expansion also means that the repertoire
of TCRs (the size and type of each T cell clone) in an individual contains information
about the current and historical immune challenges the individual has faced, and may be
able to predict the ability of their immune system to effectively counter future immune
challenges. A combination of experimental and computational techniques is necessary
to extract and interpret such information.
1.1.4 Peripheral regulation of the T cell population
Thymic selection ensures that peripheral T cells are enriched for those bearing TCRs
which are able to recognise, but which do not respond too strongly to, self-peptides
presented in the context of MHC. However, this system is not perfect, and as such both
T cells that are self-responsive and T cells that are unable to recognise MHC-presented
peptides may be present in the periphery. In order to maintain an optimal T cell pop-
ulation and to avoid harmful auto-immunity, both positive and negative processes of T
cell population regulation are required outside the thymus.
In [142], thymuses from wild type mice are grafted into RAG deficient mice, who do
not produce their own mature T or B cells, that either do or do not express MHC class
II molecules. It was found that newly generated CD4+ T cells are able to proliferate
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in the periphery even in the absence of MHC class II, but that long term maintenance
of the peripheral pool of CD4+ T cells is compromised in those mice. In [112] it is
demonstrated that the presence of MHC Class I expressing cells is required for CD8+
T cells to successfully survive in the periphery. Both these studies suggest a form of
positive regulation of the peripheral T cell population, with T cells that are not able to
interact with self-peptides presented in the context of MHC molecules being deleted.
More recent evidence of the requirement for naive T cells to recognise self-peptide
MHC complexes is reviewed in [141], including the observation that maintenance of
the naive T cell population in the absence of MHC appears to be very context depen-
dent. For example, the studies mentioned above used lymphopenic mice, in which the
response of T cells to signals that normally induce homeostatic proliferation is known
to be altered. In a study where polyclonal naive T cells are transferred into various non-
lymphopenic mice, it is seen that in MHC-deficient hosts phosphorylation of TCRζ (as
a measure of TCR signalling) in donor cells is rapidly lost but survival over a month
is equivalent to the survival seen in wild type hosts [41], suggesting that interactions
between TCR and MHC are not essential for survival of naive T cells.
In [23], a review of experimental evidence demonstrates considerable support for the
idea that survival of naive T cells requires survival signals from MHC in conjuction
with IL-7 signalling, and that there is considerable competition in the periphery for self-
peptides presented on MHC. However, maintenance of the memory T cell population
does not require MHC signalling.
If recognition of self-peptide-MHC complexes is required for long-term survival of
naive T cells, the homeostatic abundance of a T cell clone in the periphery should be
dependent on availability of peptide that its receptor is able to interact with. It has
been shown experimentally that the precursor number does affect the maintenance of
naive and memory T cells in non-lymphopenic hosts [57]. Cells of clones with lower
abundance are more likely to survive than cells from large clones, suggestive of intra-
clonal competition for peptide and therefore of dependence on MHC for T cell mainte-
nance. Competition between different clones for peptide has been modelled [138, 137],
showing that clones which have greater overlap of self-peptides recognised with other
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clones tend to become extinct more rapidly. This competition for peptide results in
a diverse repertoire, where the most successful clones occupy ‘niches’, with few other
clones recognising the same self-peptides. An alternative modelling approach is used in
[97], where the ‘optimal’ repertoire is found to be sparse when cross-reactivity between
clonotypes is present.
In addition to positive regulation of the peripheral T cell population, removing cells
which are unable to recognise peptide in the context of MHC, negative regulation is
also required in order to avoid dangerous immune response to self-peptides. Avoidance
of self-response is known to involve regulatory T cells (‘Tregs’), which suppress the
function of conventional T cells. The role of Tregs in the maintenance of self-tolerance
and the avoidance of autoimmunity has been thoroughly reviewed (e.g. [128, 129]) and
is not considered further here.
The ‘danger model’, first proposed by Matzinger in 1994 [95], suggests that APCs are
activated by alarm signals from injured or infected cells, and that only TCR interactions
with peptide presented by activated APCs are able to stimulate a T cell response. A
possible extension of this model is that APCs that have not been activated by these
alarm signals would have the potential to be tolerogenic, ensuring no immune response
is initated following interaction with the peptides being presented on resting APCs.
The evidence for the existence of tolerogenic DCs is conflicting, but as reviewed in
[135] they were first suggested in mouse experiments where an antigen was delivered to
DCs without the DC becoming activated [58]. This resulted in proliferation of antigen
specific T cells, rapidly followed by contraction of the population and the remaining
cells becoming unresponsive to later antigen challenge. However, the evidence for
true tolerogenic DCs is still relatively unclear. An additional role of DCs in peripheral
regulation of the T cell population is the ability of immature DCs to induce Tregs, as
discussed in detail in [92]. Dendritic cells have also been shown to be able to delete
CD8+ T cells [166] directly through an MHC dependent mechanism, and a particular
subpopulation of DCs which express perforin, a cytolytic protein that forms pores in
the cell wall of target cells, have been shown to be important for avoidance of tissue-
specific autoimmunity [167].
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In addition to dendritic cells, other APCs are able to regulate the peripheral T cell pop-
ulation. In secondary lymphoid organs resident stromal cells are involved in recruiting
and organising T cells, so that they are able to meet DCs presenting antigen but ad-
ditionally, as reviewed in [149], they express and present peripheral tissue restricted
antigens, and in doing so tolerise naive T cells to these peptides. There is also consid-
erable debate about the role of Langerhans cells (specialised DCs present in the skin
and mucosa) in T cell tolerance, with conflicting evidence regarding the role of these
cells in the epidermis and their mechanism of action. In some experimental models
Langerhans cells have been found to stimulate T cell responses while in other settings
they are seen to induce tolerance, as reviewed in [66, 89].
Despite understanding and modelling some of the mechanisms of positive and negative
regulation of the T cell population in the periphery, understanding how the immune sys-
tem is able to make a robust decision about whether to initiate a response to a presented
peptide remains a challenge. The flexibility of the TCR-pMHC interaction results in
much cross-reactivity, and there is overlap in the distribution of affinities with which
TCRs bind to self or nonself presented peptides. One approach to understanding this is
to consider cooperative behaviour between T cells and dendritic cells, and to consider
the decision making process as occurring not at a single cell level but at a population
level. In [28] an elegant model of quorum-sensing is described, where an immune re-
sponse is only initiated if sufficient T cells recognise presented peptide on an APC.
Once positive and negative thymic selection has skewed the distributions, across the
whole T cell population, of affinity to self and nonself peptides, a carefully selected
quorum threshold is then able to accurately discriminate between presented peptides in
the periphery.
In Chapter 3, concepts of tolergenic APCs, cooperation between cells of the immune
system and cross-reactivity between T cell clonotypes are combined in a model of
maintenance of immune tolerance at steady state in the periphery.
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1.1.5 Studying the TCR repertoire
The majority of studies into the role of T cells in an immune response either consider
the T cell population without considering clonal distinctions (e.g. measuring population
subset sizes) or investigate the role of antigen-specific lymphocytes in isolation, either
in vitro (e.g. using tetramers to isolate antigen-specific T cells) or in vivo using TCR
transgenic approaches.
In contrast, deep-sequencing studies covering the whole TCR repertoire provide a holis-
tic approach to investigating the role of the T cell population at steady state or in re-
sponse to an immune challenge, allowing systems-level questions to be asked about
how clones interact and whether these interactions affect the behaviour of the whole
system.
1.2 TCR repertoire sequencing and analysis pipeline
Initial studies into the TCR repertoire provided only low-throughput and/or coarse data
regarding the receptors present in a sample. For example, spectratyping techniques
using Vβ specific primers allowed the distribution of lengths of CDR3 within a Vβ
family to be measured [51, 52] but did not provide any sequence information regarding
the different clonotypes within the V gene family. Before the development of high-
throughput sequencing, to obtain sequence information about individual TCR clones
individual antigen specific T cells were isolated using tetramers. These single cells
were then grown up into T cell clones and their receptors sequenced via Sanger se-
quencing.
The development of high-throughput sequencing (‘HTS’) has provided the ability to ac-
quire the nucleotide sequence of millions of molecules in one experiment, and protocols
have been developed to apply this technique to libraries of TCRs. These sequencing
data provide a more comprehensive and detailed view of the TCR repertoire in a sam-
ple than was previously possible, but require careful processing and analysis to obtain
biologically relevant information.
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1.2.1 Library preparation protocols
Various TCR sequencing protocols have been developed, but all need to include steps
to extract the template nucleic acid material from the sample and amplify the template
molecules via PCR to obtain concentrations suitable for loading onto the sequencing
machine.
TCR sequencing protocols either use genomic DNA (gDNA) or messenger RNA
(mRNA) from cells as the template to be amplified and sequenced. The choice of start-
ing material affects the experimental protocol, due to different priming sites available
for PCR amplification, as well as data processing decisions, discussed later.
TCR gDNA includes intronic regions, which are removed by splicing following tran-
scription and so are not present in mRNA. The most substantial of these introns, and the
most relevant in the development of TCR sequencing protocols, is the section between
the J gene and the constant region which can be long, especially in comparison to the ca-
pabilities of the PCR reaction and of sequencing machines. The presence of this intron
means that amplification from gDNA is not feasible using primers against the constant
region, shared by all template molecules, and still ensure coverage of the CDR3 which
is generally the region of interest. Protocols sequencing from gDNA [125] therefore
generally use a panel of J region primers, covering the known functional J genes, to
avoid amplifying the intron region.
Similarly, amplification of TCR target molecules, whether from mRNA or gDNA, is
complicated by the lack of a conserved sequence at the V-gene end of the molecule that
could be used as a primer target. This can be solved by using a panel of V primers cover-
ing the known functional V genes. As an alternative to using a panel of V gene primers,
an adapter containing a known sequence can be added to the V end of the molecule to
be used as a priming site. The addition of the adapter is usually performed through a
technique known as template switching (e.g. [45, 156] and others), which exploits a
property of some reverse transcriptase enzymes, allowing the additon of non-templated
nucleotides to the end of the molecule, providing a priming site. Alternatively, as in the
protocol developed in our lab, a ligation step can be used to add a primer site onto the
V end of the template molecule. Once a known sequence has been added to each tem-
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plate molecule, PCR amplification for mRNA protocols can be performed between this
primer site and a primer site in the constant region of the TCR, meaning only one pair
of primers per constant region (α or β ) is needed to amplify all TCR rearrangements
found in the sample.
In our lab, the TCR sequencing protocol, as described in [59], uses mRNA and a lig-
ation approach to add a known primer site to the V end of the target molecules and
amplification of molecules using primers between this site and the constant region.
The mouse TCR repertoire data analysed in Chapter 4 from Nir Friedman’s group at
the Weizmann Institue is sequenced from mRNA using a PCR reaction between a panel
of V primers and the constant region as described in [91].
One of the difficulties with the current high throughput TCR sequencing protocols is
that they allow data to be collected regarding both the α and β TCR chains that are
present in a sample of cells, but do not allow identification of which α was paired
with which β in a cell. Protocols obtaining paired chain sequencing data have been
developed, which either physically link the α and β RNA from a cell before sequencing
(e.g. [148, 99]), amplify both the α and β chains from single cells and Sanger sequence
(e.g. [36]) or alternatively apply a unique cellular barcode to RNA from each cell before
sequencing (e.g. [55]). However these techniques are currently much lower throughput
and more expensive than the protocols obtaining unpaired sequencing data.
Alternatively, computational approaches are being utilised to obtain paired chain data.
PairSEQ [63] is a method that relies on the almost unique nature of clonal TCR rear-
rangements within a sample. The cells in a sample are split into multiple subsets and α
and β chains present in each subset are sequenced following a standard TCR sequenc-
ing protocol. The α and β chains that were present together in a cell should then appear
in the sequence data from the same subsets, and from no other subsets. In this manner
a combinatoral approach can be used to identify the αβ pairings present in the sample,
at lower cost and with higher throughput that the paired sequencing approaches.
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1.2.2 Processing of HTS TCR data
After TCR molecules have been sequenced, the sequence data needs to be processed
into a usable form before further analysis can be performed. The data processing can
be thought of as having three steps: (i) identification of the TCR clone (either at the
rearrangement-event level or the CDR3 level) in each sequence read, (ii) sequence error
correction and (iii) quantification of clone sizes.
1.2.2.1 Identifying clonotypes from sequence data
In order to perform analyses of the TCR repertoire from HTS data, first the receptor
rearrangements, or the CDR3 sequences, corresponding to each sequence read need to
be identified. For applications of HTS to germline encoded products, the identifica-
tion of the relevant biological product in sequence data is a relatively straightforward
sequence alignment problem, only made difficult by the quantity of sequence reads
involved. Techniques such as NCBI’s BLAST and its extensions allow for rapid iden-
tification of the portion of the genome that a sequence read covers.
In order to identify the TCR rearrangement present in a sequence read, the read needs to
be matched to one of a number of V genes, which have very similar nucleotide strings,
and to one of a number of J genes which also have high similarity. Additionally, the
sequence data from the TCR rearrangement will contain an unknown number of non-
templated nucleotides for which no alignment to a genome is possible. Both of these
features make it more difficult to identify the appropriate TCR rearrangement for each
sequence read, and more diffcult to correct sequence error.
The common approach to this problem is to determine the rearrangement events that a
sequence read represents by first identifying the constituent V and J genes. Once these
have been decided then the number of nucleotide deletions and non-germline insertions
can be predicted and the nucleotide or amino acid sequence of the CDR3 determined.
Methods for identifying the genes present in a TCR sequence read are discussed below.
It should be noted that the identification of the rearrangement that occurred in the de-
veloping thymocyte to produce a particular TCR is not a trivial problem because it is
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apparent that there is not a one-to-one relationship between rearrangement event and
sequenced TCR: the same nucleotide sequence can be created using different V or J
gene segments, different numbers of nucleotide deletions and different non-templated
nucleotide additions. This is referred to as ‘convergent recombination’ and in [42]
probabilistic models are used to infer likely rearrangement events from observed nu-
cleotide sequences. If the sequenced TCR data is being used to infer properties of the
rearrangment mechanism in developing thymocytes the probability of each of the pos-
sible rearrangement events is important to consider. However, if the characteristics of
the existing TCR CDR3 repertoire are being investigated it may be sufficient to assign
each sequence read to just one possible rearrangement event.
In order to determine the V and J genes present in the sequence read, some form of
string-matching algorithm is needed. Many pipelines make use of pairwise local align-
ment algorithms to obtain a score for each possible gene and assign the read to the high-
est scoring alignment (e.g. [85, 155]). IMGT/HighV-QUEST [5] is a high-throughput
implementation of IMGT/V-QUEST [26] in which assignment of gene segments to
sequence reads is performed by pairwise alignment techniques. It can be accessed
through a web-based interface, and is used in a number of studies including [86, 151].
Alternatives to pairwise alignment are also used to identify V and J genes within a TCR
sequence read. MiTCR [21] is software that assigns gene segments to high-throughput
TCR sequencing data by first searching for pre-specified ‘seed’ n-mers (generally cov-
ering the ends of the CDR3 region from each gene segment) in the sequence read and
then attempting to extend the alignments to identify the genes that are present, with
each potential gene segment being given an aligment score. In our lab, Decombina-
tor [145] is used to process HTS TCR data. Decombinator utilises the Aho-Corasick
algorithm [3] which constructs a finite state machine to enable efficient searching of
all sequence reads to look for instances of a set of ‘tags’ which uniquely define the
possible V and J gene segments.
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1.2.2.2 Sequence error correction
The presence of erroneous base pair calls in sequence data due to PCR or sequencer
error is a substantial issue, with up to 6% error being observed [113]. Different ap-
proaches can be taken to try to minimise the impact of this sequence error on repertoire
analysis. Common approaches are outlined below.
Sequence reads in fastq format come with an attached quality score for each base-
pair, indicating the probablity of a correct basepair call. Many groups apply a filter to
sequence reads depending on this quality score, either requiring a minimum average
quality over all base pairs or a minimum per-base quality required. It is also possible
to incorporate the quality scores into the assignment of V/J genes, allowing for mis-
matches where quality score is low [155]. In addition, many analysis pipelines choose
to discard any read where there is an uncalled basepair, any read which is out-of-frame,
or any read which does not contain the C-region primer or the expected multiplexing
index (e.g. [79, 151]).
After assignment of V/J genes and identification of the CDR3 contained in each read,
some groups restrict which TCR clones are taken forward for further analysis by dis-
carding ‘small’ clones, considered to be prone to being counted as a distinct clone due
to sequence error rather than a true biological difference. Those clones which are dis-
carded as being ‘small’ can be defined in a number of ways. Often, clones that appear
below a certain number of times are discarded automatically, and in [164] those clones
which appear below 0.5× ‘coverage’ are abandoned, where coverage is defined as the
average number of annotated sequence reads per cell of input material. Alternatively,
in [156], only those largest clones which account for 96% of the sequence reads are
retained, where 96% has been determined to be the ‘best’ cutoff to remove error by
analysis of the J genes in each sequence.
Instead of discarding sequences containing error, and therefore potentially losing quan-
tification information regarding the clones, another approach commonly used is to
group the reads from the same clones and then incorporate satellite reads into larger
clones (or discard the smaller clones) according to some algorithm. [124] uses a near-
est neighbour algorithm to group reads together into a single clone, while [164] discards
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small groups of reads if they are different from a larger group in just one position in the
CDR3 and if the number of reads in the smaller clone is < 5% of the number of reads
in the larger clone.
In [22] an error correction algorithm is proposed that starts with creating groups of
‘core’ clonotypes, containing reads with high quality sequences and identical CDR3s.
To correct for errors from the sequencing machine, low quality reads are mapped to
these core clonotypes with mismatches allowed in positions where the sequence quality
is low. Then, to correct for errors introduced during PCR, sequence reads are grouped
into larger clonotypes if the only mismatches are in the V or J regions. This approach
has been packaged into a piece of software, MiTCR [21].
1.2.2.3 Quantification of clone sizes
Many analyses of TCR sequence data are interested in the size of different clones, both
relative to other clones in the same sample or relative to the same clone in a different
sample either from a different individual or at a different time.
Simply counting the number of times each TCR clone or each CDR3 appears in a
sample, after correction for sequence error using one of the methods described above,
can give an estimate of clone size in the sample, but it is important to consider the effect
of the starting material choice on the interpretation of this number. Sequencing from
gDNA ensures that one copy of the rearranged TCR is observed per cell in the sample,
whereas there are multiple copies of mRNA per cell. Observations from our group
have suggested that the number of TCR mRNA molecules per cell are in the range
1 - 10 and it has been suggested that the per cell TCR mRNA count may vary with
antigenic stimulation [114]. If we can assume that mRNA levels are relatively stable
within a cell and consistent between cells in a sample then counts of sequenced mRNA
molecules are a proxy for clone size in the same way that sequenced gDNA molecules
are, otherwise counts of mRNA molecules should be interpreted as a function of clone
size and receptor expression levels.
Protocols that use panels of PCR primers against the V and/or J genes need to account
for the potential primer bias that these could introduce. In [111] the bias resulting from
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PCR using a panel of V region primers is corrected for via a probabilistic method of
normalising clone size in sequence data based on sequencing of a synthetic libary of
TCRs. In [30], synthetic templates are used to measure the bias in PCR using panels of
primers against both the V and J regions. It is found that each gene region has a biased
amplification but that there is no interaction between the two gene segements, and
an optimal primer mix, minimising the PCR primer biases, is found through titration
experiments. The residual bias using this optimised primer mix is measured using the
synthetic library and this gives a set of normalisation factors which are then applied to
sequenced TCR repertoire data.
Quantification of clone size is also complicated by the inherent stochasticity of the
PCR amplification process. Efficiency of amplification by PCR depends on a number
of factors, including the GC content of the template. In a heterogenous mix of template,
such as a sample of the TCR repertoire, it can’t be assumed that each initial template
molecule will amplify at the same rate. Additionally, the stochasticity of the PCR
produces a certain amount of noise in the amplified sample. In an experiment where
the same sample of T cells in blood is split into two and each is amplified under the
same conditions [124] the observed clone sizes in the two split samples are seen to be
relatively uncorrelated for ‘small’ clones (observed < 100 copies per sample).
Given this observed heterogeneity, the amplified pool of molecules that are sequenced
may not be quantitatively representative of the original sample which might affect con-
clusions drawn from analysis of the data. In order to account for this heterogeneity,
some antigen receptor sequencing studies implement a unique molecular barcoding ap-
proach where each molecule in the initial sample is uniquely tagged with a nucleotide
string. The particular techniques used to label molecules are discussed in Chapter 2.
The unique barcodes allows reads from the final sequencer output to be clustered ac-
cording to which initial molecule they are derived from, meaning that variable PCR
amplification efficiency can be corrected for and a more accurate estimate of initial
clone size can be obtained.
In Chapter 2 we investigate the bias that PCR amplification heterogenity might intro-
duce into TCR repertoire sequence data and suggest that single molecule barcoding is
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vital to ensure quantitative analyses are robust.
1.3 Analysis of TCR repertoire sequence data
Many studies inferring properties of the immune system from TCR repertoire sequenc-
ing data can be thought of either as studies into the system-level properties of the T
cell population at steady state or under immune challenge, or as studies attempting to
identify characteristics of an antigen specific response in the repertoire. We discuss
both of these approaches to the study of the TCR repertoire below.
1.3.1 Global properties of the TCR repertoire
Global properties of the TCR repertoire (including diversity, gene segment usage dis-
tributions, and repertoire similarity between different samples) are often analysed as
indicators of the health, effectiveness or immunocompetence of the T cell population.
Many studies consider the TCR repertoire of healthy individuals, to gain insight into
the mechanics of the formation of the repertoire or the baseline state of the repertoire,
while others consider the repertoire in various disease settings.
1.3.1.1 Diversity: richness and evenness
Many early TCR repertoire studies focussed on estimating the diversity of the repertoire
in a healthy individual and additional studies have considered the effect of immune
challenge on the diversity of the repertoire, to measure how disease disrupts the T cell
population.
Diversity of the repertoire can be thought of in a number of ways, and can be quanti-
fied using a number of measures. Two facets of diversity are ‘richness’ and ‘evenness’,
and most measures of diversity combine both of these. The richness of a repertoire
describes how many clones are present in a sample. This can most simply be measured
by counting the observed clones and comparing this number between samples. How-
ever this number will depend both on sample size, since the number of small clones
that are observed will be affected by sampling, and on sequencing depth, since not all
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clones present may be sequenced. The evenness of a repertoire describes how uniform
the abundance of the different clones are within the population.
The estimated richness of the TCR repertoire in a healthy individual is discussed in
Section 1.1.2, and in [79] it is found that the memory compartment is approximately
half as diverse (in terms of TCR richness) as the naive compartment in CD4+ T cells,
and between 1/3 and 1/10 as rich in CD8+ T cells.
The evenness of a TCR repertoire is measured in many studies using the Gini index,
an equality measure commonly used in economics and social sciences which describes
how equally a resource is distributed amongst a population. A Gini index of zero corre-
sponds to a completely equal distribution of resources and a value of one corresponds
to a maximally unequal distribution. In the case of TCR repertoires, it can quantify
whether a population is dominated by a few large clones or if most of the clonotypes
are of equal size.
A number of diversity metrics, often borrowed from other disciplines, are used in this
work and in other studies to describe and compare the diversity (combining richness and
evenness) of sequenced TCR repertoires. The Shannon Index, or Shannon Entropy, was
first developed with reference to the information in strings of text. In the context of TCR
repertoires, it can be thought of as describing the uncertainty involved in predicting
what clone a randomly selected read will belong to and is calculated as:
H ′ =−
R
∑
i=1
pi ln pi
where R is the number of different clones observed and pi is the proportional abundance
of the ith clone. Sometimes the Shannon Entropy is normalised by dividing by the log
of the number of observed clones. Another metric of diversity is the Simpson Index,
which calculates the probability that two TCRs, selected at random from a dataset, are
of the same clone:
λ =
R
∑
i=1
p2i
In a highly diverse sample the Simpson Index gives very small values so often the
inverse Simpson, 1/λ is quoted.
1.3. Analysis of TCR repertoire sequence data 33
1.3.1.2 Recombination biases
In [102], many examples of pre-HTS studies demonstrating biases in the recombination
of TCRs are reviewed, including studies showing that different promoter sequences
upstream of V genes affect the rates at which each is expressed and showing that there
is preferential pairing between V and D/J gene segments. All of the biases in the
recombination machinery result in non-uniform probabilities for each of the potential
TCRs to be rearranged, reducing the diversity of the repertoire.
In [108] a comprehensive study of the recombination events in non-productive rear-
rangements (to avoid effects of selection) from HTS data of the TCRβ repertoire is un-
dertaken to understand biases in the rearrangement of TCRs. The probabilitistic prop-
erties of the recombination process are inferred, using a maximum likelihood approach
since single multiple recombination events can lead to the same nucleotide sequence. It
is found that the frequencies of V and J genes vary significantly (as many other studies
have found and in [111] is attributed to the physical conformation of chromatin), but
interestingly no dependence between V choice and J choice was observed, suggesting
that previously reported correlations might be a function of selection pressure rather
than the recombination process. It is found that the number of deletions from the V
and J genes is dependent on the gene used, while the VD and DJ insertions are uncor-
related to each other, and the probability of a particular nucleotide insertion depends
strongly on the 5’ nucleotide. The derived probabilities are remarkably consistent be-
tween individuals, with the greatest variability seen in the gene usage probabilities.
This consistent probabilistic model of recombination both reduces the potential reper-
toire diversity and is able to account for the number of sequences shared between two
individuals.
1.3.1.3 Repertoire similarity and public clonotypes
Given the massive amount of potential diversity in the TCR repertoire, it might be ex-
pected that no identical TCRs are shared between two individuals. However, the biased
nature of the recombination machinery, as well as the requirements for a TCR to be
functional and able to recognise peptide fragments presented in MHC molecules, im-
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pose limits on diversity and suggest that the same TCR may be generated and selected
in multiple individuals. Clonotypes shared between many individuals are described as
‘public’, and have been consistently observed in HTS TCR repertoire data. The extent
that public clones arise simply due to highly probable recombination events or whether
convergent selection (either thymic or post thymic) is required to explain their presence
remains unclear.
The overlap between the sets of clones observed in two samples is often calculated as
a metric of repertoire similarity between two individuals or between two samples from
the same individual. The Jaccard Index is defined as the size of the intersection between
two sets divided by the size of the union i.e. J(x,y) = |∩(x,y)||∪(x,y)| . In terms of TCR reper-
toire, it calculates the proportion of distinct clones (total observed across either sample)
that are observed in both samples. In some studies an extension to this similarity met-
ric is used, where the abundances of the clones each of the samples are used to weight
the Jaccard to give more importance to highly abundant clones. Alternatively, the Bat-
tacharyya coefficient is another measure of the similarity of two sets which takes into
account the clonal abundances, and is calculated as BC(x,y) = ∑i
√
xiyi over all clones
i present in either sample, where xi,yi are the abundances of clone i in the respective
samples.
In [126], the naive CD8+ subsets of TCRβ sequences are compared for every pair of
seven individuals, finding at least 100,000 CDR3β s shared between each pair, includ-
ing a pair with no shared HLA alleles. The sharing within the memory compartment
was smaller, although there were still at least 1000 shared CDR3β s found between each
pair. The number of shared sequences in the naive compartments for a pair of individu-
als agrees well to the prediction made via a model of biased VDJ recombination. In the
same vein, [156] finds that in a pair of HLA-matched individuals, approximately 14%
of the CDR3β repertoire is shared. Shared TCRβ s were found to tend to have a shorter
CDR3 length as well as being more abundant than private sequences.
In another study considering the overlap in TCR repertoires, the naive and memory
compartments in four individuals [153] were sequenced. In this study, a lower amount
of sharing was observed, with less than 10% of the unique TCRβ amino acid sequences
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from one individual being shared with another individual. The abundance of the clone
was again found to be correlated to sharing, both between subsets and between indi-
viduals, showing that public clonotypes are more abundant. In [42], models of V(D)J
recombination suggest that observed public sequences are due to chance during the bi-
ased recombination process rather than any convergent selection. It has been suggested
that public clonotypes might be involved in autoimmune responses [91] but the function
of these T cells is still not fully understood.
In a study of antigen-specific T cells in mice, analysis of tetramer-sorted influenza
CD8+ T cells [152] from C57BL/6J mice also showed that highly shared identical
sequences (with identity being defined as Vβ , Jβ and CDR3β amino acid sequence
matches) have fewer nucleotide additions, and highly shared sequences are present with
more different encoding nucleotide sequences, suggesting a high level of convergent
recombination. A similar finding is demonstrated in full repertoire analysis (rather than
just within a tetramer positive subset) in [91].
1.3.1.4 Perturbations to the TCR repertoire in disease
Diversity and disease
The diversity of the response to a particular pathogen is thought to be related to disease
outcome. C57BL/6 mice infected with a herpesvirus (HVH-1) have a poorer survival
rate than mice (referred to as ‘bm8’ mice) that differ in the MHC class I molecule by 4
amino acids within the peptide binding site [100]. This difference is found to be CD8+
T cell dependent, and the T cell response of C57BL/6 mice mostly utilises TCRs of the
Vβ10 and Vβ8 families, while the bm8 mice use a broader range of Vβ families, and
more diverse clonotypes within the families.
In [88], spectratyping of the TCR repertoire is used to show that TB patients have a
more restricted repertoire than healthy volunteers, and the complexity of a patient’s
repertoire is negatively correlated with their disease severity, suggesting that a diverse
TCR repertoire may be required for control of disease.
Diversity as a measure of success of treatment
1.3. Analysis of TCR repertoire sequence data 36
In a study of the TCR repertoire in peripheral blood of patients undergoing anti-CTLA4
treatment (tremelimumab) for cancer it was shown that there was a significant increase
in richness (measured by the absolute number of TCR rearrangements observed) after
treatment for the majority of patients [122]. However, there did not appear to be a
change in the distribution of the repertoire, as measured by Pielou’s evenness index.
The increase in richness was not correlated to the response of the patient to treatment,
but those patients with most increased richness were those that experienced most tox-
icity, leading to the suggestion that the increase in richness of the repertoire might be
non-specific expansions, perhaps related to autoimmune clones, rather than expansion
of clones against the cancer.
The TCR response to anti-PD1 treatment (pembrolizumab) for metastatic melanoma is
considered in [147]. Regression of tumours is found to be associated with proliferating
CD8+ T cells localising to the tumour, and when the β chains of the TCRs present in
the tumour pre-treatment are sequenced it’s found that a higher ‘clonality’ is indicative
of a better response on treatment. In this study, the clonality metric is calculated as 1−
normalised entropy, where normalised entropy is the Shannon entropy divided by the
log of the number of different clones observed. In the same study, comparison of the
TCRβ clone sizes pre- and during treatment shows that the patients that successfully
respond to the anti-PD1 treatment have 10× more clones expanding during therapy.
A HTS TCR study of patient samples following haematopoietic stem cell transplanta-
tion (‘HSCT’) [151] showed that TCR repertoire diversity, as measured by the inverse
Shannon, was reduced in comparison to healthy volunteers following transplant with a
T cell depleted graft and even a year after treatment the population diversity had not
recovered. However, this appears to be dependent on whether CD4+ or CD8+ cells
are considered. The T cell repertoires in patients receiving T-cell depleted autologous
stem cell transplants to treat systemic juvenile idiopathic arthritis are studied in [161].
Spectratyping showed that the diversity in the CD4+ TCRβ repertoire is restored by
12 months after transplant, while diversity is only restored in some of the CD8+ Vβ
families by the same time point. High throughput sequencing of samples indicates that
some clones appear to survive the conditioning process, or are grafted back into the
patient during transplant.
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In work from our lab [59], the TCR repertoire in HIV+ patients before and during an-
tiretroviral treatment (‘ART’) was studied, showing that HIV+ patients have a perturbed
repertoire, with much lower diversity than healthy controls and that this is not restored
after three months of ART despite viral loads becoming undetectable.
TCR repertoire sequencing providing insights into disease mechanism
In a study of TCR repertoire in colorectal tumours [131] it is seen that although the
absolute diversity (the number of distinct TCR clones observed) is similar between
tumour and nearby mucosal tissue from the same patient, the normalised Shannon is
higher in the tumour. This suggests that the repertoire present in the tumour is less
polyclonal than that found in surrounding tissue, perhaps due to antigen specific T cell
recruitment to the tumour or retention in the tumour. However, the amount of repertoire
overlap between tumour and nearby tissue in this study was not related to the physical
distance between the two samples. Additionally no differences in V and J gene usage or
CDR3 length were found between tumour and nearby tissue repertoires, suggesting that
the observed difference in normalised Shannon cannot be fully explained by a skewed
repertoire at the global level.
In a study considering the repertoire in patients with rheumatoid arthritis, samples were
taken from multiple affected joints as well as from blood [78]. The highly expanded
clones are shared between different affected joints in a patient, but are not shared be-
tween joints and blood, again suggesting antigen specific recruitment or retention.
In a study of the repertoire in ovarian cancer [44], multiple samples from primary tu-
mour, metastatic sites and blood are taken from each patient. A weighted Jaccard
approach is taken to measure the similarity between repertoires observed at different
sites, and it is found that within a single metastatic site the repertoire is very similar,
but between a metastatic site and the primary tumour there is less similarity. All the
repertoires from tumour samples show little similarity to the repertoire in blood.
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1.3.2 Antigen specific T cells
The global properties of the whole TCR repertoire are able to provide information
regarding the status of the immune system, as discussed above, but considering the
properties of the individual T cells that comprise the immune response to a particu-
lar antigen can provide additional information regarding disease status, correlates of
protection and patient stratification. Even when an epitope (a specific peptide/MHC
complex) is known, it is not currently known how to map this to the TCRs that will
recognise it, and in many disease situations the antigenic peptide is unknown or prone
to mutations. As such, experimental techniques to identify, isolate and sequence re-
sponsive T cells are used in many studies to answer questions regarding the magnitude,
breadth and effectiveness of the T cell response.
Identification and tracking of antigen specific clones in diagnosis and treatment
One of the first applications of HTS of TCRs was in T cell leukaemias, where T cell
clonal expansion occurs independent of antigen. In the context of cutaneous T cell
lymphoma (‘CTCL’), the TCRβ and TCRγ repertoire is sequenced from punch biopsies
[76], demonstrating that the normalised entropy (referred to as the ‘clonality’) of the
full repertoire is correlated with disease severity, with the biopsies from more advanced
disease having a less polyclonal repertoire. This study also showed that the repertoire
in a skin lesion from a patient with CTCL is dominated by the single malignant TCRβ
clone. This is also the case in other diseases, such as psoriasis and dermatitis, but
is more severe in CTCL and the proportion of the repertoire occupied by the largest
clone can distinguish between CTCL and other skin conditions. The malignant clone
in CTCL patients could be tracked over time and in multiple sites in the same patient,
informing clinical treatment, for instance in one patient recurrence of disease after stem
cell transplant was identified rapidly by sequencing of the same malignant clone in a
skin lesion, allowing prompt treatment. Similarly, identification of a single clonally
expanded TCRγ in patients with mycosis fungoides was found to be a more sensitive
diagnostic than the current standard, suggesting this could be used to inform earlier or
more accurate clinical diagnosis [140].
TCR sequencing data is used in a similar manner to detect minimal residual disease
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(‘MRD’) in patients with acute T lymphoblastic leukemia (‘T-ALL’) [160]. Here, pre-
treatment HTS TCR samples were used to identify the TCR sequence of the patients’
neoplastic T lymphoblast clones, and HTS of TCR repertoire was then able to detect
MRD in post-transplant samples with more sensitivity than the commonly used flow
cytometric method. A more recent study [87] has sequenced both TCR and Ig to quan-
tify MRD in blood samples from B-ALL patients undergoing allo-HCT treatment. The
quantified level of MRD in pre-conditioning samples is predictive of transplantation
failure, while MRD quantified above a particular threshold in a post-transplant sam-
ple was 100% positively predictive of eventual relapse. However, patients with MRD
quantified below the threshold did not all avoid relapse. These studies suggest that TCR
and Ig HTS data could inform clinical intervention before symptoms of relapse present
clinically and therefore improve patient outcome.
Graft vs host disease (‘GvHD’) is a frequent complication after bone marrow transpla-
tion, and is the result of inappropriate immune response against unknown self antigens.
The standard approach is to treat with steroids, but some patients are not responsive.
The TCR repertoire in the blood of GvHD patients, after HSCT, does not predict pa-
tients which respond to steroid treatment [101]. Instead, a method tracking particular
clones in patients over a timecourse was developed. Patient specific ‘indicator clones’
were identified as the largest clones in a pre-treatment sample from diseased tissue.
Then the number of indicator clones in blood after 30 days of steroid treatment is re-
lated to the success of treatment, with the patients who require secondary treatment
being those that have fewest present.
Properties of antigen-specific clones
In [81], various functional assays of T cell responses to a CMV peptide are used to sort
CMV responsive from CMV non-responsive cells. The TCR repertoires of the unsorted
cells as well as the CMV responsive and CMV non-responsive subsets are sequenced.
For each of the functional assays considered, those clonotypes that are highly enriched
in the CMV responsive sample above the unsorted and CMV non-responsive samples
are taken to be CMV specific. There is good overlap in the sequences defined as CMV
specific in the sequence data from pentamer staining, CD137 and CD107 functional
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assays, showing that the same clones are responsive under different functional tests.
In addition, using CFSE staining as the functional assay allows identification of CMV
specific TCRs that are initially present at low frequency but proliferate strongly in the
presence of antigen, which are otherwise lost in the sequence analysis technique pre-
sented in the study. It is found that sets of CMV specific TCRs identified using the
combination of functional assay and HTS demonstrate sequence-level similarity be-
tween themselves and with previously described CMV responsive clones. However,
whether there is a sequence-level motif of CMV-specificity that is strong enough to
predict whether a cell will respond to antigen is not explored in this study.
The repertoire of tumour infiltrating lymphocytes (‘TILs’) in melanoma is studied in
[53], and the properties of those TILs that are tumour-reactive are explored. The
tumour-reactive CD8+ TILs are differentiated from other TILs by PD-1 expression,
and PD-1 positive TILs have a more skewed TCR repertoire, with the repertoire be-
ing more dominated by a few large clones, than other TIL subsets. The thirty most
frequent PD-1+ TILs occupy over half of the subset, while the equivalent in the PD-
1− subset is just 5%. Additionally, within the most frequent PD-1+ TILs are found
known mutation-specific clonotypes, while these clonotypes are only found at lower
frequency in the PD-1− subset. This study therefore suggests that PD-1 expressing
abundant clones may represent tumour-reactive TILs.
MHC alleles HLA-B*27 and HLA-B*57 have been associated with ability to control
viral load of HIV, but most people expressing these molecules are unable to control
viral load without treatment. In [33], the differences between T cells from people
who express HLA-B*2705 and are either able (controllers) or unable (progressors) to
control HIV load without treatment are studied. A dominant epitope of the HIV Gag
protein is known to be KK10, but no difference was found in the proportion of CD8+
T cells which are responsive to this epitope between controllers and progressors. Ad-
ditionally there was no difference seen in functional assays of the responsive cells,
suggesting the ability to control HIV viral load is not due to the number of T cells able
to respond to an epitope of the virus. However, when cultured with HIV in vivo, T
cells from progressors demonstrate much less ability to control viral replication than T
cells from controllers, demonstrating that the T cell population does affect the differing
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phenotype. KK10 specific T cells from controllers have increased potency and cross-
reactivity against naturally arising KK10 mutations when compared to KK10 specific
T cell from progressors. Cloning and sequencing of KK10 specific T cells from con-
trollers and progressors was performed, and those clones that were found to be immun-
odominant in vivo in controllers are found to be most effective at killing HIV infected
cells in vitro. This study suggests that the ability of an individual to control HIV infec-
tion depends on the functional properties of the particular TCRs of the T cells that are
selected for, rather than simply on the total number of clones that are selected.
In a small study of HIV-epitope responsive TCRs in a pair of identical twins simulta-
neously infected with the same strain of HIV-1 [165] it is found that the T cell clones
raised in each individual are entirely private, both against shared and distinct viral epi-
topes, demonstrating the extraordinary heterogeneity and plasticity of the TCR reper-
toire, even in genetically identical individuals.
1.4 Scope of this thesis
The aim of this thesis is to explore aspects of how the TCR repertoire is regulated both
before and after immune challenge. Specifically, this thesis will:
1. Address PCR heterogeneity and its effect on quantification of clone size
within high throughput sequenced TCR repertoire data. Amplification of tar-
get molecules by PCR is an essential component of most sequencing protocols,
but demonstrates variability in its amplification efficiency meaning that the am-
plified pool is not necessarily quantitatively representative of the original target
molecules. In Chapter 2 the extent of this heterogeneity is investigated, and single
molecule barcoding proposed as essential to produce reliable quantitative TCR
repertoire sequencing data.
2. Develop a computational model of T cell tolerance of self at steady state. This
model (Chapter 3) incorporates co-operative behaviour between antigen present-
ing cells and the T cell population, leading to a gradual reshaping of the TCR
repertoire in order to avoid excessive total affinity to self-peptides within the
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population.
3. Investigate changes in the TCR repertoire after immunisation with an adju-
vant with or without addition of a model antigen (Chapter 4). TCR repertoires
from different mice under different immunisation conditions, and with or without
any in vitro culture of cells with antigen, are studied to try to identify features
defining the response to antigen.
Chapter 2
Computational analysis of stochastic
heterogeneity in PCR amplification
efficiency revealed by single molecule
barcoding
The work presented in this chapter was published in [18].
The polymerase chain reaction (‘PCR’) is one of the most widely used techniques in
molecular biology. In combination with high throughput sequencing (‘HTS’), PCR is
widely used to quantify transcript abundance for RNA-seq as well as in the context
of analysis of T and B cell receptor repertoires. In this chapter, DNA barcoding is
combined with HTS to quantify PCR output from individual target molecules. Compu-
tational tools that simulate both the PCR branching process itself, and the subsequent
subsampling which typically occurs during HTS sequencing, are developed. We ex-
plore the influence of different types of heterogeneity on sequencing output, and com-
pare them to experimental results where the efficiency of amplification is measured by
barcodes uniquely identifying each molecule of starting template. This work demon-
strates that the PCR process introduces substantial amplification heterogeneity, inde-
pendent of primer sequence and bulk experimental conditions. This heterogeneity can
be attributed both to inherited differences between different template DNA molecules,
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and to the inherent stochasticity of the PCR process. The results demonstrate that PCR
heterogeneity arises even when reaction and substrate conditions are kept as constant
as possible, and therefore single molecule barcoding is essential in order to derive re-
liable quantitative results from any protocol combining PCR with HTS, such as those
frequently used in TCR sequencing studies.
2.1 Introduction
The efficiency of a PCR reaction is known to vary widely, depending on many different
factors. These include the properties of the primers [119, 83, 116], the sequence to be
amplified [7], in particular its GC content [38, 4], as well as the reaction conditions and
type of polymerase. If one wishes to quantify the amount of a given template by PCR
(‘qPCR’) the general approach is to compare an unknown sample to a dilution series
of standards, on the assumption that all variables remain the same between sample and
standard and hence PCR efficiency remains constant.
The introduction of high throughput sequencing [15, 94], in which many DNA
molecules are sequenced individually in parallel, allows the possibility of quantify-
ing many initial target molecules simultaneously by counting the number of times the
sequence for each molecule occurs in the output from a sequence run. This approach
forms the basis for RNA-seq, in which transcript abundance is measured by sequenc-
ing cDNA libraries, and counting the number of sequences mapping to each transcript.
Particularly relevant to this thesis, an extension of this approach is the analysis of the
antigen-specific receptor repertoire by sequencing cDNA or genomic samples of B or
T lymphocytes, and counting the number of times each different receptor is identified
[157]. Most current parallel sequencing technologies require nanomolar amounts of
starting material (typically > 1010 molecules), even when the output of the reaction
may only be in the order of 107 molecules. In order to achieve this amount of starting
material some degree of PCR amplification is usually required. This is especially true
when the amount of starting material may be extremely small, for example in the case
of single cell RNA-seq [110]. The reproducibility of the PCR amplification process
therefore becomes a key factor for accurate quantification.
2.1. Introduction 45
The use of molecular barcodes provides one approach to dealing with single molecule
quantification and mitigating the effects of PCR heterogeneity. A library of diverse
short DNA sequences (called ‘barcodes’, ‘unique molecular identifiers’ or ‘tags’ in
different studies) are introduced into the molecules to be analysed at an early step in
the protocol, in such a way that each target molecule incorporates a different barcode
which remains associated with it throughout the amplification protocol. The barcodes
can be introduced during a reverse transcription step, or by ligation. For instance,
Miner et al [104] and McCloskey et al [98] both ligate nucleotide sequences to uniquely
label initial DNA target molecules to identify sequencing redundancy as well as using
batch stamps to identify sequencing contamination from other samples. In the work of
Casbon et al [32] degenerate base regions are ligated to each DNA fragment to assess
whether observed differences between sequence reads are true variants or sequence
error. Kivioja et al [77] apply a similar unique molecular identifier technique to human
karyotyping. Mamedov et al [93] and Shugay et al [133] use barcodes to provide PCR
and sequencing error correction of TCR repertoires.
In this chapter molecular barcoding is used to investigate the extent of variation in PCR
amplification on a single molecule basis. In order to rigorously assess the possible
sources of this heterogeneity a PCR simulator is developed, which incorporates both
amplification and sampling heterogeneity, with which to compare experimental results.
The PCR amplification is an example of a branching process, and although there has
been considerable theoretical work on such processes, the complexity of heterogeneous
branching processes makes analytical modelling challenging in most realistic examples
[68, 84, 56]. Detailed models of the physical parameters involved in the PCR cycles
have been developed, to answer questions about the probability of replication in an
individual cycle or the evolution of the population over a number of cycles [139, 158,
1, 49, 34]. Additionally mathematical models have been used to investigate the error
profile in PCR protocols [118] or the presence of non-targeted product through non-
specific priming [127]. An increase in computing power has made it feasible to develop
PCR simulations using realistic numbers of starting molecules, with reasonable run
times. The model we describe includes both an amplification step and a sampling step
to simulate the typical workflow of an RNA-seq or repertoire sequencing experiment.
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These computational tools can distinguish heterogeneity which derives simply from the
sampling process itself (modelled as a zero truncated Poisson process) from stochastic
variation in each step of the PCR reaction and inherited variation which may arise from
differences between different DNA molecules within the reaction. Our study therefore
highlights the potential pitfalls in quantitative analysis of DNA or RNA abundance
involving a PCR amplification step, and provides a computational framework which
can be used to analyse barcoded PCR data, and identify and quantify the sources of
heterogeneity.
2.2 Materials and Methods
All wet lab work was performed by Theres Oakes and James Heather.
2.2.1 Sample collection and processing
Ethics
This study was approved by the joint UCL/University College London Hospitals NHS
Trust Human Research Ethics Committee and was carried out in accordance with rele-
vant guidelines and regulations. Written informed consent was obtained from all par-
ticipants (University College Hospital 06/Q0502/92).
Sample collection
5ml of healthy adult volunteer blood was drawn into Tempus Blood RNA tubes (Life
Technologies) and RNA was extracted using the Tempus RNA isolation kit (Life Tech-
nologies). Residual DNA was removed using the TURBO DNase kit, and globin
mRNA was depleted using GLOBINclear (both Life Technologies).
The KT2 T cell clone was a gift of Prof. A. Lanzavecchia (Institute for Research in
Biomedicine, Bellinzona, Switzerland). The clone was grown as described [40]. RNA
was isolated using the RNeasy Mini Kit (Qiagen). RNA was treated with RQ1 DNase
(Promega) following manufacturers instructions to remove any residual genomic DNA.
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Two different protocols were used to amplify and then sequence the T cell receptor
chains. All primers are from Sigma-Aldrich and sequences can be found in Table 2.1.
Protocol using single strand ligation (Protocol A)
The DNAse treated RNA was reverse transcribed using oligos complimentary to the 5’
region of the TCR constant regions TRAC and TRBC (αRC2 and βRC2, Table 2.1).
The mastermix for the reverse transcription was added to the RNA in two stages (mo-
larities for both mastermixes relate to the final volume of 30µl). 11µl of DNase treated
RNA were mixed with 0.5µM αRC2, 0.5µM βRC2 and 0.5mM of each dNTP (Invit-
rogen) to total 19.5µl, and then incubated at 65°c for 5 min and cooled rapidly on ice
for > 1 min. 1× FS buffer (Invitrogen), 5mM DTT (Invitrogen), 30-60 units RNasin
Ribonuclease Inhibitor (Promega) and 300 units SuperScript III reverse transcriptase
(Life Technologies) were added before incubation at 55°c for 30 min in a total volume
of 30µl. 40mM NaOH were added to remove any remaining RNA and the sample was
incubated at 70°c for 15 min. 0.5M sodium acetate were added to adjust the pH before
the cDNA reverse transcription product was purified using MinElute columns (Qiagen).
The single stranded cDNA was ligated, using T4 RNA ligase (NEB) to a 5’ phosphory-
lated 3’ blocked oligonucleotide (T4DNA 6N SP2, Table 2.1) containing 6 base pairs
of random nucleotide barcode and the Illumina sequencing primer SP2. 5µl of cDNA
were mixed with 1× T4 RNA ligase buffer (NEB), 1mM hexammine cobalt chloride,
1.5µM BSA, 0.33mM ATP (NEB), 0.33µM ligation oligo and 20 units T4 RNA ligase 1
(NEB). The ligation was carried out at 16°C for 23 hours followed by a 10 minute heat
inactivation step at 65°C. 70µl water were added to the ligation mix before samples
were purified at a 1:1 ratio with AMPure XP SPRI beads (BeckmanCoulter) follow-
ing manufacturers instructions and eluted in 30-35µl water. A second strand was then
synthesised, priming from the ligated SP2 sequence. The AMPure bead purified liga-
tion product was incubated with 1× HF buffer, 0.5µM SP2 primer, 0.5mM of dNTPs
and 1 unit of Phusion polymerase in a 50µl reaction at 98°c for 3 min, lowered slowly
(1°c/sec) to 80°c, held at 80 °c for 10 sec, lowered slowly (1°c/sec) to 58°c and held
at 58°c for 30 sec. After the final extension at 72°c for 1 min, the product was again
purified on AMPure beads.
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An additional random six base pair barcode was added to the 3’ end with a third strand
synthesis. The conditions for third strand synthesis were identical to second strand,
but using an oligonucleotide complementary to the constant region, and an extension
containing the random barcode, and the Illumina SP1 sequencing primer (SP1-6N-I-
X-αRC1, or SP1-6N-I-X-βRC1, Table 2.1). A diagram showing the structure of the
DNA at this point is shown in Fig 2.1a (top).
The barcoded TCR samples were then amplified in two different consecutive PCR re-
actions. In the first PCR the P5 and P7 adapters required for Illumina sequencing and
an index for multiplex sequencing were added with primers P5-SP1 and P7-LX (Ta-
ble 2.1). The PCR conditions used were 1× HF buffer, 0.5µM P5-SP1, 0.5µM P7-LX,
0.5mM dNTPs and 1 unit Phusion; initial cycle: 98°c for 3 min, slowly ramped to 69°c
for 15 sec and 1 min at 72°c; cycle 2-4: 98°c for 10 sec and 72°c for 1 min; final cycle:
72°c for 5 min. After bead purification the samples were amplified in a second PCR
(1x HF buffer, 0.5µM P5s (Table 2.1), 0.5µM P7 (Table 2.1), 0.5mM dNTPs and 1 unit
of Phusion); initial cycle 98°c for 3 min; cycle 1-24: 98°c for 10 sec, 69°c for 15 sec,
72°c for 40 sec; final cycle: 72°c for 5 min. PCR2 products were bead purified and
eluted in 30µl water.
Protocol A is represented schematically in Figure A.5.
Protocol using fixed V region primer (Protocol B)
DNAse treated RNA isolated from the KT2 clone was reverse transcribed using
oligonucleotides complementary to the 5’ region of the TCRβ constant region TRBC.
The oligonucleotides also contained a random 12 base pair barcode, the SP1 Illumina
sequencing primer and an index for multiplexing. We used two different indices, and
each index was placed either next to the SP1 primer sequence (thus providing a spacer
between primer and random barcode; SP1-12N-IX-βRC1.1, Table 2.1; Protocol B(i)),
or adjacent to the constant region sequence (SP1-IX-12N-βRC1.1, Table 2.1; Protocol
B(ii)). Reverse transcription was carried out as in Protocol A.
The cDNA was amplified using a V region specific primer KT2 (VBKT2 1, Table 2.1)
and an oligonucleotide complimentary to the Illumina Sequencing Primer SP1. PCR
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conditions were 1× HF buffer, 2.5µM primers, 0.5mM dNTPs and 1 unit of Phusion;
initial cycle 98°c for 3 min; cycle 1-24: 98°c for 10 sec, 69°c for 15 sec, 72°c for 40
sec; final cycle: 72°c for 5 min. PCR products were bead purified and eluted in 30µl
water. The P5, P7 and multiplex index were added in 4 additional rounds of PCR as
described for Protocol A.
Library sequencing
Final amplicon products from all sample types were quantified on a Qubit fluorometer
(Life Technologies) and sized on a Bioanalyzer (Agilent). Up to 12 samples (at a
concentration of 4nM) were multiplexed and sequenced on an Illumina MiSeq, using
version 2 chemistry 2x250PE kits.
2.2.2 Data analysis
The FASTQ files produced on the MiSeq were demultiplexed based on the indices
added through PCR and analysed using a modified version of Decombinator [145]. De-
combinator categorises each TCR sequence read by identifying its constituent V gene
and J gene, along with the number of nucleotide deletions from each and nucleotides
between V and J regions. The five-part Decombinator classifier (‘DCR’) is then given
by: V gene used, J gene used, number of V deletions, number of J deletions, junctional
nucleotide string. The modified version of Decombinator used in this chapter outputs
the DCR along with information about the random nucleotide barcode and sequence
quality in each sequence read.
For analysis of polyclonal TCR sequence data, the Decombinator output is then passed
into a PCR- and sequencing-error correction script. This script first filters sequence
reads to remove those where the barcode or sequence quality are poor. It then collects
all sequence reads according to their barcode, grouping together those DCRs that ap-
pear with identical barcodes. If more than one distinct DCR appears with the same
barcode, the DCR with the most copies is taken to be the true sequence of the initial
target molecule with that barcode. The others are aggregated into the largest DCR if
they are clearly the product of sequencing error, and are discarded otherwise. Next,
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Primer name Primer sequence
αRC1 ACGGCAGGGTCAGGGTTCTGGATAT
βRC1.1 GGTGGGAACACCTTGTTCAGGTCCTC
βRC1.2 GGTGGGAACACGTTTTTCAGGTCCTC
αRC2 GAGTCTCTCAGCTGGTACACG
βRC2 ACACAGCGACCTCGGGTGGGAA
SP1 ACACTCTTTCCCTACACGACGCTCTTCCGATCT
SP2 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT
P5 AATGATACGGCGACCACCGAGATC
P7 CAAGCAGAAGACGGCATACGAGAT
VBKT2 1 CTTGGCTATGTGGTCCTTTGC
T4DNA 6N SP2 [Phos]NNNNNNAGATCGGAAGAGCACACGTCTG-
AACTCCAGTCAC[SpcC3]
SP1-6N-I-X-αRC1 ACACTCTTTCCCTACACGACGCTCTTCCGATCT-
NNNNNNXXXXXXACGGCAGGGTCAGGGTTCTGGATAT
SP1-6N-I-X-βRC1 ACACTCTTTCCCTACACGACGCTCTTCCGATCT-
NNNNNNXXXXXXGGTGGGAACACC(G)TTG(T)TT-
CAGGTCCTC
P5-SP1 AATGATACGGCGACCACCGAGATCTACACTCTTT-
CCCTACACGACGCTCTTCC
P7-LX CAAGCAGAAGACGGCATACGAGATXXXXXXGTGA-
CTGGAGTTCAGACGTGTGCTCTTCCGATC
SP1-IX-12N-βRC1.1 ACACTCTTTCCCTACACGACGCTCTTCCGATCT-
XXXXXXNNNNTNNNNTNNNGGTGGGAACACCTT-
GTTCAGGTCCTC
SP1-12N-IX-βRC1.1 ACACTCTTTCCCTACACGACGCTCTTCCGATCT-
NNNNTNNNNTNNNNXXXXXXGGTGGGAACACCT-
TGTTCAGGTCCTC
Table 2.1: Sequences of primers used in protocols A and B, where X represents a variable but
known nucleotide (e.g. for sample indexing) and N represents a random unknown
nucleotide (for molecule barcoding)
the set of different barcodes associated with the same DCR is considered. Barcodes
that are similar and are observed in the context of the same DCR are considered to be
derived from the same initial molecule and are therefore aggregated. The size of the
set of distinct barcodes found in the context of the same DCR provides us with a mea-
sure of the number of initial copies of that T cell receptor present in our sample (the
clone size). For this study, we additionally count the number of copies of each barcode-
DCR combination (the barcode family size) to provide us with information about the
amplification of the initial molecules.
The structure of the available barcode pool is inferred from the distribution of the
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number of times each barcode is found to have labelled a different cDNA molecule
(barcode-labelling events) across all experiments in this study. The barcode-labelling
events data are fitted by various zero-truncated mixed Poisson models using custom
functions (Appendix A), minimised using the Optimise function of SciPy in Python.
The parameters of the fitted models are used to infer the structure of the pool of avail-
able barcodes.
From the healthy volunteer PBMC samples, a median of 688,001 (minimum 386,904,
maximum 1,041,485) sequence reads contain an identifiable TCR, and after clustering
by bacodes this is reduced to a median of 20,700 (minimum 9,770, maximum 50,253)
total initial molecules that are observed in the sequencer output. There are a median of
13,629 (minimum 7,134, maximum 30,614) distinct TCRβ s in these samples.
2.2.3 PCR simulator
Simulation of labelling, amplification and sequencing of samples of molecules is per-
formed with functions written in Python which are available in Appendix B. Briefly, at
each cycle a molecule has a chance to successfully replicate. The probability of suc-
cessful replication is determined by the PCR model chosen. If replication is successful,
nucleotide error is incorporated at a given rate by choosing at random whether a given
position in the sequence contains error and if so which nucleotide is incorporated in-
correctly. Molecules to be sequenced are selected at random from the amplified pool
and sequencing error is incorporated into these molecules similarly.
In this simulation, PCR is treated as a type of branching process. A general branching
process models a population where each individual produces a number (0,1,2, . . .) of
offspring after each generation. Each element of the population behaves identically, that
is, the probability of producing a given number of offspring is distributed identically for
all elements in each generation. For PCR, where a molecule of DNA can be replicated,
degraded or neither in each thermo-cycle we have the number of possible offspring
from each molecule of DNA being 0, 1 or 2 after each discrete generation of a fixed
time (i.e. the cycle time) for all molecules. A discussion of branching processes in the
context of PCR can be found in [75]. In the work presented in this chapter, a number
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of variations of the PCR simulator are used. In the most basic model implementation,
the number of descendents from a molecule in one cycle is equal to 2 with probability
p and is equal to 1 with probability 1− p. p is referred to as the efficiency of the
PCR reaction, which remains constant in the basic model across cycles and between
molecules. In other implementations of the model, described in the results section,
molecule degradation is possible (allowing for 0 offspring) or the efficiency is non-
constant in time. Additionally, we implement a model where the efficiency for each
molecule is selected from a distribution, either before the start of the PCR reaction and
inherited from ancestor to descendant molecule (creating a separate branching process
for each of the initial target molecules), or at each cycle for each molecule (disrupting
the property of branching processes that each item in the population behaves in an
identically distributed fashion).
2.3 Results
2.3.1 Heterogeneous amplification efficiency demonstrated by
unique molecular barcoding of cDNA molecules.
We reverse transcribed a sample of TCR RNA from peripheral blood T cells and then
ligated a primer that contained a unique barcode followed by a sequence corresponding
to the Illumina SP2 sequencing primer (Protocol A). The individually tagged mixtures
of different TCRα and TCRβ chains were amplified using constant region 3’ primers
and a 5’ primer homologous to the Illumina SP2 sequence on the ligated oligonu-
cleotide (Figure 2.1a, top). The resulting amplified PCR reaction was diluted and
sequenced using the standard Illumina protocol (illustrated diagrammatically in Fig-
ure 2.1b). The number of times each barcode was present in the sequence data was
then counted. We refer to all sequences that have an identical barcode as a barcode
family, and refer to the number of molecules present with this barcode as a barcode
family size. Although each cDNA molecule was ligated to a different barcode, and
the starting frequency of each barcode should then be uniform and independent of the
clone size of the TCR sequence with which it was associated, the observed distribution
of barcode family sizes in a polyclonal sample was very heterogeneous (Figure 2.2a,
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top). Thus, while the majority of barcode families were of size one, some barcodes
occurred over 100 times. A similar pattern was observed for TCRα and TCRβ se-
quences, indicating that the heterogeneity was not some special feature of the sequence
being amplified. We repeated this analysis on different polyclonal samples, sequenced
at different depths (Figure 2.2a, middle) and with different numbers of observed bar-
codes (and therefore different numbers of initial target molecules) carried through the
protocol (Figure 2.2a, bottom). Extensive heterogeneity, varying over two orders of
magnitude, was observed in each case. Without barcoding, this heterogeneity would
have a substantial impact on analysis of both the diversity and the structure of the TCR
repertoire (Figure A.2).
Figure 2.1: Schematic of the PCR amplification study
(a) Schematic of the target TCR molecule in Protocols A and B showing the posi-
tion of the barcode for molecular identification and the PCR priming sites. In the T
cell receptor portion of the molecule, V, D, J and C refer to the Variable, Diversity
(β chain only), Joining and Constant regions of the TCR α or β chains (not to
scale). The two alternative possible positions for the barcodes in protocol B(i) and
B(ii) are shown in brackets. The Illumina sequencing primers, indices to allow for
multiplexing of samples, and the Illumina adaptor sequences are not shown.
(b) Schematic of experimental and computational protocol used to sequence and
analyse TCRs from isolated RNA. Barcodes (represented here by lower case let-
ters) are included in each TCR molecule together with a known sequence (SP2).
PCR is then performed to amplify the sample. The amplified pool of molecules is
diluted and introduced to the sequencer, where a sample of molecules will adhere to
the flow cell and be sequenced. Repertoire analysis is performed on the sequencing
data, with the barcodes allowing correction of biased PCR amplification as well as
correction of sequencing errors.
One possible explanation for the observed distribution was the heterogeneous template
2.3. Results 54
mixture of cDNAs due to the diversity of the TCR repertoire. Although the primers
and the primer binding regions were the same for all amplified molecules, the in-
tervening sequences were heterogeneous since they represented many different TCR
sequences. Thus, heterogeneous amplification could reflect differences in target repli-
cation by polymerase. In order to simplify the experimental model, and limit the het-
erogeneity arising from using a complex pool of substrate molecules (a natural TCR
repertoire), we labelled and amplified a TCR sequence (α and β chain) from a human
T cell clone, KT2, which expresses only one T cell receptor. As predicted, the vast ma-
jority of sequences from these samples were identical (Figure A.1). To our surprise the
distribution of barcode frequencies was still just as heterogeneous (Figure 2.2b, top).
Thus even under conditions where we were amplifying a single target (namely the KT2
TCR α or β chain), and primer and reaction conditions were identical for all amplified
molecules, we still observed a difference of two orders of magnitude in the number of
molecules derived from single starting template cDNA molecules.
We considered two further possible sources of heterogeneity which could potentially
contribute to the observed range of barcode family sizes. The first was the single-
stranded DNA ligation step used in Protocol A (Figure 2.1a, top). Although this allows
a single primer to be used for a heterogeneous mixture of DNAs and avoids the need for
complex primer multiplexing, it creates a potential for heterogeneity at the end of the
cDNA template molecule as a result of incomplete reverse transcription of the RNA. A
second possible cause of heterogeneity are the barcodes themselves. In particular Pan
et al [116] have shown that the basepairs immediately adjacent to the PCR primer can
have a small effect on amplification efficiency.
In order to address the first issue, we performed a further PCR using a fixed primer
within the V region of the KT2 TCRβ chain instead of the single stranded ligation step
(Protocol B, Figure 2.1a, bottom). The unique barcodes were introduced during the
reverse transcription step, and were placed either adjacent to the primer as previously
(Protocol B(i)), or separated from the primer by a six base pair index region (Protocol
B(ii)). The results of these further sets of PCR are shown in Figure 2.2b (middle and
bottom panels). The omission of the ligation step (Protocol B) decreased the amount of
heterogeneity, although differences in amplification of greater than 10 fold remained.
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However, Protocol B is not ideal for TCR repertoire sequencing studies because the
use of V-gene specific primers introduces additional bias as well as possibly preventing
non-canonical rearrangements from being observed.
Figure 2.2: Long-tailed distribution of barcode family sizes observed.
(a) The distribution of observed barcode family size (the number of sequence
reads occurring in the sequencer output that originate from the same initial tar-
get molecule in the sample) in polyclonal TCR sequence data (Protocol A) from
healthy volunteer T cells. Upper: TCR α chain (solid line) and β chain (dotted
line) data. Middle: TCR repertoires sequenced at different depths. Bottom: TCR
repertoires with different numbers of observed barcodes, representing the number
of initial molecules.
(b) The observed barcode family size distribution observed in TCR sequence data
from a sample of RNA isolated from a T cell clone (KT2, responding to tetanus
toxoid [40]). Upper: TCR α chain (solid line) and β chain (dashed line) from
protocol A. Middle: TCR β chain data from protocol B, using the oligonucleotide
with 6bp spacer between the sequencing primer and the barcode. Bottom: TCR
β chain data from protocol B, using the oligonucleotide with the barcode directly
next to the sequencing primer.)
2.3.2 Barcode family size is not dependent on barcode sequence,
barcode clash or non-uniform barcode primer frequencies
The heterogeneous amplification observed could hypothetically be caused by the bar-
code itself since the polymerase must amplify the barcode in each cycle. To investigate
this, we first considered whether barcodes that appear more amplified have a tendency
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to contain more or fewer G or C nucleotides (Figure 2.3a). However, there was no ob-
vious relationship between the frequency of particular barcodes and their GC content.
Furthermore, the frequency rank of the same barcode in any two different sequence runs
was uncorrelated (Figure 2.3b). A high barcode family size did not therefore appear to
be the result of a particular barcode sequence or sequence motif. Additionally, to ac-
count for the fact that the amplification effect might be to do with relative, rather than
absolute, barcode ‘fitness’, we considered all pairs of barcodes that are both observed in
any pair of experiments. If the amplification was determined by the barcode we might
expect, for example, that if barcode A is larger than barcode B in experiment 1 then it
would also be larger in experiment 2. We found no correlation between the frequen-
cies of any two barcodes that appear together in a pair of experiments (Figure 2.3c),
implying that the barcode sequence itself does not determine the efficiency with which
each molecule is amplified. We also examined whether the observed barcode fam-
ily size might be an artefact introduced during the sequencing reactions, perhaps by
heterogeneity in bridge PCR on the flow cell. If this were the case we might expect
that molecules from large barcode families are located in close proximity on the flow
cell. However there was no observable relationship between barcode family size and
location of molecules on the flow cell (one representative frame shown in Figure 2.3d).
The barcodes used in these experiments should theoretically contain randomly cho-
sen nucleotides at each of the 12 positions, giving a total of 412 ≈ 1.7× 107 possi-
ble barcodes, each appearing an equal number of times. In practice, the methods of
oligonucleotide synthesis likely result in slightly different incorporation efficiencies of
different nucleotides at each position [54]. In addition, the number of target molecules
barcoded in our T cell samples is often within an order of magnitude of the number of
available barcodes, resulting in a significant probability that the same barcode is used
more than once (‘barcode clash’) (Figure 2.4a). In order to assess the impact that this
barcode clash might have on the observed barcode family sizes, we first simulated bar-
coding molecules from a large, uniformly distributed pool of available barcodes and
measured the proportion of molecules that were uniquely barcoded (Figure 2.4b). This
value depends on the ratio of the number of available barcodes (size of the barcode
pool) to the number of molecules to be barcoded. In these simulations we also mea-
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Figure 2.3: Final barcode family size is unrelated to proporties of the sequence being am-
plified
(a) Distribution of GC content of the 12-nucleotide random barcodes by barcode
family size percentile. Data from a sequence run of healthy volunteer PBMC TCRs.
(b) The correlation between the barcode family size ranking in any pair of runs for
those barcodes that occur in more than one of the eight monoclonal KT2 TCR
sequencing runs (Protocol A) in this study (R-squared < 0.0003). Ranking is as-
cending, and barcodes that have the same family size in a run are given the same
ranking. There is no gap introduced in rankings when more than one barcode
occupies a particular ranking, as such for small barcode family sizes ranking is
equivalent to barcode family size.
(c) For those pairs of barcodes that appear together in any pair of the eight KT2
sequencing runs (Protocol A) in this study, the relationship between the difference
in barcode family sizes in one run and in the other. R-squared < 0.0004.
(d) Position of TCR molecules on the flowcell, coloured by barcode family size
percentile. Representative example of a single frame from one flow cell from a
sequencing run in this study.
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sure the maximum observed barcode clash size (Figure 2.4c), which in contrast also
depends on the absolute number of available barcodes and molecules to be barcoded.
These simulations show that in our protocol (barcoding in the order of 106 molecules
with 107 available barcodes) around 90% of molecules get a unique barcode and the
maximum clash size is predicted to be below 4. Thus barcode clash is unable to account
for the range in barcode family sizes we observe in our data.
Figure 2.4: Barcode clashes do not explain the observed PCR amplification heterogeneity
(a) The probability that no two molecules receive the same label (barcode clash)
when initial molecules are labelled with a pool of random nucleotide barcodes of
the indicated length. The dotted lines indicate the number of molecules that can be
labelled with a 50% chance of no barcode clash occurring.
(b) The proportion of initial molecules that receive a unique barcode when bar-
coding is simulated with the indicated number of available barcodes, uniformly
distributed. The number of molecules to be barcoded is expressed as a proportion
of the number of available barcodes. Data shown is the mean and standard devia-
tion of 50 repeated simulations.
(c) The maximum number of initial molecules that receive the same barcode when
barcoding is simulated with the indicated number of available barcodes that are
uniformly distributed. The number of molecules being barcoded is indicated by
colour, expressed as a proportion of the number of available barcodes. Data shown
is the mean and standard deviation of 50 repeated simulations.
It is likely that the pool of barcodes we have available for labelling is not exactly uni-
formly distributed, which could lead to increased barcode clash. We simulated the
barcoding, amplification and sequencing protocol using normally or lognormally dis-
tributed barcode frequency distributions, but this had little effect on the observed bar-
code family size distributions when compared to uniquely barcoding every molecule
or to the expected distribution if every initial molecule was represented equally in the
post-PCR amplified pool (Figure 2.5a). We also derived the empirical distribution of
barcodes in our initial oligonucleotide pool (Appendix A) and Figure A.3) and simula-
tions using this distribution do not show a barcode family size distribution deviating far
from the sampling distribution expected from a uniformly distributed amplified pool
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(Figure 2.5b). The output of the barcoding, amplification and sequencing pipeline is
therefore robust to the likely occurrence of barcode clash and non-uniform barcode
frequencies.
Figure 2.5: Non-uniform barcode availability does not explain observed PCR amplifica-
tion heterogeneity
(a) The observed family size distribution after simulation of barcoding 250,000
initial molecules from uniformly or non-uniformly distributed pools of 500,000
available barcodes, 10 cycles of PCR at efficiency 0.5 and sequencing 300,000
molecules from the amplified pool. The distribution of available barcodes for
the non-uniform simulations is shown in the inset (green: normal distribution (re-
stricted to values > 0), orange: lognormal distribution). Data shown are the mean
and standard deviation of 10 repeated simulations. The grey dotted line shows
the barcode family size distribution that would be expected if the molecules to be
sequenced were drawn from a uniformly distributed amplified pool, in which all
molecules had been uniquely barcoded and amplified equally.
(b) The observed barcode family size distribution when the indicated numbers of
initial molecules are barcoded from a pool of 412 potential barcodes with barcode
availability distributed as predicted from empirical labelling events observed (de-
tails in Appendix A with the empirical distribution shown in Figure A.3). PCR
cycles (25 cycles, 0.75 efficiency) are simulated on the labelled molecules, and
samples of size 100,000 are selected from the amplified pool. The solid line repre-
sents the mean of 10 repeated simulations. The dashed line shows the expected dis-
tribution had the sample been drawn from a uniformly distributed amplified pool,
in which every initial molecule had been barcoded uniquely and amplified by the
same amount.
2.3.3 Inherited differences in PCR efficiency are necessary to ex-
plain the observed diversity in barcode family size.
The experimental pipeline involves amplification followed by subsampling for se-
quencing, which can introduce Poisson non-uniformity even when the amplified pool
of barcoded molecules is uniform. Furthermore, PCR efficiencies of less than 100%
can introduce non-uniformity resulting from the inherent stochasticity of the PCR pro-
cess [117]. In order to examine how variable efficiency and sampling could affect
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observed barcode family size distributions a PCR simulator was developed in which
molecules are barcoded, amplified and then sampled in silico. The simulator is out-
lined schematically in Figure 2.6a. In its most basic implementation (modelling PCR
as a straightforward branching process with no error) the simulator can perform a full
simulation (labelling initial molecules, performing 15 PCR cycles with efficiency 0.8,
sampling and sequencing including sequencing error) on 105 initial molecules in ap-
proximately 12 seconds on a standard specification laptop (Figure 2.6b). Introducing
PCR error substantially increases the simulation time, although altering the error rate
further does not alter simulation time. Use of parallelisation and cluster research com-
puting platforms would make PCR simulation including error of large numbers of initial
molecules feasible.
The simulated barcode distributions (the number of molecules present after amplifica-
tion that are derived from each initial molecule) at different efficiencies are shown in
Figure 2.6c. The introduction of less than 100% efficiency introduces some barcode
family size heterogeneity (in the amplified pool, before sampling for sequencing) as
described previously [117]. This variation arises because, in every replication cycle,
any individual molecule may or may not replicate with a probability determined by the
overall efficiency. The substantial shoulder observed in the distributions correspond to
molecules which fail to be replicated in the first cycle of PCR and hence are present at
half the average number of copies. However, the heterogeneity caused by low efficien-
cies is averaged out over many molecules and the majority of barcode family sizes are
within a factor of two of each other at the end of the PCR reaction.
When a sample of molecules is drawn at random from the amplified pool (to simulate
the process by which molecules from the amplified sample are diluted and introduced
to the flow cell to anneal to complementary capture oligonucleotides), the observed bar-
code family size is further diversified depending on the ratio of number of sequenced
molecules to number of initial molecules (the ‘sample ratio’, Figure 2.7a). These ob-
served barcode family size distributions follow a Poisson distribution (as an approxima-
tion to a binomial distribution), scaled to account for the fact that we cannot count those
barcodes with an observed family size of zero (a zero-truncated Poisson). The Poisson
distribution is the expected distribution when sampling from an amplified pool in which
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Figure 2.6: PCR simulator software
(a) Schematic of the PCR simulator software used in this study. The software in-
cludes adding barcodes to molecules (labelling), PCR amplification with a specified
number of cycles, efficiency model and error rate, and sampling and sequencing
from the amplified pool.
(b) Time taken to perform a full simulation, which includes initialisation, labelling
initial molecules, PCR cycles (using a standard branching process model), sam-
pling from the amplified pool and sequencing. Simulations are performed with
the indicated PCR error rate (per base per cycle) and the given number of initial
template molecules. Simulations consist of 15 cycles of PCR with efficiency 0.8,
a sample size equal to the number of initial molecules being chosen from the am-
plified pool and sequencing with error rate 10−4. Data shown is the mean of 5
repeated simulations at each set of conditions, as measured on a 2.8 GHz Intel
Core i7 MacBook Pro.
(c) The distribution of the number of copies of each of 100,000 initial target
molecules after 25 cycles of PCR at efficiencies of 0.85 (red), 0.9 (blue) or 0.95
(green).
each barcode is present the same number of times. If the PCR process in our experi-
ments behaved as a straightforward branching process we would expect our experimen-
tal observed barcode family size distributions to also follow a zero-truncated Poisson
distribution, with the Poisson parameter providing information about how many initial
molecules there were in our sample. However, it can be seen that our data from Protocol
A does not belong to the same distribution family as the simulated distributions (Fig-
ure 2.7a), suggesting that these samples were not drawn from a uniformly distributed
post-PCR pool and that neither heterogeneity resulting from a low PCR efficiency or
from the sampling process can account for the broad distribution of barcode family
sizes observed.
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Figure 2.7: Barcode family size distributions with fixed amplification efficiency
(a) The distribution of observed barcode family sizes (coloured lines) after simulat-
ing PCR cycles (25 cycles at 0.9 efficiency) on 100,000 initial molecules and then
sampling from the amplified pool to select those molecules that are observed in the
sequencer output. The number of molecules sequenced is expressed as a propor-
tion (the ‘sample ratio’) of the number of initial molecules (100,000). The solid
coloured lines are the mean of 5 repeated simulations, and the dashed coloured
lines are the expected distribution (a zero truncated Poisson with parameter equal
to the sample ratio) if the sample was drawn from a uniformly distributed pool
(which would occur if every initial molecule was uniquely barcoded and amplified
identically). The black solid line is a representative example of the barcode family
size distribution observed in TCR sequencing data from healthy volunteer PBMC.
We therefore tried to formulate variations of the branching process model of PCR that
could explain the broad barcode family size distribution observed. The starting point
is a standard branching process model of PCR (‘Model 1’) where the efficiency of the
PCR (between 0 and 1) refers to the probability that a molecule will replicate suc-
cessfully in a cycle. Using this model, we simulate PCR and sampling, and show that
the resulting barcode family size distributions do not diverge significantly from the
expected Poisson distribution regardless of the efficiency used (Figure 2.8a). Next, a
target degradation model (‘Model 2’) was used. Model 2 is set up as for Model 1, ex-
cept that when a molecule fails to duplicate in a cycle there is a chance that it instead
degrades and is no longer available to be amplified in later cycles of the PCR. Again,
simulation of this model does not reproduce the large deviation from the a Poisson
distribution that is seen in our data (Figure A.4a).
Next, we introduce competition for resource, which affects the success rate of dupli-
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cation of molecules. This abstract ‘resource’ covers, for example, the availability of
dNTPs and primer in the PCR mixture, and the ability of the enzyme to process the
molecules inside the time frame given in the PCR protocol. The first resource compe-
tition model (‘Model 3’) is one in which there is a fixed, constant amount of resource
available and the probability that a molecule successfully replicates in a cycle is given
by the available resource divided by the number of molecules present at the start of
the cycle. As such, the efficiency of the reaction decreases through the cycles once the
number of molecules present exceeds the capacity of the available resource to process
all those molecules in one cycle. Figure 2.8b shows that this model cannot reproduce
the spread of barcode family sizes we observe in the data. An alternative resource com-
petition model (‘Model 4’) involves degradation of resource as it is used, at a given
degradation rate. This model is also unable to account for our observed barcode family
size distributions (Figure A.4b).
Instead of a constant efficiency across all molecules and all cycles, we imagine that in
a given cycle some molecules are able to replicate more efficiently than others. For
instance this variation may depend on the position of the molecule within the sam-
ple (which may affect e.g. proximity to primer) or the conformation of the molecule
(which may affect ability of the primer to bind). We introduce a variable efficiency
model (‘Model 5’), where the probability that a given molecule will replicate in a given
cycle is chosen from a defined distribution. Model 5 is implemented by selecting effi-
ciencies from a normal distribution with a variety of parameters (Figure 2.8c). A low
mean efficiency and a large standard deviation produces the most divergence from the
expected barcode family size distribution, and is able to account for the majority of the
spread seen in barcode family size observed in the KT2 data from Protocol B. How-
ever, none of the parameters investigated was able to reproduce the observed spread of
family sizes observed in polyclonal or monoclonal data from Protocol A.
We adapted Model 5 to include the constraint that once an efficiency is chosen for a
molecule in cycle 1 this same efficiency is inherited by all molecules produced from
this initial molecule (‘Model 6’). Simulation of PCR and sampling using Model 6 was
performed, and showed that inherited efficiencies could produce a substantial amount
of spread in the barcode family size distribution when the efficiency distribution has a
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low mean and a relatively large standard deviation (Figure 2.8d). The observed barcode
family size distribution from Model 6 can be seen to be broadly comparable to that
seen in our experimental data (from Protocol A) for these parameters. In contrast,
the distribution which arises from Model 5 is sufficient to account for most of the
heterogeneity observed when using a fixed primer instead of ligating a primer to the
end of the cDNA (Protocol B).
2.4 Discussion
PCR is a fundamental and ubiquitous tool of molecular biology laboratories. The com-
bination of PCR and HTS, in particular, has driven an explosion in DNA sequence
acquisition. In many of these applications, for example RNA-seq and lymphocyte anti-
gen receptor repertoire studies, the quantification of transcripts is critical, since the
analysis is often based on counts of specific sequences. The avoidance of PCR bias is
therefore critical and much effort has been expended on trying to control and mitigate
bias. In this work the consistency of PCR amplification is examined, using molecular
barcodes to follow amplification of single molecules. The distribution of the number of
copies of an initial molecule observed in sequencer output is found to vary over a wide
range, even when primers, target sequence and bulk PCR conditions are kept constant,
and in a manner which appears to be independent of barcode sequences.
The differential binding properties of different primers, and secondary structure within
target sequences are well-established causes of PCR biases. Multiplex PCRs, for ex-
ample, frequently show different efficiencies for different primer/target combinations.
This bias is a known confounder of T cell repertoire studies, for example. As a result,
our lab and others [133] have developed techniques that use various types of 5’ RACE,
and thus can amplify with amplicon-independent primers. However, the variation in
target sequence to be amplified is obviously a variable that cannot be avoided. In this
study we therefore consider the extent to which amplification bias can be attributed
to sequence variability. We compare the amplification of heterogeneous mixtures of
α or β T cell receptor chains (typically containing > 104 different sequences) with
amplification of a monoclonal T cell receptor from a T cell clone (this clone in fact
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Figure 2.8: Barcode family size distributions under different models of PCR heterogene-
ity
Observed barcode family size distributions observed under different models of PCR
duplication. Simulations performed with 10,000 initial molecules, 25 cycles of
PCR (with no error) and sequencing of 10,000 molecules selected from the ampli-
fied pool. Simulations were repeated 10 times and the mean and standard devia-
tion are shown. The dotted lines represent the expected distribution if every initial
molecule is barcoded uniquely and represented equally in the amplified pool. Grey
and black lines represent the distributions observed experimentally in the indicated
experiments. Models described in the text but not displayed here can be found in
Figure A.4.
(a) Model 1: Standard branching process of PCR, with the indicated efficiencies.
The efficiency is the probability that a given molecule will duplicate in a given cy-
cle.
(b) Model 3: Model of PCR where the duplication efficiency depends on competi-
tion between target molecules for a constant level of resource, given as a multiple
of the number of initial molecules.
(c) Model 5: Variable efficiency model of PCR, where the probability of a given
molecule replicating in a given cycles is selected from a normal distribution (re-
stricted to [0, 1]) with the indicated parameters (mean and standard deviation).
(d) Model 6: Inherited efficiency model of PCR, where the probability of repli-
cation in a given cycle is identical for all molecules derived from the same initial
molecule. The efficiencies for the initial molecules are selected from a normal
distribution with the indicated parameters (mean and standard deviation). 25 PCR
cycles are simulated on 10,000 initial molecules, and then a sample is drawn from
the amplified pool at a multiple of 2.5 times the number of initial molecules. The
observed barcode family size distribution shown is the mean of 10 repeated simu-
lations.
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expresses more than one TCR chain, a common feature of T cells [36]). Unexpect-
edly, PCR amplification efficiency (measured by the number of observed molecules
derived from a single ancestor) varies broadly, both for the polyclonal and monoclonal
populations. Indeed the extent of variability is very similar, suggesting that the actual
sequence of the TCR variable region is not the major cause of different amplification
rates. Our results do not, of course, imply that all sequences will be amplified equally.
Indeed the length of the target and the GC content are well known to influence PCR
efficiency [4]. Rather our results suggest that even when amplifying relatively small
amplicons (<1KB) whose sequences are all rather comparable, substantial variation
remains. Some degree of heterogenous amplification of T and B cell receptors has
been observed previously [132, 154, 133], although these studies have not focused on
analysis of the distribution of the variation, or its relationship to inherent stochasticity
of the PCR process.
These data suggest that the sequence of the ligated barcodes is not the cause of the
observed differential amplification, since barcode family size is not correlated between
experiments. Although previous studies have shown a small effect of sequence variabil-
ity adjacent to the PCR primer on efficiency [116], we have directly compared placing
the random barcode sequences immediately next to the primer, or at a distance of six
base pairs, and did not observe any significant difference in heterogeneity. Indeed it
seemed a priori unlikely that if the variation cannot be attributed to differences be-
tween V region sequences it could be caused by 12 base pair barcodes. Additionally,
analysis of the structure of the pool of the random barcodes that are used to label the
initial molecules suggests that while there is potential for barcode ‘clashes’ (where the
same barcode sequence is used to label more than one initial molecule), these are not
large enough or prevalent enough to be the reason for the large barcode family sizes
observed. We do, however, present some theoretical and simulation results that can
help to guide the size of barcode pool size in different scenarios. These results suggest
that 12 base pair barcodes (providing in the order of 107 different barcode sequences)
are sufficient to label samples of DNA targets in the order of 106 molecules.
The bulk conditions in all the PCR reactions obviously cannot account for the intra-
experimental variation. However, as discussed previously, PCR is by its nature a
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stochastic process since at each cycle a molecule will be either replicated or not repli-
cated with some probability p, which will be less than 1 for all reactions in which
replication efficiency is not 100%. For example, the PCR efficiencies in our model
system (which we have measured using qPCR on plasmid dilutions) are typically in
the order of 80% - 90%. Furthermore, it is possible that there is local heterogeneity in
the PCR vessel itself: for example temperature gradients, or heterogeneity introduced
by phase shifts at the plastic/liquid or liquid/gas surfaces. We therefore examined the
implications of different models in detail using a branching process PCR simulator.
Simulation demonstrated clearly that lower efficiencies, a range of efficiencies, compe-
tition and resource limitation can all introduce some variation in the predicted output
of the PCR for different molecules. As might be predicted, the extent of variation in-
creases with cycle number, and with low and more variable efficiencies. The goal of
minimising the number of cycles, and maximising efficiency does therefore lower over-
all expected variance of product molecular counts. However, the extent of the variance
due to these properties is limited and does not explain our observed results. The only
model we considered that was able to produce substantial variance in output compara-
ble to that observed in Protocol A (Figures 2.2a and b, top) is an inherited efficiency
model, where all molecules produced from an initial molecule retain the same effi-
ciency though all cycles. This result, too, is related to well known evolutionary theory
where significant divergence can only occur when selection operates on the inherited
properties of the individual. A clue to the cause of the observed heterogeneity is pro-
vided by the observation that it is reduced, by omitting the single stranded ligation
step, and instead using a fixed primer in the V region (Figure 2.2b, middle and bottom
panels). Since the length of the cDNA molecules produced may be variable, due to
the nature of the target molecules, variation in length or composition of the cDNA at
the 3’ end may be sufficient to significantly alter PCR amplification efficiency. Thus
for TCR or BCR repertoire sequence, both multiplex PCR and RACE protocols have
the potential to introduce substantial heterogeneity in amplification efficiency, which
will materially affect quantitative features of the observed repertoire, substantially in-
creasing the range of clone sizes observed (Figure A.2). Barcoding therefore becomes
essential for accurate quantification of transcript number.
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In conclusion, we consider the implications of our findings for the community rou-
tinely using PCR for quantitative analysis of RNA or DNA populations. The major
lesson is that molecular barcoding provides an essential tool that can mitigate for the
effects of PCR heterogeneity. This is especially important for studies whose primary
output is the comparative quantification of many diverse nucleotide fragments within a
mixture, such as repertoire analysis. In situations where single molecule barcoding is
difficult, or not practical, every effort needs to be taken to maximise the efficiency of the
PCR reactions and minimise the number of cycles. In the longer term, single molecule
amplification-free DNA sequencers, which are currently in development, may remove
the requirement for a PCR amplification step altogether. In the meantime, it contin-
ues to be important to appreciate the inherent stochasticity of the PCR process, and its
possible effects on quantitative aspects of molecular biology.
Chapter 3
Immune tolerance maintained by
cooperative interactions between T
cells and antigen presenting cells
shapes a diverse TCR repertoire
The study in this chapter was undertaken in conjuction with Dr Chris Watkins and is published
in [17].
The T cell population in an individual needs to avoid harmful activation by self peptides
while maintaining the ability to respond to an unknown set of foreign peptides. This
property is acquired by a combination of thymic and extra-thymic mechanisms. We
extend current models for the development of self/non-self discrimination to consider
the acquisition of self-tolerance as an emergent system level property of the overall T
cell receptor repertoire. We propose one way in which tolerance can be established
is at the level of the antigen presenting cell/T cell cluster, which facilitates and inte-
grates cooperative interactions between T cells of different specificities. The threshold
for self-reactivity is therefore imposed at a population level, and not at the level of the
individual T cell/antigen encounter. Mathematically, the model can be formulated as
a linear programming optimisation problem that can be implemented as a multiplica-
tive update algorithm, which shows a rapid convergence to a stable state. The model
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constrains self-reactivity within a predefined threshold, but maintains the diversity and
cross-reactivity which are key characteristics of human T cell immunity. We show fur-
ther that the size of individual clones in the model repertoire remains heterogeneous,
and that new clones can establish themselves even when the repertoire has stabilised.
Our study combines the salient features of the ‘danger’ model of self/non-self discrim-
ination with the concepts of quorum sensing, and extends repertoire generation models
to encompass the establishment of tolerance. Furthermore, the dynamic and continuous
repertoire reshaping which underlies tolerance in this model suggests opportunities for
therapeutic intervention to achieve long-term tolerance following transplantation.
3.1 Introduction
Vertebrate immune system recognition uses antigen receptors produced by stochastic
and hence unpredictable molecular recombination events. In this study we propose
a new explanation for how the T cell compartment of the immune system may use a
stochastic set of receptors, whose specificities are not predetermined, to develop a use-
ful repertoire. The requirements we impose are that the repertoire of antigen receptors
should cover the set of non-self antigens as comprehensively as possible, in order to
provide robust protection against any potential exposure to infectious pathogens. At
the same time the system must remain tolerant to the set of self antigens and generally
avoid autoimmunity. The fundamental aspect of our hypothesis is that self/non-self dis-
crimination is an emergent property of the combined population of T cells, and cannot
be linked by a one-to-one mapping to the individual binding strength spectrum of in-
dividual T cells and their receptors. The model we propose has important implications
in the context of transplantation, since it suggests that the repertoire can be re-learnt
throughout life, thus allowing an opportunity for long term acquisition of graft toler-
ance.
The clonal theory of immune responses, and its corollary, clonal deletion as a mecha-
nism leading to self-tolerance, were developed primarily in the context of antibody and
B cells [27]. The theory was subsequently extended to T cells, and self-tolerance was
proposed to result from clonal deletion in the thymus [72]. Indeed thymic tolerance
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induction remains a major feature of current models of T cell function. Nevertheless, a
number of features of T cell recognition distinguish it from antibody recognition, and
have suggested that repertoire selection may obey a modified form of rules.
A first important difference lies in the average affinity of T cell receptor (TCR) for its
antigen. At least for the subset of αβ receptor carrying T cells (which is the main focus
of this study), which recognise complexes of peptide presented by MHC (pMHC), this
affinity is in the order of 10−5M to 10−6M, which is some three orders of magnitude
less than that for antibody/antigen recognition [82]. In addition, only a small proportion
of the TCR binding surface recognises the antigenic target peptide itself, while the rest
binds to the host MHC. A consequence of these characteristics is that the individual
TCRs exhibit a great deal of promiscuity and cross-reactivity: many TCRs bind to the
same peptide, while many peptides can be bound by the same TCR [159, 19]. The
combination of low individual affinities, and a large degree of cross-reactivity has led
to the development of an elegant cooperative model of T cell recognition, the ‘quorum-
sensing model’ [28], which proposes that functional T cell responses are the product
of cooperative interactions between T cells with different receptors. The decision of
whether to initiate an immune response to a particular presented peptide is made at
the population level, rather being determined solely at the level of an individual T
cell/antigen presenting cell (‘APC’) encounter.
Another fundamental distinction between T and B cells is that naive T cells require ac-
tivation by antigen presented on the surface of an APC, usually a dendritic cell (‘DC’).
The APC provides the T cells with a high density array of MHC molecules carry-
ing a diverse set of self and non-self peptides, but also a set of additional membrane
bound and secreted signals which are necessary for productive T cell activation [134].
Dendritic cells can interact simultaneously and consecutively with many different T
cells (10-20 cells at any one time, and in the order of 200-400 per hour) forming an
APC/T cell cluster [103, 14, 146]. Such a cluster is an obvious candidate for the site of
‘quorum-sensing’, with the cluster, rather than the individual cell, acting as the unit of
response. Cooperative behaviour between cells within a cluster have been documented
by our group and by others [121, 35]. However, the antigen presenting activity of den-
dritic cells is not a static property. Dendritic cells switch from a ‘resting’ state, to an
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‘active’ state, and this transition is determined to a great extent by signals from innate
immunity [70]. Since resting DCs do not provide the signals necessary for naive T
cell activation, they become the ‘gatekeepers’ of adaptive immunity, and DC activation
becomes a key decision point in whether an antigenic stimulus leads to immune activa-
tion. Resting dendritic cells may not only fail to induce productive T cell activation, but
may actively induce tolerance [96]. Indeed, subsets of immature dendritic cells have
been shown to kill T cells in particular circumstances [166]. The concept of tolerogenic
dendritic cells underlies the influential ‘danger’ model [95, 65], which postulates that
self-tolerance results from the fact that self antigens are generally presented to T cells
in the absence of innate immune responses. Thus self/non-self discrimination, at least
outside the thymus, is determined as much by the dendritic cell and its interaction with
innate immunity as by the T cell compartment itself.
Models for self-tolerance are still dominated by the concept of positive and negative
selection operating on each individual T cell independently. The question of the mech-
anism for setting precise thresholds for positive or negative selection, so as to max-
imise response to non-self but minimise response to self, continue to be much debated
[136, 47] and models have been developed that demonstrate the impact of these thresh-
olds on the T cell response to self peptides [12, 74]. The mechanisms for establishing
self-tolerance outside the thymus are also debated, although ‘natural’ T regulatory cells
seem to play an important role [31, 6].
The very extensive literature on the induction of self-tolerance has generally been dis-
tinct from the smaller corpus of papers which deal specifically with repertoire gener-
ation. A number of models for repertoire generation have been proposed. The key
experimental observations which all models must encompass are the persistently high
diversity of the naive T cell pool [11], the ability for new clones to emerge and establish
themselves in the repertoire [16], and the variable clone size which was an unexpected
feature of the naive repertoire [125]. The majority of previous models, which often have
an ‘ecological’ flavour, focus on clonal competition for a limited pool of presented self-
antigens to drive clonal diversity and clonal size heterogeneity. Competition between
T cells for access to pMHC results in stabilisation of clone sizes when all available
binding sites are occupied [39] and increased diversity as those T cells that are more
3.2. Methods 73
different from others and therefore occupy a niche are favoured [138, 137]. In order to
explain the emergence of new clones, and to prevent the development of a repertoire
dominated by the clones with optimum affinities, a natural death rate of all clones is
often assumed.
In the new model presented in this chapter, we combine repertoire generation and
self/non-self discrimination into a single process. We incorporate aspects of cooper-
ative behaviour (quorum sensing) into the process of naive T cell population reshaping,
and explicitly model a system in which T cell receptors bind many different antigens
with a range of different affinities. The model can be formalised as a linear program-
ming (LP) optimisation problem. It shows a rapid convergence to a stable state, in
which self-reactivity is maintained below a fixed threshold. The model focuses on
the shaping of the T cell repertoire in the absence of immune challenge, and in this
chapter we do not consider the changes to the repertoire following activation in detail.
Instead we investigate the potential of the system to mount an immune response and
introduce measures of the T cell population’s coverage of potential non-self antigens.
We show that despite the restrictions imposed by the linear constraints which ensure
self-tolerance, the repertoire remains diverse, coverage is preserved and the size of in-
dividual clones becomes heterogeneous. The diversity of the constrained repertoire
becomes an important factor when challenge with foreign antigens does occur, and we
find that this model is able to reshape the population to retain both TCR diversity and
the potential to respond to non-self more strongly than self.
3.2 Methods
3.2.1 A simple computational model
We introduce a simple computational model, and then we consider possible variations
of the model and possible underlying mechanisms.
We suppose that the T cell system ‘learns’ in the following way to recognise self, and
to react to self up to but not beyond response thresholds, which are determined by the
APCs (in this study we prefer the more generic term APC, although the most important
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cell type in maintenance of the naive T cell repertoire is probably the dendritic cell).
Each inactive APC carries a set of self-antigens bound to MHC and is continually
‘scanned’ by T cells. The TCR expressed by some of these T cells recognises one of
the presented pMHC complexes on the surface of the APC; T cells scan the surface
of the APC, stop for a period related to the strength of interaction with pMHC and
then release themselves, allowing other cells an opportunity to assay their affinity to
the presented antigens [14]. In this model, we ignore any potential effects of ecological
competition between T cells for pMHC binding sites in order to study the effects of the
quorum sensing behaviour.
We suppose that the APC can detect the strength of the antigen specific binding between
each T cell and the APC, and we further hypothesise that the APC maintains a record of
the total APC/T cell binding, using some (possibly leaky) integration mechanism over
a sliding time window. The APC does not need to ‘know’ which antigen has caused the
T cell to bind, and still less which TCR clonotype the T cell expresses. The strength of
signal in this model could arise from a combination of a strong affinity between pMHC
and a specific TCR, or the presence of high concentrations of a particular pMHC. The
model does not distinguish between these parameters but allocates an overall signal
strength to each T cell/APC encounter.
We suppose that the APCs regulate the numbers of T cells in the following simple way.
If the combined binding signal strength registered within a fixed time period by an
APC exceeds some threshold value, then the APC sends a ‘kill signal’ (either actively
or passively) to each T cell that is bound currently or binds subsequently [166]. These
T cells, or some fraction of them, then die. Since the APC is recording the integrated
signal over a sliding time window, this value will subsequently fall to below the signal
threshold and the APC will then switch off the kill signal. The molecular mechanisms
which could mediate such models are discussed below, but at this stage we focus on the
mathematical properties of such a model.
We implement a simplified version of the model described above. The biological va-
lidity of these assumptions, and the extension of the model to more realistic but more
complex scenarios is discussed later. We suppose that there are N different T cell clono-
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types, with abundances at time t = 0 of x0 = (x01,x
0
2, . . . ,x
0
N). In reality the abundances
would be integer counts, but in this model we treat them as positive real numbers.
We denote the binding strength between a T cell clonotype i and self-peptide MHC
complex (‘spMHC’) k as qik. We consider a model in which each (non-activated) APC
presents a particular combination (or ‘profile’) of spMHCs. The spMHC profile j con-
tains an amount ak j of spMHC k, and we suppose there are M such profiles that T cells
may encounter. The overall binding strength of a cell of clonotype i for APC profile j
is then bi j = ∑k qikak j. Note that when we refer to binding strength we are describing
a quantity that represents the amount of signal that the APC integrates due to the T
cell-APC encounter.
Each T cell may have non-zero binding strength to many spMHC complexes, and each
spMHC complex may bind to many T cells: the matrix of spMHC to T cell binding
strengths Q = (qik) is assumed to be sparse, non-negative, and with multiple positive
entries in each row and column. The matrix of binding strengths of T cells to antigen
profiles, B = (bi j), therefore, is non-negative, and less sparse than Q, because each
antigenic profile contains multiple spMHC complexes. B is non-negative because an
APC cannot present a negative amount of antigen; that is, the ak j are non-negative. Note
that in this implementation we do not consider the T cell to pMHC binding strengths
qik. Instead we generate the T cell to antigen profile binding strengths bi j by sampling
from an assumed distribution, described later.
On these assumptions, the total strength with which all T cells in the population bind
to an APC with spMHC profile j is
r j(x) =∑
i
xibi j (3.1)
where x is the vector of clonotype abundances at time t. Writing b j = (b1 j, . . . ,bN j),
we obtain:
r j(x) = b j ·x (3.2)
We set a threshold binding rate τ above which each APC will issue a kill signal to any
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T cell that is bound; that is, the APC presenting self-peptide profile j issues kill signals
to any T cells bound to it if r j(x)> τ . In principle, τ is a threshold that can be locally
defined by the antigen presenting system: it can depend on the APC microenvironment
or intrinsic antigen presenting parameters such as the MHC haplotypes. In this initial
implementation, we have assumed τ is constant over all APCs. The rate at which T
cell clone i is eliminated by ‘kill’ signals from APCs presenting self-peptide profile j is
proportional to the strength of the binding interaction of each T cell with that spMHC
profile j, such that:
Kill signals for clonotype i from APC type j = η φ(b j ·x− τ j)bi jxi (3.3)
where η is a rate parameter, φ(b j ·x− τ j) is the fraction of all T cells binding to APC
j that receive a kill signal, and xi is the abundance of T cells of type i. Our hypothesis
is that kill-signals are only issued when the rate of binding to APCs is greater than τ;
this hypothesis is expressed in terms of the function φ(z), which is some non-decreasing
function such that 0≤ φ(z)≤ 1 for all real z. φ(z) should be small or zero for z< 0, and
we suppose that φ(z) rises towards 1 rapidly for z≥ 0. The simplest choice for φ would
be the Heaviside function H(z) = 1 if z≥ 0 and H(z) = 0 if z < 0; a more biologically
realistic function would be continuous and differentiable, such as the logistic function
φ(z) = 11+exp(−αz) , for some suitable scale parameter α . The implementation captured
in equation 3.3 further assumes each APC, and hence each spMHC profile j occurs
once, but the model is easily extended to incorporate variable APC numbers for each
antigen profile.
So far, the model only has a mechanism for killing T cells: there must also be a method
for T cells to multiply. Although it is clear that naive cells must see self-antigens in
order to survive, the quantitative relationship between antigen binding strength and
proliferation in the context of T cell homeostatic proliferation remains unclear. Here
we adopt the simplest assumption, namely that all T cells spontaneously divide at some
rate ν , although a model relating ν to binding strength could also be implemented.
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Using these assumptions, we obtain that for each clonotype i:
x˙i = νxi−η∑
j
φ(b j ·x− τ j)bi jxi (3.4)
so that
x˙i
xi
= ν−η∑
j
φ(b j ·x− τ j)bi j (3.5)
We can demonstrate rather simply that the optimisation will indeed always converge.
For a suitable choice of φ the right hand side can be written as the gradient of a convex
function of x. For a function with a second derivative, it is convex on an interval if
its second derivative is non-negative in that interval, is strongly convex if the second
derivative is positive, and is concave if the second derivative is non-positive. Observe
that:
Φ(u) =
∫ u
−∞
φ(z)dz (3.6)
exists for plausible choices of φ , and is convex and differentiable provided that φ(z) is
non-decreasing and continuous. Then define:
f j(x) =Φ(b j ·x− τ j) (3.7)
Each f j is convex in x, and note that:
∂ f j(x)
∂xi
= φ(b j ·x− τ j)bi j (3.8)
Now define:
F(x) =−ν∑
i
xi+η∑
j
f j(x) (3.9)
which is a sum of convex differentiable functions. The scalar function F(x) is con-
structed so that
∂F(x)
∂xi
=−ν+η∑
j
φ(b j ·x− τ j)bi j =− x˙ixi
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so that the rate of change of x is expressed as
x˙i =−xi∂F(x)∂xi
We can now write the rate of change of F(x) as:
dF(x)
dt
= x˙ ·∇F(x) (3.10)
=−∑
i
xi
(
∂F(x)
∂xi
)2
(3.11)
≤ 0 since all xi are positive (3.12)
F is convex and differentiable, because it is the sum of convex, differentiable functions,
and F therefore has a unique minimum in the region of interest, which is the non-
negative quadrant. At this minimum, all constraints b j · x ≤ τ j will be approximately
satisfied, provided that the growth rate ν is small compared to the ‘kill rates’ from the
APCs.
From equation 3.11, we know that the value of F , which includes a sum of measures of
constraint violation, must decrease over time. However, it says little about the rate of
convergence towards the minimum of F . In Appendix C, we present a stronger analysis
of the convergence of the process of equation 3.4, by identifying it with a version of the
multiplicative weight updating algorithms surveyed by [10]. This analysis establishes
regret bounds for such updates on a possibly time-varying set of constraints. We note
that equation 3.4 could be solved by standard differential equation methods, provided
the rate of killing (and the rate of proliferation) remain constant. Under these condi-
tions, the iterations become equivalent to a fixed time step, which can be allowed to
decrease to the continuous case. However, we prefer to use the iterative algorithm we
describe because the discrete time steps are readily interpretable in terms of cellular
events (e.g. T cell/APC interactions) and because the regret bounds it establishes are
robust to variations in rate. The model therefore leaves open the possibility of intro-
ducing time-dependent and tissue-dependent variations in rates in future extensions of
the basic model.
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The implementation described here gives rise to a series of constraints on T cell abun-
dances, which are captured by a series of linear inequalities as outlined above. An
iterative method to solve this linear programming problem is set out below, and can be
given a feasible biological interpretation. Note that the proliferation rate ν is set so that
in the absence of any ‘kill signals’ the T cell population would double in one unit of
time, and the rate η of T cell killing is set relative to this.
1. Calculate the immune response to each profile, r j← ∑i xibi j for all j.
2. Determine for which self-profiles the response threshold has been violated, v j←
[r j > τ] for all j.
3. Adjust the T cell clonotype abundances, xi← xi
(
1+ν δ t−η δ t∑ j bi jv j
)
The multiplicative update analysis discussed in Appendix C provides strong guarantees
for time-varying constraints, corresponding to the case where APCs present varying
combinations of antigens over time.
3.2.2 Assessing the potential for an immune response
In order to investigate the potential of the reshaped T cell population to mount an im-
mune response to previously unencountered antigens, we create a set of new inde-
pendently generated antigenic profiles which were not part of the set on which the T
cell population has been trained. We refer to these as ‘non-self profiles’. The binding
strength of each existing TCR for each new profile is selected independently of its given
affinities for all the self profiles, although the value is selected from the same probabil-
ity distribution. We use these non-self profiles to test whether under our assumptions
the T cell repertoire will achieve the dual objectives of maintaining self-tolerance, while
at the same time maintaining as broad and strong a repertoire for non-self as possible.
Note that we do not model an immune response to these new profiles here. If the APC
remains in a tolerogenic state, the introduction of new non-self profiles will typically
violate the constraints, but this will result in additional T cell killing and the system
will gradually readjust to remain within the immune activation threshold. We envisage
that if the APC were switched to an immunogenic state (for example by exposure to
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innate immune danger signals) then crossing the threshold would result in activation of
all APC bound T cells, resulting in an effector immune response.
We measure the ability of the T cell population to respond to a non-self profile as
the total potential T cell response, calculated as r j(x) = ∑i xici j for non-self profile j,
where C = (ci j) is the matrix of binding strengths between T cell clonotypes and non-
self profiles. It is important to note that we are not simulating the behaviour of the T
cell population on immune challenge here, but assessing the potential of the reshaped
repertoire to respond to previously unencountered profiles. In order to measure the
‘success’ of the reshaped repertoire we can consider its coverage of the potential non-
self antigen space. The first coverage measure we use in this study is the ratio of the
mean total repsonse against non-self profiles to the mean total response against self
profiles: coverage = rnsrs for self profiles s and nonself profiles ns. Alternatively, we
also measure the coverage as the proportion of non-self profiles that give a potential
T cell response greater than the average response to self profiles, i.e. |{ns : rns > rs}|
for nonself profiles ns expressed as a fraction of the total number of nonself profiles
modelled.
3.3 Results
3.3.1 Clone size adjustment algorithm reaches a solution of the
repertoire constraints: violations are resolved rapidly and
repertoire is optimised slowly
We first simulate a very simplified repertoire to allow us to visualise the action of the
update algorithm. We start with two T cell clonotypes and three spMHC profiles. The
clonotypes have binding strengths for each of the profiles as detailed in Figure 3.1g. In
this simulation each profile is given the same total response threshold (τ = 1), above
which there will be harmful autoimmunity. The other parameters of the update algo-
rithm are set out in the legend of Figure 3.1.
The self-response thresholds for each profile and the binding strengths between clono-
types and spMHC profiles (Figure 3.1g) give constraints on allowable repertoires. If xi
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is the abundance of clonotype i, to avoid autoimmunity we require that:
1.2x1+1.0x2 ≤ 1
1.5x1+0.5x2 ≤ 1
0.6x1+1.4x2 ≤ 1
Figure 3.1: Optimisation of the T cell population to avoid autoimmunity while maximis-
ing T cell numbers in a simplified system.
A simplified repertoire containing two clonotypes and three spMHC profiles. The
update algorithm is initiated with different initial clonotype abundances each rep-
resented by a different colour. The coloured lines track the changes in clonotype
abundance over iterations of the update algorithm.
(a)-(e) The clone abundances after (a) 5, (b) 10, (c) 100, (d) 1000 or (e) 10,000
iterations of the update algorithm. The grey lines indicate the constraint that total
T cell response should be less than the threshold for each of the spMHC profiles.
(f) For each of the starting repertoire configurations, the relationship between the
Euclidean distance moved by the repertoire configuration in an iteration of the up-
date algorithm and the distance from the furthest violated threshold, or if there are
no violations the distance to the nearest threshold.
(g) The affinities between clonotypes and spMHC profiles.
Other model parameters for all panels are: τ = 1, the self-response threshold for
each spMHC profile, ν = ln2 δ t−1, the growth rate and η = 0.01001 δ t−1, the
learning rate.
We repeatedly simulate the update algorithm with different starting repertoire config-
urations. Each starting configuration is represented as a colour in Figure 3.1. The
panels in this figure show a time course of the update algorithm working on each initial
repertoire configuration.
We see that if the initial repertoire configuration violates one or more of the response
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constraints, the update algorithm very quickly shapes the repertoire (by adjusting clono-
type abundances) to a point where there is no autoimmunity (Figure 3.1b, 10 iterations).
In contrast, when no threshold is violated by the starting configuration of the repertoire
(yellow path in Figure 3.1) the repertoire does not move very far from the initial con-
figuration in the first cycles.
Once the repertoire has been moved to a configuration where all constraints are satis-
fied, the update algorithm continues to allow each clonotype to become as abundant
as possible while remaining inside the ‘feasible region’ (Figure 3.1c-e). For this ar-
rangement of affinities, the ‘optimum’ repertoire in terms of having the highest total
abundance while avoiding autoimmunity is at a single vertex of the feasible region,
and we can see that the update algorithm moves each of the initial repertoires slowly
towards this point.
The speed which which the clonotype abundances are adjusted is dependent on the
severity of the violation of the thresholds, as the update rule is designed to do through
the negative learning rate η . This can be quantified by considering the Euclidean dis-
tance moved by the repertoire configuration in a timestep as a function of the Euclidean
distance by which the current configuration violates a threshold (Figure 3.1f). There is
a strong positive relationship between the severity of the violation and the speed with
which the update algorithm adjusts the clonotype abundances.
3.3.2 Positive selection of clonotypes based on self-profile binding
strength is required for successful immune tolerance
We next simulated the update algorithm with a larger number of T cell clonotypes and
spMHC profiles (Figure 3.2). For each clonotype-profile pair, the binding strength (bi j
for clonotype i and profile j) is set to zero with probability 1−γ . If the binding strength
is not set to zero it is selected at random from a left-censored normal distribution. For
simplicity we set the response threshold τ to be equal to 1 for all self profiles.
We run the update algorithm and record the abundance of each clonotype at each iter-
ation. Note that under our constant growth rate assumption, iterations can be thought
of as directly equivalent to T cell generations. We set the growth rate ν such that one
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unit time is equal to one T cell generation, giving one T cell generation in approxi-
mately 1387 iterations. The total T cell response to a spMHC profile can be calculated
as the sum of abundance × binding strength for each T cell clonotype (r j =∑i xibi j for
spMHC profile j). We can then define successful immune tolerance as the reshaping of
the T cell population into one where the total T cell response to any spMHC profile (r j
for self-profile j) is below the threhsold τ . The mean total response to spMHC profiles
over time (Figure 3.2a, solid line) is initially well controlled at the allowed threshold.
However, after approximately 10,000 iterations of the update algorithm the control of
the response breaks down and there is an increased average response to self, above the
allowable threshold.
We noted that those clonotypes that are highly abundant after running our simulation for
30,000 cycles of the update algorithm have low maximum binding strength to spMHC
profiles. We can see the reason for breakdown of control of self response if we consider
a clonotype of abundance 1 that has zero binding strength for all self profiles except one,
for which it has binding strength b. Then after one iteration of the update algorithm, the
clonotype will have abundance (1+ν δ t) or (1+ν δ t−η δ t b) depending on whether
the total T cell response to the profile for which it has non-zero binding strength is
below the allowable self-response threshold τ or not. In order to avoid uncontrolled
growth of the clonotype, we would require that (1+ ν δ t − η δ t b) < 1, which is
equivalent to requiring that b > ν/η . Therefore we suggest that the inability of the
update algorithm to control average self response is due to the presence of clonotypes
for which the maximum binding strength to any of the self profiles is below ν/η . This
indicates the requirement for some form of positive selection.
In its simplest form, positive selection would take the form of a function which deletes
all clones whose maximum binding strength for any self profile is below ν/η . A more
realistic function could make the growth rate in any one cycle depend on the average
binding strength to self profiles or to the maximum binding strength to a randomly
selected sample of ‘encountered’ self profiles. In the following work we implement
the simplest form of the affinity-dependent selection, by eliminating all clonotypes
with maximum binding strength to self profiles below ν/η before the update algorithm
begins.
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Figure 3.2: Evolution of the repertoire under the constraints of dendritic cell dependent
T cell deletion.
(a) mean total T cell response to spMHC profiles over time as clone sizes are up-
dated according to the basic immune tolerance learning algorithm with or without
positive selection implemented. The total T cell response to a profile is calculated
as the sum of (abundance × binding strength) for each clonotype.
(b) the total T cell abundance (being the sum of the abundances of clonotypes
present at a particular time) in the simulation after T cell positive selection is im-
plemented
(c) the abundance of each T cell clonotype over time after T cell positive selection
is implemented. The abundance is expressed as a fraction of the maximum abun-
dance the clonotype could reach without violating any self-response thresholds if
it was the only clonotype in the population.
(d) the clone size distribution after the indicated amount of time after T cell positive
selection is implemented.
Model parameters for all panels are: self-response threshold τ = 1, growth rate
ν = ln2 δ t−1, learning rate η = 0.002001 δ t−1, number of spMHC profiles
M = 100, number of T cell clonotypes N = 1000, proportion of non-zero affini-
ties γ = 0.01.
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We implement this positive selection of clonotypes and re-run the simulation with the
same parameters (detailed in Figure 3.2 legend). The total T cell response to self pro-
files is now tightly controlled at the allowable threshold (Figure 3.2a, dashed line). It
is however possible under this model that if a clonotype escapes positive selection it
slowly increases in size indefinitely.
3.3.3 Total population size homeostasis but increased clonotype
abundance heterogeneity as a function of time
Naive TCR repertoires are made up of clonotypes with a broad range of abundances.
We therefore examined the abundance distribution produced by the model presented
in this chapter. Since our implementation of the model uses continuous rather than
discrete abundances, abundances never reach zero but become arbitrarily small. In
order to consider the abundance distribution, we therefore set a lower threshold below
which a clone is considered to be deleted. In this work we consider a clonotype to be
completely absent when its abundance falls below a threshold defined by N/108 where
N is the number of clonotypes in the simulation. This threshold was chosen based
on consideration of a mouse immune system which has in the order of 108 T cells in
total. If N different clonotypes of equal abundance are present in this repertoire, each
clonotype could be considered to have a starting abundance of 108/N. Hence if a clone
contracts by a factor of > 108/N , its abundance would fall below 1 and hence the
clonotype can be considered as eliminated. Since the abundance of each clonotype
at the start of the model is arbitrarily initiated at a value of one, this is equivalent to
defining a clone with an abundance of lower than N/108 as deleted.
We first considered the total size of the T cell compartment as a function of time. At
every timepoint during the simulation we can calculate the total size of the repertoire as
the sum of the clonotype abundances that are above the ‘presence’ threshold of N/108
(Figure 3.2b). We see that this initially contracts as self-response constraint violations
are resolved, but then expands (driven by the positive learning rate increasing the abun-
dance of each clonotype when constraints are not violated) until a stable level is reached
where growth and negative selection are balanced. If all other parameters of the model
are fixed, the eventual total size of the T cell compartment at homeostasis is strongly
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correlated to the number of clonotypes present in the repertoire at the beginning of the
simulation.
We then consider the abundances of individual clonotypes. The maximum allowable
size, mi for a clonotype in the model can be defined as the self-response threshold
divided by the maximum binding strength the clonotype has for any self profile, i.e.
mi =
τ
max
j
bi j
is the maximum allowable size for clonotype i. For each of the clonotypes in the sim-
ulation, we consider its abundance, expressed as a proportion of the maximum allow-
able abundance mi for that clonotype, across time (Figure 3.2c). Some clonotypes are
present close to their maximum allowable size mi, presumably due to lack of cross-
reactivity with other profiles or other clonotypes, while some clonotypes are quickly
removed from the repertoire. It it interesting to note that while the total T cell abun-
dance stabilises rapidly (Figure 3.2b) the individual clonotype sizes continue to be ad-
justed even in later stages of the simulation. The clone size distribution (Figure 3.2d)
spreads to include smaller clonotypes during the initial part of the simulation, then
starts to include larger clonotypes as well in later iterations. At the end of our simula-
tion there is a large spread of clone sizes in which large and small clones co-exist, as
observed experimentally, rather than a repertoire completely dominated by a few large
clonotypes.
3.3.4 Increased number of T cell clonotypes provides greater
repertoire coverage
A successful T cell population needs to be able to control immune response to self but
at the same time must provide broad coverage against a range of unknown non-self
antigens that the individual might encounter. The mean total potential T cell response
to self and non-self profiles (± standard deviation) across iterations is shown for one
set of simulation paramters in Figure 3.3a.
This shows that the response to self is well controlled at the allowed threshold τ . In
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Figure 3.3: Broad coverage to non-self is maintained during the development of a self-
tolerance repertoire.
(a) The mean (± standard deviation) total T cell response to self (blue) or non-self
(green) pMHC profiles over time with N = 2000 and M = 200.
(b) After 30,000 iterations of the update algorithm with parameters as in (a), the
distribution of total T cell response to self (blue) and non-self (green) pMHC pro-
files.
(c) The ability of the repertoire to successfully mount an immune response to non-
self pMHC profiles, measured as the average total response to a non-self profile
divided by the average total response to a self profile, over time. The number of
T cell clonotypes in a simulation is indicated by colour, with the number of self
profiles simulated ranging between 100 and 800.
(d) The relationship between number of T cell clonotypes and the average total re-
sponse to a non-self profile divided by the average total response to a self profile
after 30,000 iterations of the update algorithm.
(e) The proportion of non-self profiles that have a total T cell response greater than
the mean response towards self profiles over time. The number of T cell clonotypes
is indicated by colour.
(f) The relationship between the number of T cell clonotypes and the proportion of
non-self profiles having a stronger total T cell response than the mean response to
self profiles after 30,000 cycles of the update algorithm.
Other model parameters for all panels are: self-response threshold τ = 1, growth
rate ν = ln2 δ t−1, learning rate η = 0.002001 δ t−1 and proportion of non-zero
affinities γ = 0.01.
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contrast, the average response to nonself pMHC profiles becomes higher as the model
shapes the repertoire. However, the nonself responses become very heterogeneous.
After 30,000 iterations the response to all self profiles is at or near the allowed threshold
while the majority of nonself profiles are capable of more T cell binding, and therefore
a larger potential T cell response (Figure 3.3b). However, there are also a number of
nonself profiles that create a lower response than that to self profiles. These presumably
represent ‘holes’ in the repertoire coverage.
We assess the ability of the reshaped repertoire to cover the potential nonself antigen
pool via the two coverage measures described earlier. We ran the update algorithm
a number of times with the number of T cell clonotypes (N) ranging between 400
and 25,600 and number of spMHC profiles (M) ranging between 100 and 1600 (only
running combinations where M < N). Other parameters of the simulation are detailed
in Figure 3.3 legend. We considered the evolution of the ratio of mean self potential
response to mean nonself potential response across cycles of the algorithm (Figure 3.3c)
and see that this increases until it is above 1 (indicating higher potential response to
nonself than self profiles) for all parameter sets. The repertoire coverage, using this
measure, depends on the total number of T cell clonotypes in the repertoire at the start
of the algorithm (Figure 3.3d).
The proportion of nonself profiles that the T cell population has the potential to respond
to more strongly than it does to self profiles is initially low but is increased as the update
algorithm shapes the repertoire (Figure 3.3e). The success of the repertoire under this
measure is again strongly correlated to the number of clonotypes (Figure 3.3f).
3.3.5 Clonotype diversity and spMHC profile cross-reactivity are
preserved by the update algorithm
We have demonstrated that the model described in this study produces a TCR reper-
toire that respects self-response thresholds, but violates the thresholds when exposed
to non-self antigen profiles. It has been observed that the TCR repertoire in an indi-
vidual remains diverse (many different clonotypes are present, with cross-reactivity be-
tween clonotypes and profiles) until old-age, when a few dominant clonotypes appear
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[25]. We explored whether our selection model can retain diversity in the repertoire
or whether the multiple linear constraints favour a sparse solution with few surviving
clonotypes.
We first consider the proportion of starting clonotypes surviving (i.e. with an abun-
dance greater than the lower limit defined earlier) as a function of time. The proportion
of clonotypes present in the repertoire falls rapidly in the initial stages of repertoire re-
shaping and then stabilises (Figure 3.4a, blue). The proportion of the initial clonotypes
that remain after 30,000 cycles of the update algorithm is inversely correlated to the the
number of clonotypes in the simulation (Figure 3.4b, blue).
A key parameter of the adaptive immune system is the amount of information it can
encode. The information content encoded in the repertoire (which depends on a com-
bination of the number of different T cell clones and their relative size) can be captured
by the Shannon Information (SI) coefficient, which is the log of the true diversity of
order 1 [130]. The SI coefficient of the repertoire initially decreases rapidly before
stabilising (Figure 3.4a, red). However, there is only a weak (and not statistically sig-
nificant) correlation between the Shannon Information coefficient and the number of
clonotypes in the simulation (Figure 3.4b, red).
Cross-reactivity, such that multiple TCRs can recognise the same pMHC profile and
multiple pMHC profiles can be recognised by the same TCR, is a well-recognised fea-
ture of the T cell repertoire [159, 19]. To investigate the evolution of cross-reactivity
in our model, we measure the number (or proportion) of clonotypes which have non-
zero binding strength for a single pMHC profile (i.e. |{i : bi j > 0}| for each profile j).
The mean proportional cross-reactivity against self profiles decreases initially then be-
gins to stabilise, while the mean cross-reactivity against nonself profiles is maintained
(Figure 3.4c).
After running the simulation for 30,000 iterations of the update algorithm, the distri-
butions of cross-reactivity against self and nonself profiles are clearly different (Fig-
ure 3.4d). The majority of nonself profiles are recognised by more TCR clonotypes
than self profiles are, and the ratio of self:nonself cross reactivity is not significantly
correlated to the size of the simulation (Figures 3.4e and f).
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Figure 3.4: Clonotype diversity and pMHC profile cross-reactivity are preserved by the
update algorithm.
(a) Blue: The proportion of clonotypes (after positive selection) that are present
over time during simulation of the update algorithm. Red: The Shannon entropy of
the repertoire over time. Simulation implemented with N = 1600 and M = 400.
(b) Relationship between number of clonotypes in the simulation and proportion of
clonotypes remaining (blue) or Shannon entropy of the repertoire (red) after 30,000
iterations of the update algorithm. Simulation implemented with values of N be-
tween 400 and 25,600 and M beween 100 and 800, with M < N.
(c) Cross-reactivity of T cell clonotypes against self (blue) and nonself (green)
pMHC profiles over time, run with N = 3200 and M = 400. Cross-reactivity is mea-
sured as the proportion of present clonotypes that have non-zero binding strength
for a given profile. Data shown is mean cross-reactivity across all profiles ± stan-
dard deviation.
(d) Distribution of cross-reactivity across all self (blue) and nonself (green) pMHC
profiles after 30,000 iterations of the update algorithm with N = 3200 and M = 400.
Cross-reactivity is measured as the absolute number of present clonotypes that have
non-zero binding strength to a profile.
(e) Relationship between the number of clonotypes present at the start of the up-
date algorithm and the ratio of the mean cross-reactivity against nonself profiles
to the mean cross-reactivity against self profiles after 30,000 cycles of the update
algorithm.
(f) Relationship between the number of self profiles in the update algorithm and
the ratio of the mean cross-reactivity against nonself profiles to the mean cross-
reactivity against self profiles after 30,000 cycles of the update algorithm.
Other model parameters for all panels are: self-response threshold τ = 1, growth
rate ν = ln2 δ t−1, learning rate η = 0.002001 δ t−1 and proportion of non-zero
affinities γ = 0.01.
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3.3.6 New clonotypes can establish themselves in a stable reper-
toire
The TCR repertoire is constantly being updated by the introduction of new T cells from
the thymus, and new clonotypes can establish themselves despite competition from the
existing clonotypes. We explored whether the update algorithm of our model would
allow introduction of new clonotypes. We ran the update algorithm for 30,000 iterations
to produce a self tolerant and stable repertoire and then selected 10 of the clonotypes
present at random. We created 10 new duplicate clonotypes, with identical spMHC
profile binding strength values as the selected clonotypes, and introduced them into the
repertoire at an abundance equal to the average abundance of the exisiting clonotypes.
We then tracked both the original 10 clones, and their duplicates, for further iterations
of the simulation.
The total T cell abundance increases transiently as new clonotypes are introduced but
quickly returns to a stable level (Figure 3.5a). On introduction of the new duplicate
clonotypes the abundances of the original 10 clonotypes all fall in order to satisfy the
self-response constraints (Figure 3.5b). Clonotypes with matched self-binding strength
profiles are seen to tend towards the same abundance over the additional iterations of
the model (Figure 3.5c and d). Although the abundances of the new clonotypes do not
reach equality with the original clonotypes, the introduced clonotypes only disappear
in cases where the original clonotypes are also deleted. The introduced clonotypes are
able to remain in the repertoire even when they are introduced at a lower abundance
than an already established clonotype with the same self-response profile.
To further test the ability of new clonotypes to establish themselves in a self-tolerant
repertoire, and to investigate whether we can predict whether a clonotype will be in-
corporated into the repertoire or removed, we perform the same experiment except that
the introduced clonotypes have similar but not identical affinity profiles to the existing
clonotypes.
We create affinity profiles for new clonotypes by selecting an existing clonotype and
adding ‘noise’ to its affinity profile as follows. If the existing clonotype has affinity b j
3.3. Results 92
Figure 3.5: New clonotypes can establish themselves in a stable repertoire.
(a) Total T cell abundance over time. 10 new clonotypes, each with self profile
binding strength vector matching an existing clonotype, are introduced (at the av-
erage clonotype abundance) after 30,000 iterations of the update algorithm.
(b) The clonal abundance of 10 selected clonotypes (solid lines) over time. After
30,000 iterations of the update algorithm, 10 additional clonotypes are introduced
(dashed lines), each with a self profile binding strengths equal to one of the original
10 clonotypes. Colours represent binding strength profiles (selected clonotypes).
(c) and (d) For each of the selected original clonotypes and the binding strength-
matched introduced clonotypes, the relationship between the original and match
clone abundance when the new clonotype is introduced (open circles) and after
running the simulation for an additional 30,000 iterations of the update algorithm
(solid circles). The dashed grey line represents identical abundance of original and
introduced clonotypes.
Model parameters used for all panels are: self-response threshold τ = 1, growth
rate ν = ln2 δ t−1, learning rate η = 0.002001 δ t−1, proportion of non-zero affini-
ties γ = 0.01, number initial clonotypes N = 1000, number self profiles M = 100.
to self-peptide profile j then the affinity of the new clonotype for self-peptide profile j
is chosen from N(b j, f b j) where f is a factor which defines the amount of ‘noise’ being
introduced. Ten clonotypes present after 30,000 iterations of the update algorithm are
selected, at a range of abundances, and new clonotypes are introduced each with the
affinity profile of one of the selected clonotypes as a template. Different amounts of
‘noise’ are considered, using f = 0, 18 ,
1
4 , or
1
2 . The new clonotypes are introduced into
the repertoire at the current average clone abundance and the simulation is allowed to
run for 30,000 further iterations.
For each noise factor, the total T cell population quickly returned to homeostasis and
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Figure 3.6: New clonotypes introduced with ‘similar’ affinity profiles to existing clono-
types demonstrate diverse behaviour
The amount of noise applied to template clonotype affinity profile to create the
profile for the new clonotype is indicated by colour. Elements of the new affinity
profile are selected from a normal distribution with mean equal to the equivalent
element of the template affinity profile and standard deviation equal to the ‘noise
factor’ (given by colour) multiplied by the element of the template profile.
(a) For each of ten template clonotypes (solid lines), the abundance of the template
clonotype over time, and the abundance of the introduced clonotypes (dashed lines)
over time after introduction at 30,000 interations.
(b) Clone abundance at 60,000 iterations over clone abundance at 30,000 for clones
that were: (i) not used as templates (left hand group), (ii) used as templates (middle
group) and (ii) newly introduced (right hand group).
(c) For each template and new clonotype, the abundance of the new clonotype di-
vided by the abundance of the template clonotype at 30,000 iterations (left hand of
each pair) and 60,000 iterations (right).
All simulations run with parameters: self-response threshold τ = 1, growth rate
ν = log2δ t−1, learning rate η = 0.0020001δ t−1, proportion of non-zero affinities
γ = 0.01, number initial clonotypes N = 5000, number self-profiles M = 500.
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immune tolerance was restored, as was previously seen for f = 0 (Figure 3.5). The
abundance of each original and introduced clone over iterations (Figure 3.6a) shows
that the template clones that are smallest originally are removed from the repertoire
on introduction of the new clonotypes, as are the new clonotypes with affinity profile
derived from these smallest clones, regardless of the amount of noise applied to the
copied self-affinity distributions. This pattern was repeated in two other runs of the
simulation, not shown.
The abundance of the majority of the existing clonotypes which were not used as tem-
plates for introduced clonotypes stayed approximately constant between 30,000 and
60,000 iterations (Figure 3.6b, left) regardless of the amount of noise introduced, while
some were completely removed from the repertoire and others decreased in size. A
similar pattern was observed in the abundance of existing clonotypes that were used
as templates for the new clonotypes (Figure 3.6b, middle), although more decreased
in size or were removed than remained the same size. The reduction in abundance of
these clones appears to be correlated to the amount of noise. The introduced clono-
types are the only ones which are able to increase in abundance between 30,000 and
60,000 iterations, although most are also reduced (Figure 3.6b, right). Increase in clone
abundance only appears to be possible when there is non-zero noise.
For each template clone and the new clonotype based on its affinity profile, comparing
their abundances at 30,000 and 60,000 iterations (Figure 3.6c) demonstrates that, when
the template is copied with no noise, the proportional clone sizes, in relation to each
other, remain constant. However, including noise when the template affinity distribu-
tion is being copied results in relative clone sizes changing between 30,000 and 60,000
iterations. Some introduced clones increase in size in comparison to their templates,
while others decrease. We were interested to determine what were the particular prop-
erties of the new clones which allowed them to compete and expand within the existing
stable repertoire. In order to investigate this question the abundance of the new clones
at 30,000 iterations after introduction was compared to a number of characteristics of
the repertoire.
When affinity profiles are created from templates with the addition of noise, the final
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Figure 3.7: Ability of a clone to establish itself in the repertoire depends on change in
affinity profile from template
Relationship between abundance of new clonotypes 30,000 iterations after intro-
duction and (a) the mean number of other clonotypes with affinity for the self-
peptide profiles that the new clonotype has non-zero affinity for, (b) the total popu-
lation wide affinity to those self-peptide profiles and (c) the mean change in affinity
from the template clone to the new clone.
All simulations run with parameters: self-response threshold τ = 1, growth rate
ν = log2δ t−1, learning rate η = 0.0020001δ t−1, proportion of non-zero affinities
γ = 0.01, number initial clonotypes N = 5000, number self-profiles M = 500.
abundance of a new clone is not correlated to the mean number of other clones in
the established repertoire which have affinity to the same self-peptide profiles as the
introduced clone (Figure 3.7a), nor to the mean total potential response (affinity ×
abundance) to those self-peptide profiles that exists in the repertoire before introduction
of the new clones (Figure 3.7b).
However, when the final abundance of a clone is compared to the mean change in affin-
ity from the template clonotype, there is a statistically significant negative correlation
(Figure 3.7c). The clones that are able to most effectively establish themselves in the
repertoire are those that on average have a lower affinity to self peptide profiles than
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their template molecules. This suggests that in order to out-compete an already estab-
lished clone a new clonotype which recognises the same self-peptides will need to do
so with lower affinity.
3.4 Discussion
We have outlined a simple computational model by which the peripheral T cell reper-
toire in an individual can be continually adjusted in order to optimise the chance of a
successful response to unknown pathogens while minimising the amount of dangerous
T cell response to self. From a computational perspective the update method can be
thought of as a multiplicative weight update algorithm, and is shown to rapidly con-
verge to a solution of the constraints. From a biological perspective, the model falls
within the well-established framework of APC-based self-tolerance models, but intro-
duces the key features of cross-reactivity and T cell cooperativity. The model produces
the desirable features of maintaining self-reactivity within a predefined threshold, while
driving the development of a diverse repertoire which can respond effectively to a broad
selection of non-self antigens. The model also reproduces the heterogenous distribu-
tion of naive T cell clonotype abundances which has been described by recent high
throughput sequencing studies [120], and the extensive cross-reactivity which is an-
other recently recognized feature of the T cell repertoire [159]. We do not present a
model of an immune response in this work. If the APC remains in tolerogenic state, the
introduction of new non-self pMHC profiles will violate the constraints, but this will re-
sult in additional T cell killing and the system will gradually readjust to remain within
the immune activation threshold. If, however, the APC are switched to an immuno-
genic state (for example by exposure to innate immune danger signals) then crossing
the threshold will result in activation of all APC bound T cells, resulting in an effector
immune response.
The mechanisms whereby the vertebrate adaptive immune system avoids harmful reac-
tion with self antigens but retains the ability to react with a large and unknown set of
potential pathogens has been extensively discussed. The current molecular understand-
ing of the stochastic recombination events which generate adaptive immune receptors
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(antibody and the TCR) require self-tolerance to be learnt rather inherited. The clonal
deletion model of Burnet [27] has remained the dominant paradigm for many decades.
In the context of the T cell, this paradigm posits that T cells developing in the thymus
die if they react with antigens (which in the context of the thymus are assumed to be
predominantly self) with an affinity above a given threshold, whose value has been esti-
mated to correspond to a disassociation constant of approximately 6µM [115]. Indeed
special molecular mechanisms exist to ensure atopic expression of a whole range of
non-thymic proteins in the thymus [9], presumably to ensure robust self tolerance. The
molecular mechanism of clonal deletion has also been studied intensively [61].
More recently, a number of immunologists have proposed the need for some form of ex-
trathymic (peripheral) tolerance, since self-reactive mature T cells have been described
in many cases. Such models include those in which self/non-self discrimination was
assigned to the antigen presenting cell (typically a dendritic cell) rather than the T cell
[95, 65]. The essence of these models was to propose that APCs exist in two different
functional states. Under resting conditions (e.g. in the absence of infection) the interac-
tion between antigen on the APC and cognate T cell induces tolerance (either deletion,
or anergy). When the APC is activated (typically via the innate immune system), the
same interaction leads to activation, differentiation and T cell effector function. A fun-
damental feature of these models is that the APC continues to present self-antigens in
both states. However, since the immune system has been ‘educated’ to tolerise self-
reactive T cells during a resting period, and the majority of antigen presenting cells
at any time continue to remain in a resting state, the T cell response to self antigens
presented together with non-self by the activated antigen presenting cells is small and
transitory, and does not lead to significant pathology. The model presented in this paper
lies squarely within the conceptual framework of these antigen presenting cell focused
models of self/non-self discrimination. However, our model simplifies the system by
assuming only a single type of APC. In reality, the immune system contains a hetero-
geneous mixture of antigen presenting cells, with a spectrum of tolerizing or activating
activity [105]. The extension of our model to incorporate antigen presenting cell het-
erogeneity will be an important goal of future work.
The molecular mechanisms by which antigen presenting cells induce tolerance remains
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an open question. Tolerogenic dendritic cells which express granzyme and perforin,
and induce T cell death in an antigen specific way, have been described [166]. Den-
dritic cells also express several members of the Tumour Necrosis Factor (TNF) family,
and its cognate receptors, the TNF receptor family. Some members of this family, for
example CD40 and CD40L, are known to play a critical part in T cell activation. Im-
pairment of this interaction leads to profound immunodeficiency [29]. Furthermore,
CD40 expression on antigen presenting cells is modulated by T cells, and the antigen
presenting cell integrates signals from multiple T cells, providing a molecular mecha-
nism for T cell cooperativity [2]. Other members of the family which can be expressed
by dendritic cells, in contrast, deliver negative signals. The most well-studied example
is the Fas/FasL interaction, and impairment of this interaction leads to a breakdown of
self-tolerance [67, 109, 162]. TNF itself can also induce cell death via TNF receptor
signals, although paradoxically it can also induce cell activation [64]. The precise func-
tion of many of the more than 40 members of these families remain unknown, and their
potential role in tolerance induction remains to be explored.
An interesting feature of our model is that it imposes a homeostatic limit on the total
number of T cells which depends on the self-tolerance threshold. There is extensive
experimental evidence linking T cell homeostasis to inter-clonal competition for the
survival/proliferation cytokine IL7 [143]. An important challenge will be to integrate
the phenomenon of clonal competition for a limited resource into our model. Indeed,
it is possible to retain the computational infrastructure of our model but recast it em-
phasizing survival factors, rather than death signals. It may be the case that integration
occurs in both APC and T cells, with the APC sending survival signals to bound T
cells until a threshold level of binding is violated, at which point the survival signals
cease. T cells would integrate the amount of survival signal received over a number
of TCR-APC interactions and if this does not reach a sufficient level would die. This
mechanism would increase the specificity of clonotype size adjustment, only reduc-
ing those clonotypes that repeatedly encounter APC for which the binding threshold is
violated.
Of necessity, both our basic model and its implementation make a number of simpli-
fying assumptions. The impact of some of these could be explored further by in silico
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experimentation. For example, it would be relatively straightforward to implement a
model in which the proliferation of the T cells is likely to be dependent on the strength
of the receptor/pMHC interaction. A more complex, but important, question to explore
is the extent to which the averaging of the response over all antigen presenting cells
adequately captures the real scenario, where self-tolerance must be distributed anatom-
ically over the whole body, and where each antigen presenting cell only presents a
subset of all possible self antigens.
Our model does not incorporate regulatory T cells, which are clearly an important part
of the mechanisms of self-tolerance, and have been the basis for several previous the-
oretical models of self-tolerance [31, 6]. These cells may be of particular importance
for regulating those T cells with the highest affinity for self, which will still exist albeit
at reduced numbers in our model, and which could be inadvertantly triggered in the
context of responses to non-self with potential pathogenic consequences.
The model we propose has interesting implications for inducing organ specific toler-
ance in the context of allo-transplantation, which remains an unsolved problem in the
context of clinical transplantation. The natural mechanisms which maintain tolerance to
self are clearly insufficient in most cases to re-establish complete and lasting tolerance
to an allograft in the absence of immune-suppression. This is perhaps not surprising
since extra-thymic tolerance is only one component of tolerance, and in isolation may
be insufficient. However, with better understanding of the molecular cell biology of
tolerogenic dendritic cells, it may be possible to experimentally increase the activity or
number of these cells and thus re-educate the peripheral repertoire towards tolerance.
In conclusion we propose a model of self-tolerance which incorporates T cell co-
operativity (‘quorum-sensing’) into the mechanism for balancing self-tolerance with
immuno-competence. Once a stable repertoire has been produced, we imagine that
on immune challenge individual groups of antigen presenting cells are switched into
an activated state, where they present antigens and drive the establishment of effector
and memory cells. However, the repertoire will have learnt tolerance and hence the
response to self will be small and not pathogenic. A useful feature of the model is that
the threshold for self reaction can be set locally, and hence may vary in different tis-
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sues. The balance between response and tolerance may therefore be dependent on the
local micro-environment. The key prediction of our model is that perturbation of either
the existing T cell repertoire, or the presented pMHC landscape will cause widespread
distributed changes to the overall repertoire which will involve clones of many different
specificities. The nature of these changes can be predicted by our model, and can be
measured using the power of high throughput sequencing of TCR repertoires. Thus our
model will stimulate further hypothesis building and falsification, and lead to a better
understanding of adaptive immunity and self tolerance.
Model improvements
The implementation of the model described in this chapter has a number of limitations,
including clone sizes being represented by real numbers (rather than integers) and lack
of ability to model an immune response explicitly. In order to address these points, an
agent based implementation of the model is being developed. The agent based model
(ABM) will track each dendritic cell and each T cell individually, avoiding the problem
of clone sizes becoming arbitrarily small. Additionally, it will include integration of
signal on the part of the T cell to allow for positive selection to be included in a more
flexible manner than the current implementation. The ABM will be used to model
the situation where APCs are activated by the innate immune system, presenting a new
‘foreign’ peptide (along with existing self peptides) to the T cell population and causing
the activation of T cells that recognise presented peptide. This will allow questions
regarding the extent of activation of self-responsive T cells under an immune challenge
to be explored.
Chapter 4
Heterogeneity in the antigen-specific T
cell response at the level of the T cell
receptor
4.1 Introduction
Much of the field of mouse immunology relies on the use of an adjuvant, in addi-
tion to the antigen of interest, to initiate a T cell response against the antigen. A
commonly used adjuvant, Complete Freund’s Adjuvant (CFA), consists of inactivated
M.Tuberculosis (TB) emulsified in oil. Since T cell activation requires interactions with
antigen presenting cells providing signal from peptide-MHC via their TCR as well as
costimulatory signals, administering antigen alone to mice does not provoke a strong
immune response. The presence of adjuvant (particularly the bacterial components) fa-
cilitates effective uptake of antigen by macrophages as well as initiating costimulatory
signals in the antigen presenting cells as discussed in [69], allowing a T cell response
to be studied.
Previous work from our lab [144] demonstrated that changes in the TCR repertoire
could be used to discriminate between the TCR repertoires of unimmunised mice and
mice immunised with CFA (with or without additional model antigen). Amino acid
triplets are clustered into ‘codewords’ according to their Atchley factor properties, and
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the occurences of these codewords in samples of CDR3β s from immunised and unim-
munised mice are counted. Support Vector Machines are then used to predict whether a
sample is from an unimmunised or immunised mouse, and additionally what timepoint
post immunisation the sample is taken at. It was shown that whether a sample is from
an immunised or unimmunised mouse is able to be predicted with 100% accuracy, and
the timepoint is able to be fairly well predicted for mice sacrificed at month 2, but day
5 and day 14 repertoires are indistinguishable under this method. This classification
efficiency is retained if only the largest clones from each sample are used, and remark-
ably is also retained if only the smallest clones are used, suggesting that the immune
response is distributed across clones of different sizes.
In this chapter, we extend this work to try to identify characteristics of the TCR reper-
toire that change on immunisation with a model antigen, to understand more about the
global effects of immunisation or the TCR-level features determining recognition of a
single antigen.
4.2 Methods
4.2.1 Sample collection and sequencing
All experiments were performed by Nir Friedman’s group at the Weizmann Institute,
Rehovot, Israel.
C57BL/6 mice were immunised with Complete Freund’s Adjuvant (‘CFA’), with or
without an additional antigen. Control mice were left unimmunised or were mock im-
munised with phosphate buffered saline (‘PBS’). Additional antigens used in this study
were ovalbumin (‘OVA’), a protein commonly used as a model antigen, and a peptide
from the heatshock protein, VLGGGCALLRCIPALDSLTPANED (‘p277’). After im-
munisation, mice were sacrificed at either early time points (day 5 or day 7), mid time
points (day 10 or day 14) or a late time point (month 2). Mice sacrificed at month 2
were given a booster of Incomplete Freund’s Adjuvant at day 14.
CD4+ T cells were isolated from spleens and TCRβ chains from these cells were se-
quenced via the protocol described in [111]. Briefly, total RNA was reversed tran-
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scribed with a primer specific to the TCRβ constant region, and resulting cDNA was
amplified via PCR using a set of TCRVβ primers. Illumina adaptors were ligated to the
product, including indexes to identify each sample, and the sequencing was performed
using a Genome Analyzer II.
For some of the mice, additional splenic CD4+ T cells were taken for in vitro culture.
3×106 cells per well were cultured for a week, in the presence of irradiated autologous
splenocytes and an antigen. The antigens used were heat-inactivated Tb, a peptide
from ovalbumin (323-339, ISQAVHAAHAEINEAGR, referred to as ‘OVA’), or the
p277 peptide that was also used for in vivo immunisations. After culture, TCRβ chains
were sequenced using the same protocol as outlined above.
Details of the immunisation, time point and in vitro culture of each sample used in this
Chapter are outlined in Table 4.1.
Immunisation Time point In vitro culture Number
untreated d0 8
PBS d5 1
PBS m2 1
CFA d5 3
CFA d7 2
CFA d14 3
CFA m2 5
CFA d7 TB 2
CFA d7 OVA 2
CFA+OVA d5 3
CFA+OVA d7 3
CFA+OVA d14 3
CFA+OVA m2 6
CFA+OVA d7 TB 2
CFA+OVA d7 OVA 3
CFA + p277 d10 6
CFA + p277 d10 TB 5
CFA + p277 d10 p277 5
Table 4.1: Details of mouse TCR repertoire samples analysed in Chapter 4.
4.2.2 Data processing
Raw sequence data was processed first by demultiplexing using the ligated index to
sort reads into the appropriate samples. Reads that did not contain any of the expected
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indexes in the correct position were discarded. In order to identify the TCR present in a
sequence read, our lab has previously developed software called Decombinator [145],
which uses the Aho-Corasick algorithm to assign V and J genes to each read based on
the presence of short ‘tags’ defining each potential gene. Then each read is given a
five-part classifier (a ‘DCR’) defining the TCR, consisting of:
1. an index defining the V gene
2. an index defining the J gene
3. the number of nucleotides deleted from the 3’ end of the V gene
4. the number of nucleotides deleted from the 5’ end of the J gene
5. a string of nucleotides present between 3’ V and 5’ J.
The sequence reads from the Genome Analyzer II are 50bp long, which covers the
CDR3 region of the TCRβ but does not provide coverage of the gene-specific tags
used by Decombinator to assign V and J genes. Instead, to assign V and J genes to
each sequence read in this dataset an adaptation of Decombinator, referred to as Short
Read Decombinator (‘SRD’) was developed, as described in [144]. Details of the SRD
algorithm are found in Appendix D. Briefly, instead of searching the sequence read for
any of a set of tags uniquely identifying each gene, SRD searches the sequence read
for any appropriately located substring from the 3’ end of each V gene or the 5’ end of
each J gene. Based on the substrings that are found, the algorithm assigns a gene on the
basis of length of substring matches. Once V and J genes are assigned to a sequence
read, the remaining fields of the DCR can be calculated.
The genes that were used by SRD to search the sequence reads were taken from IMGT
[50], and were selected from IMGT/GENE-DB (http://www.imgt.org/genedb/) with the
following parameters:
– Species: Mus
– Gene type: variable/joining
– Functionality: functional
– Molecular component: TR
– Locus: TRB
– Main locus: TRB
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giving 22 V genes and 11 J genes (ignoring alleles) that each sequence read could be
assigned to. However, three of the V genes in this set were removed from the search
due to being indistinguishable in the 3’ region covered by the sequence data from other
V genes (details in Appendix D).
Once each raw sequence read has been assigned a DCR, or discarded if assignment
isn’t possible, the data was further processed to remove those that did not describe a
functional TCRβ protein. A DCR was removed if any of the following applied:
1. there was a nucleotide that the sequencing machine called ambiguously (giving
an ‘N’ in the fastq file) in the region between the V and J genes (the fifth field of
the DCR)
2. the nucleotide sequence constructed from the DCR was out-of-frame. For
TCRβ s, a sequence is in-frame if the 3’ nucleotide of the J gene forms a codon
with the two 5’ nucleotides of the constant region.
3. the nucletoide sequence constructed from the DCR included a stop codon
4. the amino acid sequence translated from the DCR did not contain the conserved
cysteine defining the start of the CDR3 in the correct position of the V region
5. the amino acid sequence translated from the DCR did not contain the FGXG (or
related) motif in the J region defining the end of the CDR3
After processing the data files to remove non-functional TCR sequences, remaining
sequences were translated and CDR3s were extracted. The analysis in this chapter
mostly uses the CDR3β repertoires rather than DCR repertoires, except where gene
usage is discussed.
4.2.3 Data analysis
The diversity of the CDR3β repertoires is calculated using the Simpson, Shannon,
normalised Shannon and Gini indexes, as described in Section 1.3.1.1 and the Jaccard
index (Section 1.3.1.3) is used to measure the similarity between pairs of repertoires.
In order to assess the distance or similarity between two CDR3β amino acid sequences,
two measures are used. The Levenshtein distance counts the number of ‘edits’ (inser-
tions, deletions or substitutions) that are needed to transform one of the CDR3s into
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the other, while the p-spectrum kernel is a similarity measure, counting the number of
substrings of length p that are shared between the CDR3s.
Other analysis techniques are described in the relevant results section. Analysis is
performed in Python, using the SciPy and NumPy packages.
4.3 Characteristics of the TCR repertoire
Figure 4.1: Numbers of TCR sequences obtained from each sample
For CD4+ T cell receptor samples from in vivo immunised mice, coloured by im-
munisation status, the (a) number of raw reads, decombinated reads and reads with
a valid CDR3 from each sample, (b) proportion of raw reads (mean ± standard de-
viation) that are succcessfully decombinated or have a valid CDR3 and (c) number
of total observations and distinct DCRs (Decombinator classifiers) or CDR3s.
For CD4+ T cell receptor samples from in vivo immunised mice after in vitro stim-
ulation (immunisation status and in vitro stimulation indicated by colour), the (d)
number of raw reads, decombinated reads and reads with a valid CDR3 from each
sample, (e) proportion of raw reads that are successfully decombinated or have a
valid CDR3 for each sample and (f) number of total observations and distinct DCRs
or CDR3s per sample.
The dataset analysed in this Chapter contains 63 TCRβ repertoire samples. 44 of these
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samples are from splenic CD4+ T cells without any in vitro culture. These are referred
to as in vivo samples, while the remaining 19 samples which are from splenic CD4+ T
cells after in vitro culture are referred to as in vitro samples.
The majority of the 44 in vivo samples contain between 106 and 107 sequence reads,
and for most samples between 5×105 and 107 of these raw reads contain a valid CDR3
after processing by Decombinator (Figure 4.1a). The proportion of raw reads that are
assigned a Decombinator 5-part classifier (‘DCR’) is lower for p277 immunised sam-
ples than unimmunised, CFA only immunised or CFA+OVA immunised samples, but
the proportion of raw reads that contain a valid CDR3 is similar between immunisation
groups (Figure 4.1b). The total number of TCR molecules sequenced from the in vivo
samples (after data has been processed) is higher for CFA only and CFA+OVA immu-
nised samples, and this difference is also seen in an increased number of distict DCRs
and CDR3s observed in these samples (Figure 4.1c).
In the in vitro stimulated data, numbers of reads per sample are similar to the in vivo
data, with the exception of one sample (p277 immunised and Tb stimulated) which
contains only approximately 105 raw reads of which approximately 104 contain a valid
CDR3 (Figure 4.1d). With the exception of this smaller sample, the proportion of
raw reads that are successfully decombinated or contain a valid CDR3 (Figure 4.1e)
is comparable to the in vivo samples, as is the number of distinct DCRs and CDR3s
observed.
The proportional gene usage in the TCR repertoire samples (Figures 4.2a and b) for all
samples used in this chapter shows that some genes have more variable usage between
samples than others. Usage of TRBJ1-1 is highly variable, while usage of the other J
genes is much more consistent. Similarly, usage of TRBV12-1 is more variable than
the other V genes.
The proportional gene usage data from in vivo samples, grouped by immunisation sta-
tus (Figure 4.2c and d) demonstrates that some genes differ between groups. However it
has been shown previously in our group that these differences are not enough to distin-
guish between unimmunised and CFA only or CFA+OVA immunised samples. There
are four J genes which show statistically significant (p < 0.01 by the Mann Whitney
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Figure 4.2: Gene usage in TCRβ samples
(a,b) Proportional V and J gene usage across all samples. (c,d) For samples from
immunised mice with no in vitro stimulation, mean ± standard deviation of pro-
portional V and J gene usage grouped by immunisation type (indicated by colour).
U test and the Kolmorgorov Smirnoff 2 sample test) different usage between both CFA
only and unimmunised samples and between CFA+OVA and unimmunised samples
(J1-1, J2-1, J2-5 and J2-6). Only one V gene (V3) demonstrates statistically differ-
ent usage between CFA only and unimmunised samples and between CFA+OVA and
unimmunised samples.
The gene usage profile in p277 immunised samples is markedly different from the other
groups, with four J genes (J1-1, J1-3, J1-4 and J2-2) being differentially used in p277
samples when compared to any of the other groups. The V gene usage profile is less
different in p277 samples, with only V5 being differentially used in p277 samples when
compared to any of the other groups. However, other V genes are differentially used
in p277 samples in comparison to at least one of the other samples. For example,
V13-1 and V15 are both statistically significantly over-expressed in p277 samples in
comparison to CFA+OVA samples.
In terms of identifying a repertoire signature of antigen-specific immune response to
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ovalbumin, there are no V or J genes which have a proportional usage which is statisti-
cally significantly different between CFA only and CFA+OVA immunised groups. This
indicates that the antigen specificity of the immune response cannot be identified at the
level of whole repertoire gene usage.
Figure 4.3: Repertoire diversity measures
The diversity of the repertoire in each sample, measured by the Simpson, Shannon,
normalised Shannon and Gini indexes. Top row: diversity of in vivo immunised
repertoires, without any in vitro stimulation, coloured by immunisation status. Bot-
tom row: diversity of in vitro stimulated repertoires, coloured by immunisation
status and in vitro culture peptide.
Global measures of the diversity of the repertoires (Figure 4.3) also do not show sub-
stantial differences between immunisation groups. In the in vivo samples, there are no
statistically significant differences (by Mann Whitney U test or Kolmorgorov Smirnoff
2 sample test, with significance being p < 0.01) between the groups when diversity is
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measured by the Simpson or Shannon indexes. By the normalised Shannon, p277 im-
munised samples have a higher diversity than CFA only immunised samples under the
Mann Whitney U test, but not under the Kolmorgorov Smirnoff test. The Gini index,
measuring the evenness of the repertoires, shows that p277 immunised samples have
a lower Gini (more even distribution of clones) than other immunised samples (CFA
only or CFA+OVA). None of these measures of diversity show any difference between
untreated and CFA only or CFA+OVA immunised samples, and no difference between
CFA only and CFA+OVA immunised samples.
For the in vitro samples, assessment of differences between groups is made difficult
by the number of samples per group. No statistically significant differences are found
between groups when samples are grouped if they are concordant in both in vivo immu-
nisation status and in vitro stimulating peptide. When samples are grouped by either the
in vivo immunisation status or the in vitro stimulating peptide then some differences are
seen, although none of the groups demonstrate consistently different diversity across all
measures.
The in vitro stimulated repertoires of p277 immunised samples demonstrate statisti-
cally significant lower diversity than CFA only or CFA+OVA immunised in vitro stim-
ulated samples when diversity is measured by the Simpson index, but when diversity
is measured by the Shannon or normalised Shannon this pattern is reversed and p277
immunised in vitro stimulated samples have higher diversity than CFA only immunised
samples. p277 immunised in vitro stimulated samples also have a lower Gini (indicat-
ing a more even repertoire) than CFA only immunised samples.
When samples are grouped by the in vitro stimulating peptide, samples stimulated with
p277 demonstrate lower diversity than OVA stimulated samples by the Simpson Index
but higher diversity by the Shannon and normalised Shannon. When OVA stimulated
and TB stimulated samples are compared using the Mann Whitney U test, OVA stim-
ulated samples demonstrate higher diversity under the Simpson Index, but lower di-
versity under the Shannon and normalised Shannon. Samples stimulated in vitro with
p277 have a lower Gini (more even repertoire) than samples stimulated with OVA.
Applying diversity metrics to these samples results in a complicated and inconsistent
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picture of how immunisation and in vitro stimulation affects the repertoire, made diffi-
cult to interpret by the number of samples in each group. A more detailed analysis of
the characteristics and composition of the repertoire in each sample is required in order
to identify signatures of antigen specific response.
4.4 TCR repertoire changes on in vivo immunisation
The CD4+ TCR repertoire samples from spleens of mice left unimmunised or immu-
nised with CFA ± OVA are analysed to ask whether there is a set of CDR3β s that
identify the immune response to OVA.
4.4.1 Known OVA-responsive CDR3β s do not distinguish reper-
toires from OVA-immunised mice
We measure the frequency of known OVA-responsive CDR3β s in each of our samples.
The OTII T cell is a CD4+ T cell expressing a TCR known to be responsive to the OVA
peptide in C57BL/6 mice (e.g. [123]), and the frequency of this CDR3β is increased in
immunised mice (Figure 4.4a). However, the frequency is not further increased in mice
which have been immunised with CFA+OVA rather than CFA only or CFA + p277.
This is not an artefact of sample size, since the same pattern is observed in absolute
abundances. Additionally, the distribution of frequencies across all observed CDR3β s
and the number of CDR3β s observed is not substantially altered by immunisation,
suggesting that the increased frequency observed on immunisation is due to clonal
expansion of cells expressing the β chain of OTII, but not in an OVA-specific manner.
The OTI T cell is a CD8+ T cell with a TCR recognising a peptide of ovalbumin.
The CDR3β of OTI is observed at low frequency in some of our samples (Figure 4.4b),
suggesting that either OTI is also present on some CD4+ T cells or that the experimental
sorting of CD4+ from CD8+ T cells was not completely pure. The frequency of OTI
CDR3β is not increased in immunised mice. The OTII CDR3α is not observed in any
sample in this data, nor is the DO11.10 CDR3β , a TCR responsive to ovalbumin in the
context of I-Ad, an MHC molecule not expressed in the mice in our experiment.
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Figure 4.4: Frequency of known OVA-responsive CDR3s: in vivo samples
The frequency in TCR repertoire samples of (a) OTIIβ , (b) OTIβ , (c,d) CDR3s
identified in [46] as OVA-responsive.
In a study investigating the T cell response in mice to skin sensitisation assays [46]
TCRs were sequenced from skin and organs before and after applying ovalbumin (with
cholera toxin as adjuvant) to the ear. A number of CDR3s are identified which are
undetectable before sensitisation and highly abundant in skin and lymph nodes once
acute inflammation is resolved. Of these OVA-responsive CDR3s identified, two are
present in our samples (Figure 4.4c,d) but again are not observed to be increased in
mice that have been immunised.
4.4.2 OVA-responsive TCRs are not public between mice
Since known OVA-responsive CDR3β s do not differentitate between samples from
mice immunised with or without ovalbumin, it seems that the antigen-specific TCR
response might be distributed amongst many different CDR3β s. We hypothesise that
these CDR3β s might be shared between mice, and therefore samples from mice that
have been subject to immunisation with the same antigens might have more CDR3β s in
common than samples from mice who have not been subject to the same immunisation.
There is no increase in number of CDR3β s that are highly public in groups of immu-
nised mice in comparison to unimmunised mice (Figure 4.5a), suggesting that the T cell
response to immunisation does not involve the same CDR3β s in all the mice. Next, the
convergence of immune response between pairs of mice is considered using the Jaccard
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Figure 4.5: Immune response at the CDR3β level is not shared between mice
(a) The proportion of CDR3β s that are observed in exactly the number of mice
on the x-axis, with mice grouped by immunisation status. Equal sized subsamples
of mice are repeatedly selected from each group, with mean ± standard deviation
shown.
(b) The Jaccard index between the spleen sample CDR3β repertoires from every
pair of mice, grouped by immunisation status. Lines indicate mean ± standard
deviation for each group.
(c) The mean± standard deviation Jaccard Index for each group, as in (b), when the
repertoire considered is restricted to the largest CDR3β s observed in each sample.
Index. The Jaccard index is a measure of similarity of two sets, and here measures the
number of distinct CDR3β s that are common to both repertoires as a proportion of the
number of distinct CDR3β s that appear in either repertoire.
The distribution of pairwise Jaccards between repertoires from unimmunised mice or
immunised mice, either under the same or different immunisation conditions (Fig-
ure 4.5b) does not suggest any convergence of repertoire on immunisation can be de-
tected at the full repertoire level. Next, a restricted repertoire for each sample, including
only those CDR3β s with the largest abundances in the sample, is considered. Restrict-
ing the repertoire in this manner increases the absolute Jaccard index between samples
when considering the 10% or 1% most abundant CDR3β s (Figure 4.5c), showing that
moderately frequent CDR3β s are more public than rare CDR3β s and very highly fre-
quent CDR3β s. However, there is no statistically significant difference between the
distribution of Jaccards from unimmunised and immunised pairs of mice (also seen in
the same data set in [91]), suggesting that this increased absolute value of the Jaccard
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is not due to convergence of the repertoire on immunisation. Taking only the 0.1%
most abundant CDR3β s does give a statistically significant increase in the distribution
of pairwise Jaccards on immunisation (p < 10−3 for unimmunised vs CFA and unim-
munised vs CFA+OVA under both the Mann Whitney U test and the Kolmorgorov-
Smirnoff 2 sample test). This suggests that in the very largest CDR3β s there may be
convergence of repertoire due to immunisation, but no convergence in response to the
OVA element of the immunisation.
4.4.3 Expansion with respect to unimmunised samples identifies
privately responding CDR3β s
The most abundant CDR3β s are not necessarily those that have undergone the most
clonal expansion on immunisation and therefore they might not demonstrate a conver-
gent immune response. In order to identify the most highly proliferated CDR3β s, the
frequency observed in a sample needs to be compared to a ‘background’ frequency.
Here the background frequency is defined as the frequency of the CDR3β when all
observations from unimmunised mice are pooled. If a CDR3β is found in none of the
unimmunised samples it is allocated a background frequency equal to the minimum
background frequency observed.
Expansion coefficients for each CDR3β in each immunised mouse sample are calcu-
lated by dividing the CDR3β frequency in the immunised sample by the CDR3β back-
ground frequency, obtained as described above. The proportion of observed CDR3β s
in each sample that have expansion coefficient greater than a given threshold is cal-
culated, with means for each immunisation group shown in Figure 4.6a. There is no
statistically significant difference between the proportion of CDR3β s expanded in CFA
only and CFA+OVA immunised group at any of the expansion thresholds (by the KS 2
sample test, all p-values > 0.01).
For the following analysis we define ‘highly expanded CDR3β s’ in a sample from a
mouse as those that have an expansion coefficient greater than 29. The proportion of
CDR3β s from each sample that are defined as highly expanded does not differ between
CFA only and CFA+OVA immunised groups (Figure 4.6b). There is also no statisti-
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Figure 4.6: Expanded CDR3β s identified with reference to frequency in unimmunised
mice
For each CDR3β in a sample from an immunised mouse, an expansion coefficient
relative to the frequency in pooled samples from unimmunised mice is calculated.
(a) The proportion of observed CDR3β s in immunised samples with expansion
coefficient greater than expansion thresholds on the x-axis. Data show is mean
across all mice from an immunisation condition and colour indicates immunisation
condition. Using a definition of expanded CDR3β s as those with an expansion co-
efficient in the sample > 29, the proportion of CDR3β s in each sample defined as
expanded, with samples grouped by (b) immunisation condition or (c) immunisa-
tion condition and time of sample extraction. Early: d5 or d7 post immunisation,
mid: d10 or d14 post immunisation, late: m2 post immunisation. Colour indicates
immunisation condition. (d) Venn diagram demonstrating overlap between sets of
highly expanded CDR3β s. Set A: The CDR3β s highly expanded in at least one
CFA-only immunised mouse. Set B: The CDR3β s highly expanded in at least one
CFA+OVA immunised mouse. (e) For CDR3β s defined as highly expanded in any
mouse (total 4,332), the number of mice (from either immunisation group) that they
are present (dotted line, open circles) or highly expanded (solid line, solid circles)
in. For CDR3β s defined as highly expanded in at least one CFA+OVA immunised
mouse (total 2,124), the number of (f) CFA+OVA immunised mice and (g) CFA
only immunised mice that they are present (dotted line, open circles) or highly ex-
panded (solid line, solid circles) in. (h) The mean number of CFA+OVA immunised
mice (total 15) that a CDR3β defined as highly expanded in at least one CFA+OVA
immunised mouse (total 2,124) falls into each category within. CDR3β s are cat-
egorised as being (i) absent from a sample if not observed at all, (ii) contracted if
they are observed with an expansion coefficient < 1, (iii) less expanded if expan-
sion coefficient is > 1 but < 29 and (iv) highly expanded if expansion coefficient is
> 29. Error bars represent standard deviation.
4.4. TCR repertoire changes on in vivo immunisation 116
cally significant difference between the CFA only and CFA+OVA immunised groups
when the samples are separated according to time post-immunisation before sample
collection (Figure 4.6c, by the KS 2 sample test all p-values > 0.1 for CFA-only vs
CFA+OVA within a timepoint). While the ‘magnitude’ of the response to immunisa-
tion does not appear to depend on the presence of OVA antigen, the clonal composition
of the response might alter, allowing identification of OVA-responsive CDR3β s.
The CDR3β s that are highly expanded in any CFA-only immunised mouse (2,291 to-
tal) and those that are highly expanded in any CFA+OVA immunised mouse (2,124
total) show little overlap (Figure 4.6d). This suggests an individual-specific response
to CFA is being observed, since if the CDR3β s expanding in response to CFA were
shared between mice the set of CDR3β s highly expanded in CFA-only mice might be
expected to be a subset of those highly expanded in CFA+OVA mice. This is further
demonstrated by counting the number of mice (of either immunisation group) that each
highly expanded CDR3β (total 4,332) is present or highly expanded in (Figure 4.6e).
Although many of these CDR3β s are present in a number of mice, the majority (4,195)
are only highly expanded in a single mouse and the most publicly highly expanded
CDR3β is highly expanded in just seven of 28 mice.
The CDR3β s that are highly expanded in at least one CFA+OVA immunised mouse
we call ‘OVA highly expanded’. The OVA highly expanded CDR3β s are also not very
public among CFA+OVA immunised mice (Figure 4.6f), with 2,049 of the 2,124 being
highly expanded in only one mouse and the most public OVA highly expanded CDR3β
being highly expanded in just five of the 15 mice, despite some of them being present in
many of the mice. Similarly, the OVA highly expanded CDR3s are not highly expanded
in multiple CFA-only immunised mice (Figure 4.6g).
The clonal expansions in the T cell population in response to immunisation with OVA
appear to be mostly private to each mouse. This privacy of response could be due to T
cells of a responsive CDR3β not being present in multiple mice before immunisation,
so not being available for expansion. Alternatively, it could be that cells bearing the
CDR3β are present in multiple mice but are not selected for expansion in all mice, pos-
sibly due to differential competitive effects from the rest of the T cell population. For
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each of the OVA highly expanded CDR3β s, the expansion coefficient of the CDR3β
in each of the CFA+OVA immunised mice was collected and the ‘behaviour’ of the
CDR3β in each of the mice was allocated to one of four categories. If the CDR3β
isn’t observed in the sample from a mouse it is classed as ‘absent’, while if it is present
but with an expansion coefficient < 1 it is categorised as ‘contracted’. If the CDR3β
has an expansion coefficient > 1 it is either ‘less expanded’ if the expansion coefficient
isn’t greater than the 29 threshold, or ‘highly expanded’ if it is. For each OVA highly
expanded CDR3β the number of CFA+OVA immunised mice (total 15) that it demon-
strates each of these behaviours in is counted. The mean of these numbers across all
OVA highly expanded CDR3β s (Figure 4.6h) shows that in very few mice is an OVA
highly expanded CDR3β contracted and for the majority of mice it is completely ab-
sent from the sample. This suggests that the privacy of the clonal response to OVA is
due to the expanding CDR3β s not being available in other mice.
To identify a clonal signature of response to OVA, we attempt to separate the CDR3β s
that are proliferating in response to the CFA from those proliferating in response to the
OVA. Initially, the OVA highly expanded CDR3β s (those with expansion coefficient
> 29 in at least one CFA+OVA immunised mouse) are filtered by their maximum ex-
pansion coefficient in any CFA only immunised mouse. A lower expansion coefficient
threshold is defined, and if a CDR3β is OVA highly expanded and does not exceed this
threshold in any CFA only immunised mice we refer to it as ‘OVA specifically highly
expanded’.
The number of OVA specifically highly expanded CDR3β s from each CFA+OVA im-
munised mouse are counted (Figure 4.7a). This number remains relatively stable across
different values of the lower expansion coefficient threshold, and when this threshold
is set to 24 all CFA+OVA immunised mice contain at least one OVA specifically highly
expanded CDR3β . However, the OVA specifically highly expanded CDR3β s are very
private, with only one meeting the criteria in more than one CFA+OVA immunised
mouse, and therefore may not be suitable to define a CDR3-level signature of T cell
population response to OVA immunisation. We collect the total set of these OVA
specificially highly expanded CDR3β s and refer to them as a set of OVA-associated
CDR3β s.
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Figure 4.7: Identification of OVA-associated CDR3β s in in vivo data
(a) For each CFA+OVA immunised mouse, the number of CDR3β s defined as
OVA specifically highly expanded at different lower expansion coefficient thresh-
olds. (b)-(d) Representative examples of OVA highly expanded CDR3β s that are
categorised as (b) unclassified, (c) endogenous peptide stimulated, (d) CFA stimu-
lated or (e) OVA stimulated. (f) The number of OVA highly expanded CDR3β s that
are classified into each of these four categories. (g) The number of OVA-associated
CDR3β s present in each mouse sample. (h) The total frequency of OVA-associated
CDR3β s in each mouse sample.
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Next, we consider the reasons why the OVA highly expanded CDR3β s might have
proliferated, and use the frequency of the CDR3β in all samples to determine which
reason is most likely as follows. A CDR3β might clonally expand due to recognition
of an endogenous peptide, in which case we would expect the CDR3β to be present
in an unimmunised mouse at a comparable frequency to the lowest non-zero frequency
observed in a CFA+OVA immunised mouse. Alternatively, it might have clonally ex-
panded in response to a peptide from the adjuvant. In this scenario we would expect
to observe the CDR3β at comparable frequency in at least one CFA only immunised
mouse sample. We classify each of the OVA highly expanded CDR3β s into one of the
following four categories:
Unclassified: An OVA highly expanded CDR3β which is not present in any sample
from an unimmunised or CFA only immunised mouse
Endogenous stimulated: An OVA highly expanded CDR3β with maximum frequency
across unimmunised mice > 0.5×minimum non-zero frequency across CFA+OVA im-
munised mice.
CFA stimulated: An OVA highly expanded CDR3β which is not unclassified or clas-
sified as endogenous peptide stimulated and which has maximum frequency in CFA
immunised mice > 0.5× minimum non-zero frequency across CFA+OVA immunised
mice.
OVA stimulated: An OVA highly expanded CDR3β which is observed in at least one
sample from unimmunised or CFA only immunised mice but which is not classified as
endogenous stimulated or CFA stimulated.
Representative examples of OVA highly expanded CDR3β s falling into each of these
categories are shown in Figures 4.7b-e. Of the 2,124 OVA highly expanded CDR3β s,
291 cannot be classified, 586 appear to be expanded due to endogenous peptide, 1,002
are classified as CFA stimulated and 245 are classified as OVA stimulated (Figure 4.7f).
These form a second set of OVA-associated CDR3β s. Despite these OVA-associated
CDR3β s being highly expanded (relative to pooled unimmunised mice) in a CFA+OVA
immunised sample and being present at a higher frequency in CFA+OVA immmunised
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mice than any unimmunised or CFA immunised mouse, they do not seem to define a
cross-animal signature of immune response. In particular, in one CFA+OVA immu-
nised mouse none of these OVA-associated CDR3β s appear and the number of them
that are present (at any frequency) in each of the CFA+OVA immunised mice is not
higher than the number that are present in the CFA only immunised samples (Fig-
ure 4.7g). The total frequency of this set of OVA-associated CDR3β s in CFA+OVA
immunised samples is higher than in CFA only immunised samples (Figure 4.7h), but
the distributions do overlap.
4.5 In vivo TCR repertoires: discussion
We have seen that CDR3β s previously described as being part of an OVA-specific TCR
do not have increased frequency in OVA immunised samples in comparison to CFA im-
munised samples in these TCR repertoires. However, they do have increased frequency
in immunised samples in comparison to unimmunised samples. We propose that this
observation can be explained by one of the following: (i) these β chains are paired
with multiple αs giving different specificities for either CFA or OVA in different mice,
(ii) these β chains create cross-reactive TCRs, responding to both the OVA peptide
and a presented antigen from the adjuvant, or (iii) the cells bearing these β chains are
activated via a ‘by-stander’ effect of some description, perhaps because of increased
presentation of a particular self-peptide due to the immune response or recruitment by
activated clones. It would be interesting to perform the same experiment in the context
of a different adjuvant, to determine if the CFA component of the immunisations is
driving the proliferation of these CDR3β s.
We also see in these data that concordant immunisation status does not increase the
amount of CDR3β sharing between pairs of repertoires when the full repertoire is con-
sidered, and only slightly increases the level of sharing between repertoires when just
the very largest clones are considered. This suggests that immunisation does not drive
a convergent immune response at the CDR3β level even in genetically identical mice,
so it will not be possible to define the TCR response to antigen challenge in terms of
frequency of single CDR3β s.
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We can use these TCR repertoires to identify CDR3β s that have high frequency in an
immunised sample in comparison to pooled unimmunised samples, which could result
from clonal expansion on immunisation. We are able to define a set of OVA-associated
CDR3β s that each appear to have been highly expanded in a CFA+OVA immunised
animal, but not highly expanded in any CFA-only immunised animals. These OVA-
associated CDR3β s were remarkably private, with most only being highly expanded
(relative to unimmunised samples) in one or two CFA+OVA immunised animals, sug-
gesting that each animal employs a distinct set of CDR3β s in their ovalbumin response.
Further, these OVA-associated CDR3β s are completely absent from the majority of
other mice rather than being present but not abundant, suggesting that the privacy of
the ovalbumin response is due to lack of availability of the same clone in multiple mice
rather than differential selection.
The privacy of expanded clones was reinforced in analysis which defines OVA-
associated CDR3β s by comparison of their minimum non-zero frequency in CFA+OVA
immunised mice with their maximum frequency in other mice. This analysis obtains a
set of 245 OVA-associated CDR3β s, which are again found to be predominantly pri-
vately OVA-associated and the most ‘public’ of these is present in only four of the
CFA+OVA immunised mice. Additionally, this analysis inferred that the majority of
CDR3β s that are highly expanded in a CFA+OVA immunised sample compared to
unimmunised mice can be classified as stimulated by a CFA peptide or by an endoge-
nous peptide. It may be that in this experimental set up the T cell response to the OVA
peptide is dwarfed by the possibly broader and stonger response to the adjuvant. The in
vitro stimulation data from these experiments, where CD4+ T cells are cultured in the
presence of TB or OVA peptide may provide more insight into the repertoire changes
in response to OVA and is discussed next.
4.6 TCR repertoire changes on in vitro stimulation
For a number of the immunised mice, splenic CD4+ T cells were cultured in vitro
with heat-killed TB, OVA peptide or p277 for 7 days and the TCR repertoire was then
sequenced. These samples are used here to identify CDR3β s which are potentially
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responsive to ovalbumin.
4.6.1 Known OVA-responsive CDR3s are not increased in fre-
quency in OVA stimulated in vitro cultures
The frequency of OVA-responsive CDR3s described in Section 4.4.1 is measured in the
in vitro cultured samples and the fresh spleen samples of the same mice (Figure 4.8).
OTIIβ is found at relatively high frequency in all samples (Figure 4.8a), but is not
increased in OVA stimulated samples. OTIβ (Figure 4.8b) is not observed in many in
vitro stimulated samples and is at low frequency when observed, similar to the pattern
in the in vivo samples (Figure 4.4b). The OVA-responsive CDR3s identified in [46]
(Figure 4.8c,d) are also not increased in frequency on in vitro stimulation with OVA.
Figure 4.8: Frequency of known OVA-responsive CDR3s: in vitro stimulated samples
The frequency in TCR repertoire samples of (a) OTIIβ , (b) OTIβ , (c,d) CDR3s
identified in [46] as OVA-responsive. Colour indicates the in vivo immunisation
treatment of the mouse. Values in the spleen column are the frequency in the sample
sequenced directly from the spleen, other columns are the frequency in the sample
sequenced after in vitro stimulation for 7 days with the indicated antigen. Lines
join samples derived from the same animal.
4.6.2 In vitro stimulation of pools of spleen cells with different anti-
gens
Within the dataset there are four mice for which there are sequenced TCR samples taken
directly from the spleen, after in vitro culture with TB and after in vitro culture with
OVA. These samples are used to search for OVA-responsive CDR3β s. In this analysis
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these mice are referred to as A, B, C and D. Mice A and B were in vivo immunised
with CFA only, and sacrificed at d7 post immunisation. Mice C and D were in vivo
immunised with CFA+OVA and were also sacrificed at d7 post immunisation. There
are a total of 12 samples sequenced from these four mice.
Figure 4.9: Similarity between repertoires
The similarity, as measured by the Jaccard index, between pairs of CDR3β reper-
toires from four mice with spleen, OVA stimulated and TB stimulated samples
when pairs are grouped by (a) whether they are from the same or different animals
and (b) whether they are from the same or different sample types.
For any pair of these 12 samples, there is no increased similarity (as measured by the
Jaccard Index) between the CDR3β repertoires when the samples are from the same
mouse (Figure 4.9a). Additionally there is no increased similarity between pairs of
samples of the same sample type (spleen, TB stimulated or OVA stimulated) when
compared to samples of different types (Figure 4.9b).
4.6.3 Expansion relative to ex vivo spleen sample identifies pri-
vately OVA associated CDR3β s
For each of these 12 samples, we consider the distribution of CDR3β clone sizes (Fig-
ure 4.10a-c). In the samples sequenced directly from ex vivo spleen (Figure 4.10a)
the CDR3β abundances are comparably distributed, regardless of in vivo immunisa-
tion condition. In the TB stimulated samples (Figure 4.10b), the distributions are less
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similar. Three of the four samples contain fewer distinct CDR3β s than the spleen sam-
ples, and the most abundant CDR3β s from mouse D have smaller observed clone size
than the most abundant CDR3β s from the other mice. In the OVA stimulated samples
(Figure 4.10c) again fewer distinct CDR3β s are observed when compared to spleen
samples. Additionally, the samples from CFA+OVA immunised mice (red lines) ap-
pear to have more abundant CDR3β clones than samples from CFA only immunised
mice after in vitro OVA stimulation.
Figure 4.10: CDR3β clone sizes and expansion coefficients of in vitro samples
Mice A and B immunised with CFA only (blue), mice C and D immunised with
OVA + CFA (red). The abundance of ranked CDR3β s from each mouse in (a) ex
vivo spleen samples, (b) TB stimulated samples and (c) OVA stimulated samples.
Expansion coefficients for each CDR3β in the stimulated samples are calculated
by dividing their frequency by their frequency in the ex vivo spleen sample from
the same animal. The number of CDR3β s from each mouse that have an expan-
sion coefficient greater than the indicated threshold in (d) TB stimulated samples
and (e) OVA stimulated samples.
For each CDR3β observed in an in vitro stimulated sample, an expansion coefficient
can be calculated by dividing its frequency by the frequency of the same CDR3β in
the ex vivo spleen sample from the same animal. If the CDR3β is not observed in the
spleen sample it is assigned the minimum observed frequency to use as a denominator
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to calculate the expansion coefficient. The expansion coefficient estimates the prolifer-
ation of the CDR3β due to the in vitro stimulation condition, and does not include the
proliferation of the CDR3β due to the immunisation that the animal was given in vivo.
An expansion coefficient is calculated in this way for every CDR3β observed in each
in vitro stimulated sample. The number of CDR3β s that have expansion coefficient
greater than a given threshold in the TB stimulated samples (Figure 4.10d) and in the
OVA stimulated samples (Figure 4.10e) are broadly similar for each mouse. In a similar
manner to the analysis of the in vivo data, we define OVA-associated CDR3β s for each
mouse as those with a high expansion coefficient in the OVA stimulated sample and a
low expansion coefficient in the TB stimulated sample.
The relationship between the expansion coefficient of a CDR3β in the TB and OVA
stimulated samples from a mouse are shown in Figure 4.11. In each of the mice there
is statistically significant correlation in the expansion coefficients (Pearson correlation,
p < 0.002 for each mouse). However, if only the CDR3β s that are expanded at least 8
fold in one of the in vitro stimulated samples relative to the spleen sample are included
in the analysis the correlation becomes non-significant (p > 0.05) for mice C and D
while remaining highly significant for mice A and B. This suggests that after immu-
nisation with CFA only (mice A and B), CDR3β s proliferate equivalently on in vitro
exposure to TB or OVA. However, after immunisation with CFA+OVA (mice C and
D), subsequent in vitro exposure to OVA stimulates a different set of CDR3β s than are
proliferated on exposure to TB.
We define OVA-associated CDR3β s in each of these mice as those that fall into the
top left quadrant of the plots in Figure 4.11, that is, CDR3β s which have an expansion
coefficient < 25 on exposure to TB but > 29 on exposure to OVA. These criteria define
75 OVA-associated CDR3β s in mouse A, 2 in mouse B, 38 in mouse C and 9 in mouse
D. This gives a total set of 124 OVA-associated CDR3β s derived from the in vitro
sequence data, each of which is completely privately OVA-associated, i.e. it is only
defined as OVA-associated in one of the four mice.
While these 124 CDR3β s are privately OVA-associated, they are not completely pri-
vate. Figure 4.12a shows the abundance of each of the 124 OVA-associated CDR3β s,
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Figure 4.11: Correlation between CDR3β expansion coefficients in TB and OVA stimu-
lated samples
For each CDR3β in an in vitro stimulated sample an expansion coefficient is cal-
culated by dividing the frequency of the CDR3β by its frequency in the ex vivo
spleen sample from the same animal. The relationship between the expansion
coefficients for each CDR3β in TB and OVA in vitro stimulated sample. ‘abs’
denotes absence from the indicated sample and ‘con’ denotes contraction (i.e.
expansion coefficient < 1). Diagonal line is y = x, horizontal and vertical lines
indicate the expansion coefficients used as thresholds to define OVA-associated
CDR3β s. OVA-associated CDR3β s are coloured red.
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Figure 4.12: Patterns of abundance and expansion of OVA-associated CDR3β s
For the CDR3β s defined as OVA-associated in any of the four mice (124 in to-
tal), (a) their abundance in each of the samples from each of mice A-D, (b) their
expansion coefficients (defined as frequency in stimulated sample divided by fre-
quency in ex vivo spleen sample) in the TB and OVA stimulated samples from
each mouse. CDR3β s are grouped by the mouse in which they are defined as
OVA-associated.
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grouped by the mouse in which they are defined as OVA-associated, in all of the sam-
ples considered here. This demonstrates that many of these CDR3β s are present in
samples from other mice, but not at appropriate abundances to be considered OVA-
associated. Figure 4.12b is an equivalent plot, but demonstrating the expansion co-
efficient of each OVA-associated CDR3β in each of the in vitro stimulated samples.
These data suggest that in the in vitro stimulated samples there is differential selection
of particular CDR3β s, such that some are able to be increased in abundance on OVA
stimulation in samples from one mouse but not another.
Figure 4.12 also highlights some other interesting patterns of CDR3β response to in
vitro OVA stimulation. The CDR3β s defined as OVA-associated in mouse A have a
qualitatively similar pattern of abundance (and of expansion) in the samples from mice
A and B (the CFA-only immunised mice), but do not demonstrate this pattern in mice
C or D (the CFA+OVA immunised mice). This might suggest that these CDR3β s are
only able to respond to in vitro OVA stimulation when there has been no pre-exposure
(by in vivo immunisation) to OVA.
There are a number of CDR3β s (including the two defined as OVA-associated in mouse
B) that demonstrate an opposite pattern of behaviour in the CFA-only immunised mice
(mice A and B) to the CFA+OVA immunised mice (mice C and D). These CDR3β s
are present at low abundance in the spleen samples, are somewhat expanded in TB
stimulated samples and are more highly expanded in OVA stimulated samples from
CFA-only immunised mice (A and B). In contrast, they are present at relatively high
abundance in the spleen samples from CFA+OVA immunised mice (C and D), perhaps
suggesting that they have been expanded in vivo in response to OVA. However, they are
contracted or deleted in the OVA stimulated sample from the these mice, suggesting that
in vitro stimulation with OVA is not able to cause proliferation of these CDR3β s when
they have already been exposed to ovalbumin via in vivo immunisation.
Interestingly, the OVA-associated CDR3β s defined by their expansion coefficients
in mouse D (CFA+OVA immunised) demonstrate completely opposite behaviour in
mouse C (also CFA+OVA immunised), with high abundance and expansion coefficient
after TB stimulation but not after OVA stimulation. There are also some CDR3β s
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that are highly public, being abundant in all samples from all mice, but that are only
responding substantially to OVA in one of the mice, again suggesting differential se-
lection by OVA between these samples.
4.7 In vitro data: discussion
The TCR repertoires from in vitro stimulated samples of CD4+ T cells have the poten-
tial to provide a clearer picture of the T cell response to OVA peptide, since repertoires
can be measured from the same mice before and after in vitro culture. As seen in the in
vivo data, we observed that the frequency of the CDR3β s from known OVA-responsive
TCRs does not increase on OVA exposure (Figure 4.8) and that in vitro stimulation with
the same antigen does not drive an increased similarity in repertoires (Figure 4.9).
An expansion coefficient can be calculated for each CDR3β in an in vitro stimulated
sample with reference to the frequency of the CDR3β in the ex vivo sequenced spleen
sample from the same mouse. This expansion coefficient provides a more direct esti-
mate of the proliferation of a T cell clone in response to in vitro stimulation than was
possible with the in vivo data. It is important to note that the expansion coefficient
measured in this way captures the proliferation of a clone due to in vitro stimulation
and does not include the effect of the in vivo immunisation.
For the four mice from which we have ex vivo spleen, TB stimulated and OVA stimu-
lated samples, the number of CDR3β s that have an expansion coefficient above a given
threshold in response to OVA stimulation does not appear to be dependent on previous
OVA immunisation (Figure 4.10e). This suggests, unexpectedly, that the ‘magnitude’
of response to OVA stimulation is equivalent regardless of prior exposure to the antigen
but additional data would be required to further test this finding. It might be interesting
to test the hypothesis that the response to in vitro OVA stimulation by cells from CFA
only mice is less functionally active despite being of the same ‘magnitude’ by obtaining
functional read-outs from the samples, perhaps measuring T cell proliferation by CFSE
dilution or effector function by IFNγ assays.
When we considered the relationship between expansion coefficients in TB stimulated
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and OVA stimulated samples from the same mouse (Figure 4.11), we found that clones
were equivalently expanded (statistically significant positive correlation) in both sam-
ples when the mouse had been immunised with CFA only, but were differentially ex-
panded (a non-significant positive correlation) in the two samples when the mouse had
been immunised with CFA+OVA. This suggests that in OVA containing wells without
prior OVA exposure, this response is not specific since the same clones expand in re-
sponse to TB stimulation. In contrast, the expansion in response to OVA peptide is
not related to the expansion in response to TB stimulation when the mouse has been
previously exposed to ovalbumin in the immunisation.
Comparison of expansion coefficients in OVA and TB stimulated samples from each
mouse allowed us to define OVA-associated CDR3β s in a similar, if more direct,
method as was used for the in vivo data. The identified CDR3β s are only defined
as OVA-associated in a sample from one of the mice analysed. However, in contrast
to our findings in the in vivo data, these CDR3β s are found to be relatively public in
terms of their presence in other mice (Figure 4.12). In particular, some CDR3β s have
high abundance (and high expansion coefficient) in the OVA stimulated sample, but not
the TB stimulated sample from one mouse and exhibit opposite behaviour in another
mouse. These data are highly suggestive of a differential and complicated pattern of
selection of clones on in vitro stimulation in samples of cells from different animals.
To confirm this, further experiments will be required to validate that the CDR3β s iden-
tified in this analysis are responding to OVA peptide (perhaps by tetramer sorting). It
might also be interesting to test whether clones that are exhibiting differential behaviour
in samples from different mice are functionally or transcriptionally distinct.
4.8 Identifying amino acid based motifs of OVA-
associated CDR3β s
From the in vivo data (Section 4.4.3) and in vitro data (Section 4.6.3) three sets of
CDR3β s have been identified that appear to be expanded in response to ovalbumin and
are being referred to as ‘OVA-associated’ here. These sets are:
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Set 1 CDR3β s that are highly expanded in vivo (expansion coefficient > 29) relative
to unimmunised samples in at least one CFA+OVA immunised spleen sample
and are not highly expanded (expansion coefficient < 24) in any of the CFA only
immunised spleen samples.
Set 2 CDR3β s that are highly expanded in vivo (expansion coefficient > 29) relative to
unimmunised samples in at least one CFA+OVA immunised spleen sample and
are not classified as stimulated by endogenous peptide or CFA (i.e. maximum
frequency in either CFA or unimmunised samples is at least 2 fold smaller than
minimum non-zero frequency in CFA+OVA samples).
Set 3 CDR3β s that are highly expanded (expansion coefficient > 29) relative to spleen
sample from the same mouse in an in vitro OVA stimulated sample but are not
highly expanded (expansion coefficient < 25) in the TB stimulated sample from
the same mouse.
Set 1 contains 603 CDR3β s, of which 160 are also present in set 2 (Figure 4.13a). Set
2 contains 245 CDR3β s in total, and set 3 consists of 124 CDR3β s, none of which are
present in sets 1 or 2.
To assess whether there is an amino acid sequence motif which characterises OVA
associated CDR3β s the pairwise distance or similarity between CDR3β s within each
of the sets is measured. We used the Levenshtein distance (the number of insertions,
substitutions or deletions required to transform one string into another) as a distance
metric and the p-spectrum kernel (number of substrings of length p shared between two
strings) as a similarity metric. For comparison, we repeatedly randomly selected sets
of CDR3β s from the total combined data, with these control sets being size-matched to
the OVA-associated sets. We measured pairwise distance and similarity in the control
sets in the same way as for the OVA-associated sets. In order to reduce any contribution
of sequencing error to the control sets, only CDR3β s which appeared at least 5 times
across the data were available for sampling.
The CDR3β s from the in vitro (Set 3), but not the in vivo (Set 1 and Set 2) sets of
OVA-associated CDR3β s, showed a reduced average pairwise Levenshtein distance,
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Figure 4.13: Sets of OVA-associated CDR3β s demonstrate amino acid sequence similarity
For the three sets of CDR3β s identified in sections 4.4.3 and 4.6.3: (a) overlap
between the sets. Mean ± standard deviation of (b) pairwise Levenshtein dis-
tance between CDR3β s within a set (red) and (c-e) pairwise similarity between
CDR3β s within a set (red), measured by p-spectrum kernels, compared to the
same measure in size-matched random samples of CDR3β s (grey).
compared to random sampling (Figure 4.13b). However, increased similarity could
be observed for both in vitro and in vivo OVA associated CDR3β sets when using p-
spectrum kernels with p = 3 (Figure 4.13e). Shorter length spectrum kernels did not
show any increased similarity (Figures 4.13c and d).
The results presented in Figure 4.13 suggest that short contiguous stretches of amino
acids might define enriched motifs within the sets of OVA-associated CDR3β s. A
similar phenomenon was observed when the usage of each p-tuplet, for p = 1,2 and 3
(i.e. amino acid, amino acid pair and amino acid triplet) in the OVA-associated sets was
counted, and ranked in comparison to the usage counts in 500 random CDR3β samples
(selected as detailed above). Results are expressed as the percentile rank of the usage
found in OVA associated sets in comparison to random sets.
No individual amino acid is consistently over- or under-represented across all three sets
of OVA associated CDR3β s (Figure 4.14a). However seven pairs of amino acids and
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Figure 4.14: Amino acid motif usage in OVA-associated sets of CDR3β s
For the three sets of CDR3β s identified in sections 4.4.3 and 4.6.3:
(a) The amino acid usage within the sets of CDR3β s, expressed as the percentile
rank when compared to the usage observed in repeated random size-matched sam-
ples.
(b) and (c) The usage within the OVA-associated sets, expressed as percentile rank
as in (a), of amino acid pairs and triplets which have high or low expression in all
three sets.
seven triplets are over- or under-represented (> 95th or < 5th percentile of usage in the
control randomly sampled sets) in all three sets (Figure 4.14b,c). Many of these amino
acid motifs appear to be related to the V or J encoded parts of the CDR3β (e.g. CA,
CS, CAS, FGA), but others, such as LEK and RPT, likely occur towards the center of
the CDR3β and could be responsible for contact with OVA peptide.
The presence of these amino acid duplet and triplet motifs in the full sequenced reper-
toires in spleen samples from immunised and unimmunised mice is counted (Fig-
ure 4.15a and b). None of the motifs alone distinguish CFA only from CFA+OVA
immunised samples, although the usage of AS, CA, ASS and CAS is significantly dif-
ferent (KS test, p < 0.01) between unimmunised and immunised samples. Neither
does the presence of a combination of motifs within a CDR3β differentiate between
CFA only and CFA+OVA immunised samples (Figure 4.15c and d) with the proportion
of CDR3β s that contain at least x of the over-expressed duplet or triplet motifs not
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Figure 4.15: Usage of OVA associated duplets and triplets in full CDR3β repertoires
(a) and (b) The proportional usage (mean ± standard deviation) in the full reper-
toire samples of in vivo samples from immunised mice of amino acid duplets and
triplets identified as being consistently over- or under-expressed in sets of OVA-
associated CDR3β s.
(c) and (d) The proportion of CDR3β s in an in vivo sample (mean ± standard
deviation) that contain multiple (at least the number shown on the x-axis) duplets
or triplets that are over-expressed in OVA-associated CDR3β s.
Immunisation status of the mouse is indicated by colour for all panels.
being statistically different between CFA only and CFA+OVA immunised samples for
any value of x.
4.9 Discussion
Identification of a TCR signature of immune response to a single antigen is an essen-
tial initial step in exploiting the potential of the TCR repertoire to act as a marker or
signature of the immune challenges faced by an individual. The characteristics of such
a signature may also reveal interesting features of the T cell response, both in terms
of the structural recognition of antigen by individual TCRs and at a T cell population
level (breadth, diversity etc.). In this chapter, the TCR repertoire of genetically identi-
cal mice in response to immunisation with ovalbumin has been considered, to attempt
to identify a signature of antigen-specific T cell response above a background of re-
sponse to an adjuvant. In the data analysed in this chapter the adjuvant employed in
the experimental model is CFA, commonly used to induce a response to ovalbumin e.g.
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[13, 43, 73].
We first looked for CDR3β s that are part of previously reported OVA-specific TCRs.
Unexpectedly, the CDR3β s of these known OVA-specific clones are present at a similar
frequency in samples from CFA+OVA immunised mice as in CFA immunised mice;
and similar frequency after in vitro stimulation with OVA or with TB. These results
suggest either that these ‘public’ β chains are found paired with many different αs,
giving differing TCR specificities only some of which are OVA specific, while others
are specific for some component of MTb; or that the reported OVA specific clones using
these β chains are in fact cross-reactive to peptides from the adjuvant as well as from
ovalbumin. Using the frequency of previously reported antigen specific clones does
not appear to be a feasible approach to defining a signature of antigen exposure in these
data.
The approach used in this work to identify OVA-associated CDR3β s has been to esti-
mate an ‘expansion coefficient’ for each CDR3β in an immunised or stimulated sample,
calculated as its observed frequency in the sample divided by the frequency in a ‘con-
trol’ sample. For the in vivo samples, the control is pooled unimmunised repertoires,
while for the in vitro stimulated samples the control is the ex vivo spleen sample from
the same mouse. Then OVA-associated CDR3β s can be defined on the basis of having
a high expansion coefficient in an OVA exposed repertoire, but not in repertoires not
exposed to OVA. The analysis in this chapter defines and analyses three sets of OVA-
associated CDR3β s: two from in vivo data, using different criteria to exclude CDR3β s,
and one set from in vitro data.
The key feature of all three sets of OVA-associated CDR3β s is that they are almost
all private sequences. The majority of CDR3β s defined as OVA-associated only have
this property in one of the OVA immunised mice or one of the OVA stimulated in
vitro samples, suggesting a highly individual specific clonal response. This is also
consistent with the lack of increased overlap between repertoires after immunisation
with ovalbumin, compared to unimmunised pairs: ovalbumin immunisation does not
drive a convergent CDR3β repertoire. Finding a single CDR3β , or even a small set
of CDR3β s, whose abundance in a sample can predict antigen exposure also does not
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therefore appear to be a feasible approach, even in this relatively simple experimental
model.
The privacy of OVA-associated CDR3β s from the in vivo repertoires appears to be
a feature of availability: the CDR3β that are OVA-associated in one mouse are of-
ten simply not present in the sampled repertoires of the majority of the other mice
(Figure 4.6h). The simplest interpretation is therefore that the privacy of the OVA-
associated CDR3β s is due to effects of stochastic repertoire generation rather than
differential selection after immunisation. However, in the in vitro stimulated data the
CDR3β s that are defined as OVA-associated in one mouse are often present, but not de-
fined as OVA-associated, in other mice (Figure 4.12), suggestive of differential antigen
selection in different animals. However, without paired αβ sequence data we can-
not conclusively assess whether selection of T cell clones to proliferate in response to
the in vitro antigen stimulation is differential in these repertoires, or whether in vitro
expansion favours more ‘public’ T cell clones.
The overwhelming privacy of the OVA-associated CDR3β s suggests that any signa-
ture of ovalbumin exposure will require a metric which will map ‘similar’ TCRs by
sequence to sets of similar TCRs by antigen recognition. A number of detailed studies
have identified particular residues of the peptide bound within the MHC binding pocket
which are key for TCR recognition [19, 24]. We hypothesised that these specific anti-
gen residues may impose some sequence restrictions on the CDR3 of the cognate TCR.
We therefore further hypothesised that the set of OVA peptide specific TCRs might be
enriched for common short stretches of amino acids necessary for this specific anti-
gen recognition. We initially explored this hypothesis by measuring the amino acid
sequence-level similarity of the OVA-associated sets of CDR3s using different mea-
sures of sequence distance or similarity. We observed that, as predicted, string kernel
measures (which capture the number of shared short amino acid stretches between two
CDR3β s) showed that these sets are more similar than randomly selected control sets
when triplets of amino acids are considered. Consistent with this observation, we also
found that some specific amino acid triplets were found to be either over- or under-
represented in OVA-associated sets of CDR3β s compared to randomly sampled sets of
CDR3β s. Interestingly, a number of these motifs appear to be present in germline V
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or J regions, and hence found towards the beginning or end of the CDR3 region. In
contrast, others were not germline encoded and look to be present in the non-templated
middle of the CDR3. The frequency of each over- or under-represented motif alone,
however, was not sufficient to discriminate between OVA and CFA+OVA repertoires.
Current studies in our group are exploring how machine learning techniques can be
used to select amino acid motif ‘features’ from repertoires and combine them to pro-
duce classifiers to predict the immunisation status from these TCR repertoires.
Limitations of the data and further work
The ability of this study to identify a TCR signature of response to ovalbumin is lim-
ited in a number of respects. Key to the work is a successful immunisation of the mice,
particularly with respect to the ovalbumin. The inclusion of functional assays, such as
measurement of IFNγ production or Ki67 expression of the isolated CD4+ T cells that
are taken for sequencing, could have confirmed an increase in activation of T cells on
immunisation and might be considered for future experiments. The success of the oval-
bumin immunisation could be confirmed by measuring the proportion of T cells from
each mouse that are positive in an OVA peptide-MHC multimer assay, and additionally
multimer sorted cells could be taken for sequencing to validate the CDR3β s defined as
OVA-associated in each mouse using the techniques described in this chapter.
The analysis in this chapter is heavily reliant on measurements of the abundance of each
CDR3β in each sample. As discussed in Chapter 2, there is variability in PCR amplifi-
cation efficiencies which might affect these results. Additional experiments have been
performed by Nir Friedman’s group (currently being sequenced) which use a unique
molecular barcoding protocol, allowing more reliable quantification of CDR3β abun-
dance.
The ex vivo spleen samples taken at early, mid and late timepoints after immunisation
potentially allow the kinetics of the response to ovalbumin immunisation to be studied.
The sample sizes in these experiments, with only a few mice at each time point, restricts
our ability to draw general conclusions from the repertoires and additional samples
from each timepoint would allow more detailed analysis. Alternatively, longitudinal
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samples after immunisation, perhaps in the form of repeated blood draws, might give
smaller but more informative TCR repertoire samples.
The in vitro stimulation data could provide a cleaner system than in vivo immunisation
to identify motifs of TCR repsonse to peptides. A more comprehensive set of samples,
including T cells from unimmunised mice and from mice at different timepoints after
immunisation, could allow for a more robust signature identification. The immunised
mice in the in vitro stimulation experiments used in this chapter were sacrificed at 7
days post immunisation, probably at the peak of effector T cell response. T cells from
mice after the acute immune response has resolved and T cell memory has been estab-
lished might demonstrate a response on in vitro stimulation with a clearer ovalbumin
signature.
It might be useful if the sequence data was accompanied by phenotypic information
regarding the sequenced cells. Splitting T cells into subsets (e.g. naive, effector, mem-
ory) before sequencing could help with identification of the clones that are responsible
for response to ovalbumin. Obtaining paired TCRαβ information, either using sin-
gle cell analysis, protocols which allow paired sequence analysis or possibly by post-
sequencing computational techniques, would also go some way to strengthening the
conclusions summarised above and answering outstanding questions regarding the re-
sults seen in this work.
Chapter 5
Discussion
The TCR repertoire is inherently complicated, containing a large number of different
clones, each present at an abundance which changes both in response to signals from
the environment and in relation to the other clones present. Therefore the TCR reper-
toire is difficult to measure and analyse, but also has the potential to provide much
information regarding the status of an individual’s immune system. In this thesis a
number of aspects of the TCR repertoire have been considered. Much of the work pre-
sented attempts to capture the complexity of data in the form of models describing the
underlying behaviour of a system.
In Chapter 2, we observed that the efficiency of PCR amplification was very heteroge-
nous, even when reaction conditions and nucleotide sequences are kept as constant
as possible. We model PCR amplification as modified branching processes, and find
that the observed ‘family sizes’ after amplification cannot be explained with any in-
tuitive process, but require inheritance of variable amplification efficiencies from one
molecule to its copies. The data described in this chapter demonstrate that for sequenc-
ing studies requiring robust quantification of multiple types of initial molecules, such
as immune repertoire studies, unique molecular barcoding prior to PCR amplification
is essential.
The model of maintenance of self-tolerance presented in Chapter 3 describes a way
in which the output of the stochastic TCR rearrangement process can be reshaped in
order to produce a T cell population which is tolerant to the multitude of self-antigens
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continually presented by DC. This is achieved via a relatively simple model, which can
be expressed as a series of linear inequalities, involving DC integrating TCR binding
signals received, and acting to adjust T cell clone abundances when too much signal is
experienced. This model restricts total T cell affinity to self-antigens, while preserving
the known features of the TCR repertoire, including clone richness, heterogenous clone
sizes and cross-reactivity between clones and peptides.
Sequenced TCR repertoires from immunised mice are analysed in Chapter 4, demon-
strating the complexity present in the immune response even in a relatively simple
model system. We find extraordinarily private CDR3β responses to ovalbumin in these
mice, including evidence of differential selection of clones in samples taken from dif-
ferent mice and stimulated in vitro. However, there is some evidence that the clones
associated with the response to ovalbumin in these data share features at the amino acid
sequence level. We show that studying the CDR3β s present in the repertoire does not
appear to identify cross-individual signatures of immune response against a particular
antigen, likely due to both the privacy of the clones present and their cross-reactivity.
However, this work suggests that searching for motifs of amino acids defining antigen
response might be more fruitful.
Limitations and further work
Amplification heterogeneity in the PCR reaction
The data and models presented in Chapter 2 demonstrate that, in order for PCR ampli-
fication to result in the heterogenous family sizes observed, some form of inheritance,
from one molecule to its copies present in the next cycle, of a variable amplification
efficiency is required. When these molecules are identical for the majority of their nu-
cleotide sequence (apart from the molecular barcode) and conditions within the PCR
reaction should ensure the samples are well mixed it is hard to envisage what mecha-
nism could explain this inheritance. Additional experiments to confirm that the barcode
is not causing the differential amplification observed would be useful in strengthening
the results of the work, as would a clearer idea of the molecular mechanism that could
cause the observed heterogeneity. More detailed modelling of the PCR process itself,
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rather than simply modelling stochastic replication events, might help in this respect.
Model of maintenance of immune tolerance in the periphery
The work presented in this thesis on the model of maintenance of immune tolerance
(Chapter 3) is by necessity a simplified model of potential reshaping of the T cell popu-
lation through interactions between T cells and resting DC. A major assumption of the
current implementation of the model is that within the time period that a DC is able to
integrate signal over, it experiences enough T cell/DC interactions such that the switch
to a tolerising state is essentially based on the number of cognate T cells in the whole
population. Similarly, we assume that ‘kill’ signals from a tolerising DC affect all T
cells when averaged over a sufficient number of time steps.
This assumption can be addressed by using an agent based model (ABM) implemen-
tation, where each DC and each T cell is modelled explicitly, rather than modelling T
cell clones and self-peptide presentation profiles, as is presented in this thesis. Random
encounters between T cells and DCs would result in signal integration on the part of
the DC in order to determine whether to switch to a tolerising state, as well as signal
integration of ‘survival’ or ‘death’ signals on the part of the T cells.
An ABM implementation would also enable another limitation of the work presented
here to be addressed more easily. The results presented in Chapter 3 are all based on the
state of the T cell population while DCs are all resting. It does not consider activation
of the DCs by signals from other innate immune system cells, and therefore does not
explicitly model a T cell immune response. An ABM would allow exploration of the
situation where some DCs begin to present non-self (or previously unencountered) pep-
tides, along with activation signals, to T cells of a self-tolerant population. Questions
such as how well self-tolerance can be maintained by the DCs that remain resting while
others are activated could be asked with such a model, allowing predictions to be made
regarding the extent of immune activation before autoimmunity becomes harmful.
The model implemented in Chapter 3 makes a number of parametrisation assumptions,
particularly around the proliferation rate of T cells, the rate at which tolerising DCs are
able to kill T cells, and the distribution of binding strengths between TCRs and peptide-
142
MHC complexes. These could be improved with more experimental data. For instance,
screening a range of TCR clones for affinity to a range of peptide-MHC tetramers
could provide information on the sparsity of the matrix Q describing the TCR-pMHC
affinities as well as the distribution of its non-zero values. Additionally, the current im-
plementation of the model is not operating at physiological scales of number of T cells
and APCs. Parallelisation and use of computing clusters would allow more physiolog-
ically relevant simulations to be performed and therefore more accurate predictions to
be made.
Private T cell responses to ovalbumin
The mouse TCR repertoire sequence data analysed in Chapter 4 has a number of limi-
tations. Crucially, it is not barcoded data which means conclusions drawn on the basis
of clone abundance within samples are less robust. A repeated experiment, using a pro-
tocol that uniquely labels each molecule of TCR RNA before amplification, has been
performed and the data should be available soon. Analysis of the barcoded data should
allow for confirmation or rejection of the finding that the CDR3β s that are highly abun-
dant after immunisation with ovalbumin are private to each animal.
Additionally, the analysis of these repertoire data are limited by only including β chains
from each TCR. We are unable to say anything about T cell clones that might be re-
sponding to ovalbumin, but only about the TCRβ s, which might each be paired with
multiple αs. Extraction and sequencing of the corresponding α chains, preferably
paired with the β occuring in the same heterodimer, would greatly increase the speci-
ficity of the conclusions that can be drawn.
If additional experiments could be performed, it would be useful to immunise with
the same model antigen in the context of different adjuvants. If particular amino acid
motifs comprise a signature of T cell response to ovalbumin this should be the case
in multiple contexts, and a signature derived from CFA+OVA data should be able to
distinguish OVA immunised repertoires in conjunction with other adjuvants.
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General considerations
The work presented in this thesis uses modelling and computational techniques to ex-
tract useful information from what could be termed ‘big data’. As experimental tech-
niques develop and the data produced becomes ‘larger’, both in terms of the number
of observations measured and the dimensionality of the measurements for each obser-
vation, analysis becomes more complicated. In the majority of realistic experimental
models, multi-dimensional measurements mean that system-level effects become very
apparent. A single perturbation to an experimental system results in multiple changes
in ‘outputs’ measured, and in order to obtain a desired change in the measurements in
the model there might be multiple possible interventions. These observations, and the
combinatorial effect of multiple possible interventions, means that mathematical mod-
elling and other computational approaches are essential to gain understanding of the
behaviour of an experimental system and to direct experimental effort.
A common feature emerging from analysis of multi-dimensional and high throughput
data from many experimental models is that individual cells often demonstrate com-
pletely different behaviours in response to the same conditions, which would not be
revealed in measurements on bulk populations. However, it is often the bulk popula-
tion measurement that is the objective of experimental or medical intervention, and that
is thought to be clinically relevant. Mathematical models, parametrised by data from
single cell experiments, will be invaluable in these situations to understand the effect
of single cell behaviour on bulk population measurements and to predict what level of
intervention is required to reach a desired effect.
In terms of the TCR repertoire, acquistion of large datasets appears to be progress-
ing faster than analysis frameworks are developing. Any application of TCR whole
repertoire sequencing and analysis to address clinical questions regarding diagnosis
or prediction of prognosis requires assessment of patient repertoire in comparison to
healthy controls. However, although common features across all healthy repertoires
can be identified (for instance, relatively consistent gene usage, clone size distributions
and diversity metrics) it is unclear which characteristics of the repertoire are essential
for ‘health’. Similarly it is not obvious how changes to any of the measured features of
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the TCR repertoire affect the individual’s ability to respond to immune challenge or to
clinical intervention in disease. It is essential that the variability in repertoires amongst
healthy individuals is well understood before we are able to apply and interpret mea-
sures of repertoire in clinical settings.
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Appendices
Appendix A
PCR amplification heterogeneity:
Supplementary Information
A.1 Empirical distribution of barcodes
Aggregating barcode data from a number of sequence runs allows us to infer informa-
tion about the structure of the pool of barcode-oligos. We counted barcode labelling
events across our experiments (Figure A.3a, black dots) and found that the majority
of barcodes we observed have only been seen in one labelling event while some have
been observed up to 12 times. If the pool of barcodes was uniformly distributed we
would expect the barcode labelling event counts to be zero-truncated Poisson distribu-
tion, while if the pool follows some other distribution we expect the barcode labelling
event counts to follow a zero-truncated mixed Poisson distribution. We fitted, via max-
imum likelihood, zero-truncated Poisson and mixed Poisson distributions, and saw that
the zero-truncated Poisson mixed with a lognormal distribution provided the best fit to
the observed barcode labelling event counts (Figure A.3a, coloured lines). This sug-
gests that the pool of barcodes we are labelling our molecules from is lognormally
distributed. Zero-truncated mixed Poisson models are fitted to data via maximum like-
lihood optimisation in R. Maximum likelihood optimisation was performed using the
maxNR of the MaxLik package [60].
From the fitted parameters of the zero-truncated Poisson-lognormal distribution we are
A.1. Empirical distribution of barcodes 164
able to infer the structure of the available barcode pool (Figure A.3b), showing that
in a pool of 108 barcode-oligos most labels occur fewer than 5 times while a small
proportion occur up to 30 times.
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A.2 Supplementary Figures
Figure A.1: KT2 TCR sequences
The proportion of sequenced KT2 TCR molecules (α chain in (a), β chain in (b))
categorised by Decombinator as each of the identified TCR clonotypes. The largest
identified clonotypes are coloured and described by the five-part Decombinator
identifier (V region, J region, V deletions, J deletions, junctional nucleotides).
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Figure A.2: Effect of error correction on observed TCR repertoire
The effect of the correction of sequencing error and biased PCR amplification on
sequencing runs of TCRs from healthy volunteers for alpha and beta samples at
two different time points from 4 healthy volunteers (Figures i-iv).
Top panels: The number of distinct TCR clones observed in the indicated sequenc-
ing run of healthy volunteer peripheral blood (‘PB’) when barcodes are not con-
sidered (‘raw’) and when barcodes are used to correct for PCR amplification bias
and sequencing error (‘corrected’).
Bottom panels: The correlation between TCR clone size observed in the raw or
corrected data of the indicated sequencing run of healthy volunteer PB.
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Figure A.3: Distribution of available barcode oligonucleotides
(a) Black circles: The proportion of barcodes that are observed with the given
number of labelling events across all healthy volunteer PBMC sequencing runs
in this study. Coloured lines: fitted mixed Poisson models, zero-truncated to ac-
count for unobservable zeros. The distributions considered are the zero-truncated
Poisson (ZTP), the zero-truncated mixed Poisson-Gamma (ZTPG), and the zero-
truncated mixed Poisson-Lognormal (ZTPLN). Zero-truncation occurs after mix-
ing, and best fitting parameters are found via maximum likelihood estimation.
(b) From the parameters of the best-fitting ZTPLN in (a), the inferred structure of
the available barcode pool, giving the distribution of barcode copy numbers in a
pool of 108 oligos.
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Figure A.4: PCR simulator - models 2 and 4
Observed barcode family size distributions observed under different models of
PCR duplication. Simulations performed with 10,000 initial molecules, 25 cy-
cles of PCR (with no error) and sequencing of 10,000 molecules selected from the
amplified pool. Simulations were repeated 10 times and the mean and standard
deviation are shown. The dotted lines represent the expected distribution if every
initial molecule is labelled uniquely and represented equally in the amplified pool.
(a) Model 2: PCR cycles with target degradation. In each cycle, a molecule repli-
cates with probability 0.8. If successful replication does not occur, degradation of
that target molecule occurs with the indicated probability.
(b) Model 4: Resource degradation model of PCR. An initial amount of abstract
resource is available at the start of the process, given as a multiple (the initial
resource multiple) of the number of initial molecules. The efficiency of the reac-
tion in a given cycle depends on the amount of resource available. A successful
replication depletes resource at a fixed rate, here 0.5.
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Figure A.5: Schematic of Protocol A (using single strand ligation)
Figure producd by James Heather
A: TCR RNA is reverse transcribed using oligonucleotides directed against the 5’
of the alpha and beta constant regions (blue arrow). Red circle represents mRNA
5’ cap.
B: RACE is achieved through ligation of DNA adapter to the 3’ end of the cDNA;
adapter consists of Illumina sequencing primer SP2 and a hexamer of random nu-
cleotides (6N).
C: Separate single round second (i) and third strand (ii) reactions allow incorpo-
ration of another random hexamer at the other end of the amplicons (as well as
SP1, the other sequencing primer, and an index for demultiplexing), completing
the unique 12-mer barcoding of TCR cDNA.
D: A four-cycle PCR is used to add: another index (that which is sequenced in
the dedicated Illumina indexing read) and P7 at one end (i) and P5 at the other
(ii). P5 and P7 are the elements required for cluster generation, as they bind to the
oligonucleotides that coat the flow-cell, permitting bridge amplification.
E: A final PCR directed against the P5 and P7 elements (for 23 cycles) amplifies
full-length amplicons to sufficient concentrations for sequencing. Amplicons are
finally purified, quantified, sized and normalised before sequencing on the MiSeq.
Appendix B
PCR simulator code
Below is the Python code used for the models of PCR amplification presented in Chap-
ter 2.
####################################################################################################
# PCRsim v 1.1
#
# Functions simulating PCR amplification of cDNA with unique molecular labelling and high
# throughput sequencing
#
# Run as a script to see output of example usage in the
# "if __name__ == __main__" section at the bottom
####################################################################################################
from __future__ import division
import collections as coll
import random
import itertools
import numpy as np
####################################################################################################
# 1. Create intial pool of molecules
def create_initial_molecules(
number_initial_molecules, nt_string=False, length=10, identical=True):
"""
Creates a dictionary representing the initial sample to be used in further steps of the
simulator
Returns a dictionary in the form {template_molecule_identifier: number_of_copies}
- if nt_string is True, template_molecule_identifier will be a nucleotide string, of specified
length. This is created randomly.
- if identical is False, a different template_molecule_identifier string will be created for
each of the molecules in the initial sample, representing a polyclonal sample.
Note that if nt_string is False, error cannot be simulated in later steps.
"""
if nt_string == False:
return coll.Counter({’target’: number_initial_molecules})
if nt_string == True:
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if identical == True:
template = ’’.join([random.choice([’A’, ’C’, ’G’, ’T’]) for _ in range(length)])
return coll.Counter({template: number_initial_molecules})
if identical == False:
molecule_dictionary = coll.Counter()
for n in xrange(number_initial_molecules):
molecule = ’’.join([random.choice([’A’, ’C’, ’G’, ’T’]) for _ in range(length)])
molecule_dictionary[molecule] += 1
return molecule_dictionary
####################################################################################################
# 2. Label initial pool of molecules
def label_initial_molecules(
initial_pool, unique=True, nt_string=False, label_length = 6,
number_labels_available=10**6, label_distribution=’uniform’):
"""
Takes a dictionary representing the initial sample
Returns a dictionary representing the intial sample with ligated identifying barcodes
- If unique is True, each initial molecule is guaranteed to be uniquely labelled. If unique is
set to False, the labels are chosen from the available pool randomly and there is a chance
that the same label is ligated to more than one molecule.
- The format of the label is determined by the nt_string argument:
- If nt_string is False, the molecules are labelled by a number, and the label_length
argument is not used.
- If nt_string is True, the molecules are labelled by a nucletoide string and the
number_labels_available argument is not used.
- If nt_string is False and unique is False, the label number is selected at random from the
integers between 1 and number_labels_available.
- If nt_string is True and unique is False a random nucleotide string of length label_length is
ligated to each initial molecule.
- The label_distribution argument describes the structure of the pool of labels that is being
selected from to barcode each molecule. The options are normal or lognormal, and should be
given in the format "distribution,parameter1,parameter2" (eg "normal,5,2" for a normally
distributed barcode pool with mean 5 and standard deviation 2)
Note that if unique=True is used in conjunction with nt_string=True the assigned labels are
taken sequentially from the possible labels, meaning that the labels are ’closer’ to each other
(in terms of string distance) that if they were chosen at random. This may have an impact on the
effect that PCR or sequencing error has on the output.
"""
labelled_pool = coll.Counter()
# Unique = True overrides barcode_distribution option
if unique == True and nt_string == False:
count = 0
for k in initial_pool.keys():
for molecule in range(initial_pool[k]):
labelled_pool[count] += 1
count += 1
return labelled_pool
if unique == True and nt_string == True:
labels = itertools.imap(’’.join, itertools.product(’ACGT’, repeat=label_length))
for k in initial_pool.keys():
for molecule in range(initial_pool[k]):
mol_str = labels.next()+k
labelled_pool[mol_str] += 1
return labelled_pool
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if label_distribution.lower().startswith(’u’):
# Uniformly distributed available barcodes
if unique == False and nt_string == False and label_distribution == ’uniform’:
labels = xrange(number_labels_available)
for k in initial_pool.keys():
for molecule in range(initial_pool[k]):
mol_str = str(random.choice(labels))+’_’+k
labelled_pool[mol_str] += 1
return labelled_pool
if unique == False and nt_string == True and label_distribution == ’uniform’:
for k in initial_pool.keys():
for molecule in range(initial_pool[k]):
label = ’’.join([random.choice([’A’, ’C’, ’G’, ’T’]) for _ in range(label_length)])
mol_str = label + k
labelled_pool[mol_str] += 1
return labelled_pool
if label_distribution.lower().startswith(’n’):
# Normally distributed available barcodes.
distribution_mean = float(label_distribution.split(’,’)[1])
distribution_sd = float(label_distribution.split(’,’)[2])
if not nt_string:
barcode_weights = {x:max(random.gauss(distribution_mean, distribution_sd),0) for x \
in xrange(number_labels_available)}
for k in initial_pool.keys():
for molecules in range(initial_pool[k]):
mol_label = weighted_sample_with_replacement_from_counter(barcode_weights, 1).keys()[0]
mol_str = str(mol_label) + ’_’ + k
labelled_pool[mol_str] += 1
return labelled_pool
if nt_string:
barcode_weights = coll.defaultdict(float)
for bc in itertools.product(’ACGT’, repeat=label_length):
barcode_weights[’’.join(bc)] = max(random.gauss(distribution_mean, distribution_sd), 0)
for k in initial_pool.keys():
for molecules in range(initial_pool[k]):
mol_label = weighted_sample_with_replacement_from_counter(barcode_weights, 1).keys()[0]
mol_str = ’’.join([mol_label, k])
labelled_pool[mol_str] += 1
return labelled_pool
if label_distribution.lower().startswith(’l’):
# Lognormally distributed available barcode
distribution_lmu = float(label_distribution.split(’,’)[1])
distribution_lsd = float(label_distribution.split(’,’)[2])
if not nt_string:
barcode_weights = {x:random.lognormvariate(distribution_lmu, distribution_lsd) for x \
in xrange(number_labels_available)}
for k in initial_pool.keys():
for molecules in range(initial_pool[k]):
mol_label = weighted_sample_with_replacement_from_counter(barcode_weights, 1).keys()[0]
mol_str = str(mol_label) + ’_’ + k
labelled_pool[mol_str] += 1
return labelled_pool
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if nt_string:
barcode_weights = coll.defaultdict(float)
for bc in itertools.product(’ACGT’, repeat=barcode_length):
barcode_weights[’’.join(bc)] = random.lognormvariate(distribution_lmu, distribution_lsd)
for k in initial_pool.keys():
for molecules in range(initial_pool[k]):
mol_label = weighted_sample_with_replacement_from_counter(barcode_weights, 1).keys()[0]
mol_str = ’’.join([mol_label, k])
labelled_pool[mol_str] += 1
return labelled_pool
####################################################################################################
# 3. PCR models
def pcr_model1(molecules, error=0, number_cycles=10, efficiency=0.9):
"""
Takes a dictionary representing the initial sample of molecules.
Returns a dictionary representing the amplified sample of molecules.
PCR model 1 is a straightforward branching process model where in every cycle every molecule has
the same chance of being replicated once, given by the efficiency argument.
If error > 0, at every cycle the molecule being produced has a chance of having error
incorporated, given by the error argument (chance of error per base).
"""
d = molecules.copy()
if error == 0:
for c in range(number_cycles):
for k, v in d.iteritems():
number_successfully_replicated = np.random.binomial(v, efficiency)
d[k] += number_successfully_replicated
return d
elif error > 0:
for c in range(number_cycles):
print ’cycle ’+str(c+1)+’ (’+"{0:,}".format(sum(d.values()))+’ molecules)’
new_d = d.copy()
for k, v in d.iteritems():
for _ in range(v):
successful_replication = np.random.binomial(1, efficiency)
if successful_replication:
new_string = create_error(k, error)
new_d[new_string] += 1
d = new_d.copy()
return d
def pcr_model2(molecules, error=0, number_cycles=10, efficiency=0.9, degradation=0.1):
"""
Takes a dictionary representing the initial sample of molecules.
Returns a dictionary representing the amplified sample of molecules.
PCR model 2 is a target degradation model. In every cycle every molecule has the same chance of
being replicated once, given by the efficiency argument. If a molecule does not successfully
replicate then it might degrade, with probability given by the degradation argument.
If error > 0, at every cycle the molecule being produced has a chance of having error
incorporated, given by the error argument (chance of error per base).
"""
d = molecules.copy()
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if error == 0:
for c in range(number_cycles):
for k, v in d.iteritems():
if v > 0:
number_successfully_replicated = np.random.binomial(v, efficiency)
number_not_replicated = v - number_successfully_replicated
if number_not_replicated:
number_degraded = np.random.binomial(number_not_replicated, degradation)
else:
number_degraded = 0
d[k] += (number_successfully_replicated - number_degraded)
return d
elif error > 0:
for c in range(number_cycles):
print ’cycle ’+str(c+1)+’ (’+"{0:,}".format(sum(d.values()))+’ molecules)’
new_d = d.copy()
for k, v in d.iteritems():
for _ in range(v):
successful_replication = np.random.binomial(1, efficiency)
if successful_replication:
new_string = create_error(k, error)
new_d[new_string] += 1
else:
molecule_degrades = np.random.binomial(1, degradation)
if molecule_degrades:
new_d[k] -= 1
d = new_d.copy()
return d
def pcr_model3(molecules, error=0, number_cycles=10, available_resource_multiple=50):
"""
Takes a dictionary representing the initial sample of molecules.
Returns a dictionary representing the amplified sample of molecules.
PCR model 3 is a competition model. In every cycle every molecule has the same chance of being
replicated once. This chance is determined by the amount of abstract "resource" available, which
is constant throughout the experiment as given as a multiple of the number of initial molecules
(the available_resource_multiple argument). The chance of successful replication in a given
cycle is calculated as the available resource divided by the number of molecules present at the
start of the cycle (restricted to 0 - 1).
If error > 0, at every cycle the molecule being produced has a chance of having error
incorporated, given by the error argument (chance of error per base).
"""
d = molecules.copy()
available_resource = available_resource_multiple * sum(d.values())
if error == 0:
for c in range(number_cycles):
cycle_efficiency = min(available_resource/sum(d.values()), 1)
for k, v in d.iteritems():
number_successfully_replicated = np.random.binomial(v, cycle_efficiency)
d[k] += number_successfully_replicated
return d
elif error > 0:
for c in range(number_cycles):
print ’cycle ’+str(c+1)+’ (’+"{0:,}".format(sum(d.values()))+’ molecules)’
new_d = d.copy()
cycle_efficiency = min(available_resource/sum(new_d.values()), 1)
for k, v in d.iteritems():
for _ in range(v):
successful_replication = np.random.binomial(1, cycle_efficiency)
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if successful_replication:
new_string = create_error(k, error)
new_d[new_string] += 1
d = new_d.copy()
return d
def pcr_model4(
molecules, error=0, number_cycles=10, initial_resource_multiple=50, resource_degradation=0.2):
"""
Takes a dictionary representing the initial sample of molecules.
Returns a dictionary representing the amplified sample of molecules.
PCR model 4 is a competition model, incorporating resource degradation. In every cycle every
molecule has the same chance of being replicated once. This chance is determined by the amount
of abstract "resource" available, which is degraded as the reaction progresses. The initial
amount of available resource is given by the number of initial molecules multipled by the
initial_resource_multiple argument. Every successful replication reduces the available resource
by an amount given by the resource_degradation paramter. The chance of successful replication in
a cycle is given by the amount of resource available at the start of the cycle divided by the
number of molecules present at the start of the cycle (restricted to 0 - 1).
If error > 0, at every cycle the molecule being produced has a chance of having error
incorporated, given by the error argument (chance of error per base).
"""
d = molecules.copy()
current_resource = initial_resource_multiple * sum(d.values())
if error == 0:
for c in range(number_cycles):
cycle_efficiency = min(current_resource/sum(d.values()), 1)
for k, v in d.iteritems():
number_successfully_replicated = np.random.binomial(v, cycle_efficiency)
d[k] += number_successfully_replicated
current_resource -= (number_successfully_replicated * resource_degradation)
current_resource = max(current_resource, 0)
return d
elif error > 0:
for c in range(number_cycles):
print ’cycle ’+str(c+1)+’ (’+"{0:,}".format(sum(d.values()))+’ molecules)’
new_d = d.copy()
cycle_efficiency = min(current_resource/sum(d.values()), 1)
for k, v in d.iteritems():
number_successfully_replicated = 0
for _ in range(v):
successful_replication = np.random.binomial(1, cycle_efficiency)
if successful_replication:
number_successfully_replicated += 1
new_string = create_error(k, error)
new_d[new_string] += 1
current_resource -= (number_successfully_replicated * resource_degradation)
current_resource = max(current_resource, 0)
d = new_d.copy()
return d
def pcr_model5(
molecules, error=0, number_cycles=10, efficiency_distribution=’normal’,
efficiency_parameters=(0.8,0.1)):
"""
Takes a dictionary representing the initial sample of molecules.
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Returns a dictionary representing the amplified sample of molecules.
PCR model 5 is a variable efficiency model. In every cycle, the probability that a molecule will
successfully replicate is chosen from a distribution of efficiencies. The arguments
efficiency_distribution and efficiency_parameters determine the distribution that the efficiency
for one molecule in one cycle is selected from.
Valid efficiency distribution families are normal and lognormal. If a value < 0 or > 1 is chosen
from the specified distribution this is replaced with 0 or 1 as appropriate.
If error > 0, at every cycle the molecule being produced has a chance of having error
incorporated, given by the error argument (chance of error per base).
"""
d = molecules.copy()
avg_effs = list()
if error == 0:
for c in range(number_cycles):
print ’cycle ’+str(c+1)+’ (’+"{0:,}".format(sum(d.values()))+’ molecules)’
for k, v in d.iteritems():
efficiencies = pick_efficiencies(efficiency_distribution, efficiency_parameters, v)
avg_effs.append(np.mean(efficiencies))
number_successfully_replicated = 0
while efficiencies:
number_successfully_replicated += np.random.binomial(1, efficiencies.pop(0))
d[k] += number_successfully_replicated
print ’average efficiency ’, np.mean(avg_effs)
return d
elif error > 0:
for c in range(number_cycles):
print ’cycle ’+str(c+1)+’ (’+"{0:,}".format(sum(d.values()))+’ molecules)’
new_d = d.copy()
for k, v in d.iteritems():
efficiencies = pick_efficiencies(efficiency_distribution, efficiency_parameters, v)
avg_effs.append(np.mean(efficiencies))
for i, _ in enumerate(range(v)):
successful_replication = np.random.binomial(1, efficiencies[i])
if successful_replication:
new_string = create_error(k, error)
new_d[new_string] += 1
d = new_d.copy()
print ’average efficiency ’, np.mean(avg_effs)
return d
def pcr_model6(
molecules, error=0, number_cycles=10, efficiency_distribution=’normal’,
efficiency_parameters=(0.8,0.1), eff_seq_dependent=False):
"""
Takes a dictionary representing the initial sample of molecules.
Returns a dictionary representing the amplified sample of molecules.
PCR model 6 is a variable inherited efficiency model. In every cycle, the probability that a
molecule will successfully replicate is inherited from its ancestors. Before the PCR reaction
begins, each initial molecule is assigned an efficiency from the efficiency distribution defined
by the efficiency_distribution and efficiency_parameters arguments. This is then the probability
that this molecule and all its descendants successfully replicate in any given cycle.
Valid efficiency distribution families are normal and lognormal. If a value < 0 or > 1 is chosen
from the specified distribution this is replaced with 0 or 1 as appropriate.
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If error > 0, at every cycle the molecule being produced has a chance of having error
incorporated, given by the error argument (chance of error per base).
When PCR error occurs, the eff_seq_dependent argument determines whether the new molecule (which
has a different nucleotide sequence from its ancestors) continues to have the same probability
of replication. If eff_seq_dependent is True, then a new efficiency is selected whenever a
different nucleotide sequence is encountered.
"""
d = molecules.copy()
efficiencies = coll.defaultdict(float, {k:pick_efficiencies(efficiency_distribution,
efficiency_parameters, 1)[0] for k in d.keys()})
if error == 0:
for c in range(number_cycles):
for k, v in d.iteritems():
number_successfully_replicated = np.random.binomial(v, efficiencies[k])
d[k] += number_successfully_replicated
return d
elif error > 0:
for c in range(number_cycles):
print ’cycle ’+str(c+1)+’ (’+"{0:,}".format(sum(d.values()))+’ molecules)’
new_d = d.copy()
for k, v in d.iteritems():
for _ in range(v):
successful_replication = np.random.binomial(1, efficiencies[k])
if successful_replication:
new_string = create_error(k, error)
new_d[new_string] += 1
if not eff_seq_dependent:
efficiencies[new_string] = efficiencies[k]
if eff_seq_dependent:
if not efficiencies[new_string]:
efficiencies[new_string] = pick_efficiencies(efficiency_distribution,
efficiency_parameters, 1)[0]
d = new_d.copy()
return d
def create_error(nt_string, error_rate):
"""
Introduces error at the specified error_rate (rate per base) to the provided nucleotide string.
Returns the new nucleotide string with error (if any introduced).
"""
original_string_split = list(nt_string)
new_string_split = [’’]*len(original_string_split)
for pos, nt in enumerate(original_string_split):
error_here = np.random.binomial(1, error_rate)
if error_here:
nts = [’A’, ’C’, ’G’, ’T’]
nts.remove(nt)
new_nt = random.choice(nts)
new_string_split[pos] = new_nt
else:
new_string_split[pos] = nt
return ’’.join(new_string_split)
def appropriate_efficiency(a):
"""
Returns a number between 0 and 1 inclusive.
"""
a = max(a, 0)
a = min(a, 1)
return a
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def pick_efficiencies(efficiency_distribution, efficiency_parameters, n):
"""
Selects replication efficiencies from the specified distribution
"""
if str.lower(efficiency_distribution) in [’normal’, ’norm’, ’n’, ’gaussian’, ’gauss’]:
return [appropriate_efficiency(random.gauss(efficiency_parameters[0],
efficiency_parameters[1])) for _ in xrange(n)]
if str.lower(efficiency_distribution) in [’lognormal’, ’lognorm’, ’ln’]:
return [appropriate_efficiency(random.lognormvariate(efficiency_parameters[0],
efficiency_parameters[1])) for _ in xrange(n)]
####################################################################################################
# 4. Sampling function
def weighted_sample_no_replacement_from_counter(counter, sample_size):
"""
Takes a dictionary representing a pool of molecules.
Returns a dictionary representing a sample selected from the provided pool.
"""
keys_weights_tuples = [(k, v) for k, v in counter.iteritems()]
sample = coll.Counter()
totals = np.cumsum([p[1] for p in keys_weights_tuples])
for i in xrange(sample_size):
rnd = random.random() * totals[-1]
idx = np.searchsorted(totals, rnd, "right")
sample[keys_weights_tuples[idx][0]] += 1
totals[idx:] -= 1
return sample
def weighted_sample_with_replacement_from_counter(counter, sample_size):
keys_weights_tuples = [(k, v) for k, v in counter.iteritems()]
sample = coll.Counter()
totals = np.cumsum([p[1] for p in keys_weights_tuples])
for i in xrange(sample_size):
rnd = random.random() * totals[-1]
idx = np.searchsorted(totals, rnd, "right")
sample[keys_weights_tuples[idx][0]] += 1
return sample
####################################################################################################
# 5. Sequencing
def sequence_amplified_pool(amplified_pool, sample_size=10**5, error_rate=10**-3):
"""
Takes a dictionary representing the amplified pool.
Returns a dictionary representing the sequenced molecules.
Selects a sample of the given sample_size from the amplified_pool, using the sampling function
above. For each molecule in the sample, applies the given per base error_rate to simulated
sequencing error.
"""
sample = weighted_sample_no_replacement_from_counter(amplified_pool, sample_size)
if error_rate == 0:
return sample
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else:
sequenced_sample = coll.Counter()
for k, v in sample.iteritems():
for _ in range(v):
new_string = create_error(k, error_rate)
sequenced_sample[new_string] += 1
return sequenced_sample
####################################################################################################
# Example usage:
if __name__ == ’__main__’:
number_initial_molecules = 1000
target_length = 25
barcode_length = 6
number_pcr_cycles = 12
pcr_error_rate = 10**-5
seq_error_rate = 10**-3
sequence_depth = 500
# create molecules, identified by nt string, polyclonal
initial_molecules = create_initial_molecules(number_initial_molecules, nt_string=True,
length=target_length, identical=False)
# label molecules, no guarantee of unique labelling, barcode length 6
labelled_molecules = label_initial_molecules(initial_molecules, unique=False,
nt_string=True, label_length=barcode_length)
# alternatively label molecules again from a non-uniformly (normally) distributed pool of available labels
labelled_molecules_v2 = label_initial_molecules(initial_molecules, unique=False,
nt_string=False, number_labels_available=1000, label_distribution="n,10,4")
# use nt labels, normally distributed
labelled_molecules_v3 = label_initial_molecules(initial_molecules, unique=False,
nt_string=True, label_length=4, label_distribution="n,10,4")
# numerical labels, lognormally distributed
labelled_molecules_v4 = label_initial_molecules(initial_molecules, unique=False,
nt_string=False, number_labels_available=1000, label_distribution="l,2,1")
# nt labels, lognormally distributed
labelled_molecules_v5 = label_initial_molecules(initial_molecules, unique=False,
nt_string=True, label_length=5, label_distribution="l,2,1")
# amplify molecules according to pcr model 1 with no error
print ’amplifying via model 1 with no PCR error...’
amplified_molecules_model1 = pcr_model1(labelled_molecules, error=0,
number_cycles=number_pcr_cycles, efficiency=0.8)
# sequence a sample of molecules
print ’sampling...’
sequenced_molecules_model1 = sequence_amplified_pool(amplified_molecules_model1,
sample_size=sequence_depth, error_rate=seq_error_rate)
print ’effect of sequencing error:’
intersect = len(set(sequenced_molecules_model1.keys()).intersection(set(labelled_molecules.keys())))
total = len(sequenced_molecules_model1.keys())
print intersect, ’out of’, total, ’sequenced clonotypes were in the initial sample’
print ’’
# amplify molecules according to pcr model 2 (including degradation of target)
print ’amplifying via model 2...’
amplified_molecules_model2 = pcr_model2(labelled_molecules, error=pcr_error_rate,
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number_cycles=number_pcr_cycles, efficiency=0.8, degradation=0.1)
# sequence a sample of molecules
print ’sampling...’
sequenced_molecules_model2 = sequence_amplified_pool(amplified_molecules_model2,
sample_size=sequence_depth, error_rate=seq_error_rate)
print ’effect of PCR and sequencing error:’
intersect = len(set(sequenced_molecules_model2.keys()).intersection(set(labelled_molecules.keys())))
total = len(sequenced_molecules_model2.keys())
print intersect, ’out of’, total, ’sequenced clonotypes were in the initial sample’
print ’’
# amplify molecules according to pcr model 3 (fixed available resource)
print ’amplifying via model 3...’
amplified_molecules_model3 = pcr_model3(labelled_molecules, error=pcr_error_rate,
number_cycles=number_pcr_cycles, available_resource_multiple=1.5**number_pcr_cycles)
# sequence a sample of molecules
print ’sampling...’
sequenced_molecules_model3 = sequence_amplified_pool(amplified_molecules_model3,
sample_size=sequence_depth, error_rate=seq_error_rate)
print ’effect of PCR and sequencing error:’
intersect = len(set(sequenced_molecules_model3.keys()).intersection(set(labelled_molecules.keys())))
total = len(sequenced_molecules_model3.keys())
print intersect, ’out of’, total, ’sequenced clonotypes were in the initial sample’
print ’’
# amplify molecules according to pcr model 4 (resource degradation)
print ’amplifying via model 4...’
amplified_molecules_model4 = pcr_model4(labelled_molecules, error=pcr_error_rate,
number_cycles=number_pcr_cycles, initial_resource_multiple=1000,
resource_degradation=0.5)
# sequence a sample of molecules
print ’sampling...’
sequenced_molecules_model4 = sequence_amplified_pool(amplified_molecules_model4,
sample_size=sequence_depth, error_rate=seq_error_rate)
print ’effect of PCR and sequencing error:’
intersect = len(set(sequenced_molecules_model4.keys()).intersection(set(labelled_molecules.keys())))
total = len(sequenced_molecules_model4.keys())
print intersect, ’out of’, total, ’sequenced clonotypes were in the initial sample’
print ’’
# amplify molecules according to pcr model 5 (variable efficiency)
print ’amplifying via model 5...’
amplified_molecules_model5 = pcr_model5(labelled_molecules, error=pcr_error_rate,
number_cycles=number_pcr_cycles)
# sequence a sample of molecules
print ’sampling...’
sequenced_molecules_model5 = sequence_amplified_pool(amplified_molecules_model5,
sample_size=sequence_depth, error_rate=seq_error_rate)
print ’effect of PCR and sequencing error:’
intersect = len(set(sequenced_molecules_model5.keys()).intersection(set(labelled_molecules.keys())))
total = len(sequenced_molecules_model5.keys())
print intersect, ’out of’, total, ’sequenced clonotypes were in the initial sample’
print ’’
# amplify molecules according to pcr model 6 (variable efficiency)
print ’amplifying via model 6...’
amplified_molecules_model6 = pcr_model6(labelled_molecules, error=pcr_error_rate,
number_cycles=number_pcr_cycles)
# sequence a sample of molecules
print ’sampling...’
sequenced_molecules_model6 = sequence_amplified_pool(amplified_molecules_model6,
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sample_size=sequence_depth, error_rate=seq_error_rate)
print ’effect of PCR and sequencing error:’
intersect = len(set(sequenced_molecules_model6.keys()).intersection(set(labelled_molecules.keys())))
total = len(sequenced_molecules_model6.keys())
print intersect, ’out of’, total, ’sequenced clonotypes were in the initial sample’
print ’’
Appendix C
Immune tolerance model:
Supplementary Information
The following was primarily written by Chris Watkins in support of the work presented
in Chapter 3.
The clonotype update equation (Equation 3.4 in Chapter 3) is an example of a type of
‘multiplicative weight update algorithm’ which has been extensively studied in machine
learning and game theory. These algorithms have excellent convergence properties; a
recent expository survey of this work is [10], which develops a unified presentation and
analysis of many applications of these algorithms.
Our approach is to write the rate of change of clonotype frequencies as minus the
gradient of a convex function F on vectors of N clonotype frequencies. F is defined on
the positive quadrant. The updates of clonotype abundances in the model then match
exactly a multiplicative update algorithm for finding the minimum of a convex function.
F has a unique minimum, and we can derive an estimate of the rate at which this
minimum is approached.
A formal development is below: the analysis is adapted from [10].
We follow the approach of [10] closely. Our multiplicative weights algorithm (de-
scribed below) is similar to theirs, but without the weight normalisation step. Our
Theorem 3 is adapted from their Theorem 2.4, with the difference that in ours there is
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no weight normalisation, and we therefore use generalised KL-divergence, which is a
measure of similarity of two positive vectors q and x:
D(q‖x) =∑
i
qi ln
(
qi
xi
)
+∑
i
xi−∑
i
qi (C.1)
Our final result, Proposition 5 is essentially their Theorem 3.11, with the difference that
we take the limit in continuous time.
C.1 Model and update algorithm
Let there be N T-cell clones, and let the number of cells in clone i at time t be denoted
xti , and the vector of all N clone abundances at time t is x
t = (xt1, . . . ,x
t
N); sometimes
we will speak of clone abundances without mentioning a specific time, and denote
the counts by x = (x1, . . . ,xN). Although in reality the clone sizes would be positive
integers, we do not consider small population size effects here, and we model the clone
abundances as positive real numbers.
The clone count update algorithm is as follows. Let R+ = {x ∈ R | x > 0}.
Multiplicative Weights Update Algorithm
The update algorithm for clonotypes is presented below as a sequence of deterministic
update steps at discrete times. At each time, the ‘signal’ for each clonotype is the
sum of divide (negative) and die (positive) signals received by cells of that type: for
the proof below, these signals are assumed in the range [−1,1], but this normalisation
becomes automatic when we take the limit in continuous time.
Initialisation: Fix η ≤ 12 . Let x1 = (x11, . . . ,x1N) ∈ RN+.
for t = 1,2, . . . ,T :
1. Let mt = (mt1, . . . ,m
t
N) be the signals received by each of the N clonotypes; these
signals are always in the range [−1,1].
2. For all i, xt+1i = x
t
i(1−ηmti)
end
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Lemma 1 Let 0 < η ≤ 12 .
For −1≤ m < 0,
ln
1
1−ηm ≤ m ln(1+η) (C.2)
For 0≤ m≤ 1,
ln
1
1−ηm ≤ m ln
1
1−η (C.3)
Proof Case −1 ≤ m < 0: By concavity of ln, |m| ln(1+η) ≤ ln(1+ |m|η). Remem-
bering m is negative, it follows that:
m ln(1+η)≥− ln(1+ |m|η)
= ln
1
1−mη
Case 0≤ m≤ 1: Observe that ln 11−η is convex in η , since:
d2
dη2
ln
1
1−η =
1
(1−η)2 > 0
Since ln 11−η = 0 when η = 0, it follows from convexity of ln
1
1−η that
1
1−mη ≤ m ln 11−η .
Lemma 2 For 0 < η ≤ 12 ,
ln
1
1−η ≤ η+η
2 (C.4)
and
ln(1+η)≥ η−η2 (C.5)
Proof To prove (C.4), consider the derivatives of u(η) = ln 11−η and v(η) = η+η
2:
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u(η) = ln
1
1−η v(η) = η+η
2
u′(η) =
1
1−η v
′(η) = 1+2η
u′′(η) =
1
(1−η)2 v
′′(η) = 2
Observe that u(0) = v(0) and u′(0) = v′(0), but for small η , u′(η) < v′(η), hence
u(η) ≤ v(η) over some interval [0,η∗], where u(η∗) = v(η∗); we need to show that
1
2 ≤ η∗. At η = η∗, the graph of u(η) crosses that of v(η) from below, hence u′(η∗)≥
v′(η∗). Both u′ and v′ are monotonically increasing; observe that u′(η) = v′(η) only
when η = 0 or η = 12 , where u
′(12) = v
′(12) = 2. It follows that η
∗≥ 12 , and u(η)≤ v(η)
for η ∈ [0, 12 ] as required.
For (C.5), consider the derivatives of w(η) = ln(1+η) and y(η) = η−η2.
w(η) = ln(1+η) y(η) = η−η2
w′(η) =
1
1+η
y′(η) = 1−2η
w′′(η) =
−1
(1+η)2
y′′(η) =−2
Observe that w(0) = y(0), w′(0) = y′(0), and w′′(η) > y′′(η) for all η > 0. Hence
w(η)> y(η) for all η > 0, which includes what was to be proved.
Theorem 3 Assume that all costs mti ∈ [−1,1] and 0 < η ≤ 12 . Then the multiplicative
weights algorithm described above guarantees that after T rounds of learning, produc-
ing the sequence of weight vectors x1, . . . ,xT , and for any positive vector q,
1
T
T
∑
t=1
mt ·xt ≤ 1
T
T
∑
t=1
(mt +η |mt |) ·q+ D(q‖x
1)
ηT
(C.6)
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Proof
D(q‖xt+1)−D(q‖xt) =∑
i
((
qi ln
qi
xt+1i
+ xt+1i −qi
)
−
(
qi ln
qi
xti
+ xti−qi
))
=∑
i
qi(lnxti− lnxt+1i )+∑
i
xt+1i − xti
=∑
i
qi(lnxti− lnxti(1−ηmti))+∑(1−ηmti)xti− xti
=∑
i
qi ln
1
1−ηmti
−η∑
i
mtix
t
i
= ∑
i:mti≥0
qi ln
1
1−ηmti
+ ∑
i:mti<0
qi ln
1
1−ηmti
−η∑
i
mtix
t
i
using lemma 1, we obtain
≤ ln 1
1−η ∑i:mti≥0
qimti + ln(1+η) ∑
i:mti<0
qimti−η∑
i
mtix
t
i
and using lemma 2, we obtain
≤ (η+η2) ∑
i:mti≥0
qimti +(η−η2) ∑
i:mti<0
qimti−η∑
i
mtix
t
i
= η
(
∑
i
(mti +η |mti|)qi−∑
i
mtix
t
i
)
= η
(
(mt +η |mt |) ·q−mt ·xt)
Summing from t = 1 to T , we obtain:
D(q‖xT+1)−D(q‖x1) = η
(
T
∑
t=1
(mt +η |mt |) ·q−mt ·xt
)
Rearranging, we obtain:
1
T
T
∑
t=1
mt ·xt ≤ 1
T
T
∑
t=1
(mt +η |mt |) ·q+ D(q‖x
1)−D(q‖xT+1)
ηT
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KL divergence is non-negative, so that D(q‖xT+1)≥ 0; we can therefore add this term
to the RHS, obtaining
1
T
T
∑
t=1
mt ·xt ≤ 1
T
T
∑
t=1
(mt +η |mt |) ·q+ D(q‖x
1)
ηT
which is what was to be proved.
We envisage the T-cell birth-death process operating in continuous time. To approach
continuous time in the limit of a sequence of small time-steps, we re-write this inequal-
ity in terms of time-steps of length δ , so that the total number of time-steps becomes
T
δ , and within each time-step there is a multiplicative update with factor ηδ :
1
T/δ
T/δ
∑
t=1
mt ·xt ≤ 1
T/δ
T/δ
∑
t=1
(mt +δη |mt |) ·q+ D(q‖x
1)
ηT
Using a bar to denote the time-average during the period 1 to T , and letting δ tend to
zero, it follows immediately that:
Corollary 4
m ·x≤m ·q+ D(q‖x
1)
ηT
(C.7)
assuming that the averages exist in the limit as δ tends to zero; this will be the case for
the benign choices of m that we make below.
C.2 On-line minimisation of a convex function
As [10] describe, the multiplicative weights algorithm can be applied to on-line min-
imisation of a convex function, and theorem 3 can be applied to obtain explicit bounds
on the average regret. Let F be a differentiable convex function on RN+, and let
ρ = max
x,i
∣∣∣∣∂F(x)∂xi
∣∣∣∣ (C.8)
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That is, ρ is the maximum absolute partial gradient of F anywhere in any of the N
coordinate directions. In fact it is only necessary to take ρ to be the maximum absolute
such gradient that is actually encountered during the optimisation: in our optimisations,
and for the F we use, ρ is unproblematically finite. Now define
mt =
1
ρ
∇F(xt) (C.9)
so that mti ∈ [−1,1] for all i and t; since F is assumed convex and differentiable then
for all q and x:
F(x)−F(q)≤ ∇F(x) · (x−q) (C.10)
Combining this with equation (C.7) we obtain
F(x)−F(q)≤ ∇F(x) · (x−q) (C.11)
= ∇F(x) ·x−∇F(x) ·q (C.12)
= ρ(m ·x−m ·q) (C.13)
≤ D(q‖x
1)
(η/ρ)T
(C.14)
For our model, (η/ρ)∂F(x)∂xi is the rate of growth of the count of cells in clonotype i,
and we assume that is always negative for sufficiently large x; F must therefore have
an infimum in the positive quadrant (including the axis planes, to allow for zeros): let
this infimum of F be achieved at q. Then, taking 0ln0 = 0 so that D(q||x1) exists even
if some elements of q are zero, we have:
Proposition 5
F(x)− inf
q∈RN+
F(q)≤ D(q‖x
1)
(η/ρ)T
(C.15)
The RHS of the equation above is of the form C/T , where C is a constant, because
D(q‖x1), η , and ρ do not vary throughout learning. From the gradient descent ar-
gument of equation 10 in the main manuscript, F(x) decreases monotonically during
learning; it follows that F(xt) declines at least as fast as 1t2 . It follows that the con-
straints are rapidly satisfied since F rapidly approaches its minimum. However, the
C.2. On-line minimisation of a convex function 189
number N of clonotypes appears greater than the number of constraints, so that we
cannot say how rapidly the clonotype concentrations x approach q; this may allow
clonotype diversity to persist for considerable time, even though the constraints are
approximately satisfied.
Appendix D
Short Read Decombinator
D.1 Short Read Decombinator (‘SRD’) Algorithm
Decombinator [145] is modified for use with short sequence read data as follows.
First, a keyword trie is built for each possible V and J region to be assigned. These tries
consist of every contiguous subsequence of at least four nucleotides taken from the 3’
portion of a V gene and the 5’ portion of a J gene. A Python implementation of the
Aho-Corasick algorithm [3] is then used to search the sequence read for all instances of
matches from any trie. These matches are used to first determine which V gene should
be assigned to the sequence read as follows, and then the same process is followed for
J genes.
1. If the longest of all the matches between any gene subsequence and the sequence
read is longer than a specified parameter (the ‘match threshold’) and the longest
match to a substring of a different gene is shorter than this longest match by an-
other specified parameter (the ‘match differential’) then the gene with the longest
match is assigned.
2. If the sequence read is unable to be assigned a gene based on the longest match
to a gene substring, then the second part of the SRD method is called. Here each
gene is given a score of ∑elength(x) for all matches x between the sequence read
and a substring of the gene. An exponentially increasing score function is used
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to ensure that a long match carries more weight than two half-length matches.
3. If the score for all gene regions is below a set parameter (the ‘score threshold’)
then the sequence read is discarded as not being similar enough to any gene to
justify an assignment. Otherwise, the sequence read is assigned to the highest
scoring gene, provided this highest gene score exceeds the next highest by at
least an amount defined by a parameter (the ‘score differential’).
4. If the two highest gene scores are too similar to allow assignment of the gene
region that the TCR sequence read contains, the SRD algorithm moves to the
final stage where a pairwise alignment is considered between the sequence read
and the two highest scoring regions. The sequence read is assigned the gene with
the best pairwise alignment to the read.
Once these steps have been implemented for both V and J regions, and a sequence read
has been assigned both genes, the number of deletions from each gene is calculated
and the nucleotides between the genes are recorded as for standard Decombinator and
a 5-part classifier (a ‘DCR’) fully defining the sequence read is obtained.
The parameters for SRD used in to process the data presented in Chapter 4 are: match
threshold = 10, match differential = 2, score threshold = 1400 and score differential =
1.05. These were selected by running a set of artificial sequences (with varying levels
of sequencing error) through the method with different sets of parameters. A set was
chosen based on a compromise between the accuracy of sequence assignment and the
percentage of reads being classified.
D.2 V region pairing
The mouse data analysed in Chapter 4 is obtained through a protocol where V gene
specific primers are used and sequence data is obtained from 3’ of the primer position.
Keyword tries for each V gene for use in the Aho-Corasick search in SRD can then be
built based on the sequence of each gene from 3’ of the primer site. However, due to the
short length of the sequence data and the similarity of some of the V genes at the 3’ end,
this presents difficulties. The following pairs of genes are unable to be distinguished
D.2. V region pairing 192
by SRD because of their 3’ similarity:
Gene name 3’ sequence
TRBV24*01 GACTCAGCACTGTACCTCTGTGCCAGCAGTCTGTA
TRBV26*01 GACTCAGCACTGTACCTCTGTGCCAGCAGTCTGTC
TRBV12-1*01 AACTGGAGGACTCTGCTATGTACTTCTGTGCCAGCTCTCTC
TRBV12-2*01 TAGAGGACTCTGCCGTGTACTTCTGTGCCAGCTCTCTC
TRBV13-1*01 TCAGACATCTTTGTACTTCTGTGCCAGCAGTGATG
TRBV13-3*01 CAGACAGCTGTATATTTCTGTGCCAGCAGTGATG
Instead of attempting to distinguish these genes in this work, we instead ignore the
second of each pair and assign all matching sequence reads to the first gene.
